

EXHIBIT 291-A

1 IN THE UNITED STATES DISTRICT COURT
2 FOR THE EASTERN DISTRICT OF OHIO
3 EASTERN DIVISION
4 - - -

5 IN RE: NATIONAL : MDL NO. 2804
6 PRESCRIPTION OPIATE :
7 LITIGATION :

8 : CASE NO.
THIS DOCUMENT : 1:17-MD-2804
9 RELATES TO ALL CASES:

10 : Hon. Dan A.
11 : Polster
12 - - -

13 Friday, August 3, 2018
14 - - -

15 HIGHLY CONFIDENTIAL - SUBJECT TO FURTHER
16 CONFIDENTIALITY REVIEW
17 - - -

18 Videotaped deposition of
19 CHRISTOPHER ZIMMERMAN, taken pursuant to
20 notice, was held at the law offices of
21 Reed Smith, LLP, Three Logan Square, 1717
22 Arch Street, Suite 3100, Philadelphia,
23 Pennsylvania 19103, beginning at 9:00
24 a.m., on the above date, before Amanda
Dee Maslynsky-Miller, a Certified
Realtime Reporter.

19 - - -
20
21
22

23 GOLKOW LITIGATION SERVICES
877.370.3377 ph | 917.591.5672 fax
deps@golkow.com
24

Page 2	Page 4
<p>1 APPEARANCES:</p> <p>2</p> <p>3 BARON & BUDD P.C. BY: MARK PIFKO, ESQUIRE BY: STERLING CLUFF, ESQUIRE 15910 Ventura Boulevard #1600 Encino, California 91436 (818) 839-2333 mpifko@baronbudd.com Scluff@baronbudd.com - and - BY: SCOTT SIMMER, ESQUIRE Washington, DC (202) 333-4562 Ssimmer@baronbudd.com Representing the Plaintiffs</p> <p>13 REED SMITH, LLP BY: ROBERT A. NICHOLAS, ESQUIRE BY: JOSEPHY J. MAHADY, ESQUIRE BY: JEFFREY R. MELTON, ESQUIRE BY: SHANNON E. MCCLURE, ESQUIRE BY: THOMAS H. SUDDATH JR., ESQUIRE Three Logan Square 1717 Arch Street Philadelphia, PA 19103 (215) 851-8100 Rnicholas@reedsmith.com jmahady@reedsmith.com Jmelton@reedsmith.com Smclure@reedsmith.com Tsuddath@reedsmith.com Representing the Defendant, Amerisource Bergen Drug Corporation</p>	<p>1 APPEARANCES: (Continued)</p> <p>2</p> <p>3 PELINI CAMPBELL & WILLIAMS, LLC BY: ERIC J. WILLIAMS, ESQUIRE 8040 Cleveland Avenue NW Suite 400 North Canton, OH 44720 330.305.6400 ejwilliams@pelini-law.com Representing the Defendant, Prescription Supply, Inc.</p> <p>9 WILLIAMS & CONNOLLY, LLP BY: MATTHEW C. MONAHAN, ESQUIRE 725 Twelfth Street, N.W. Washington, DC 20005 202.434.5000 mmonahan@wc.com Representing the Defendant, Cardinal Health</p> <p>15 ARNOLD & PORTER KAYE SCHOLER LLP BY: SAMUEL LONERGAN, ESQUIRE 250 West 55th Street New York, New York 10019 (212) 836-8000 samuel.lonergan@arnoldporter.com Representing the Defendant, Endo Pharmaceuticals</p> <p>20 BARTLT BECK HERMAN PALENCHAR & SCOTT LLP BY: KATHERINE M. SWIFT, ESQUIRE Courthouse Place 54 West Hubbard Street, Suite 300 Chicago, Illinois 60654 (312) 494-4400 kate.swift@bartlit-beck.com Representing the Defendant, The Walgreens Company</p>
<p>1 APPEARANCES: (Continued)</p> <p>2</p> <p>3 COVINGTON & BURLING LLP BY: EMILY KVESELIS, ESQUIRE 850 Tenth Street, NW Suite 856N Washington, DC 20001 202.662.5000 ekveselis@cov.com Representing the Defendant, McKesson Corporation</p> <p>10 MARCUS & SHAPIRA LLP BY: JAMES F. ROSENBERG, ESQUIRE One Oxford Centre 35th Floor Pittsburgh, PA 15219 412.338.4683 rosenberg@marcus-shapira.com Representing the Defendant, HBC Service Company</p> <p>16 JONES DAY BY: SARAH G. CONWAY, ESQUIRE 555 South Flower Street Los Angeles, California 90071 (213) 489-3939 sgconway@jonesday.com Representing the Defendant, Walmart</p>	<p>1 VIA TELECONFERENCE:</p> <p>2</p> <p>3 LOCKE LORD LLP BY: BRANDAN MONTMINY, ESQUIRE 2200 Ross Avenue Suite 2800 Dallas, Texas 75201 (214) 740-8000 brandan.montminy@lockelord.com Representing the Defendant, Henry Schein Medical Systems, Inc.</p> <p>10 ROPES & GRAY LLP BY: JESSICA F. SORICELLI, ESQUIRE BY: FEIFEI (ANDREA) REN, ESQUIRE 1211 Avenue of the Americas New York, New York 10036 (212) 596-9000 Jessica.Soricelli@ropesgray.com Andrea.Ren@ropesgray.com Representing the Defendant, Mallinckrodt</p> <p>16 MORGAN LEWIS & BOCKIUS, LLP BY: ELLIOT E. BROWN, ESQUIRE 1111 Pennsylvania Ave. NW Washington, D.C. 20004 (202) 739-3000 elliott.brown@morganlewis.com Representing the Defendants, Teva Pharmaceuticals, Inc., Cephalon, Inc., Watson Laboratories, Actavis LLC, and Actavis Pharma, Inc.</p>
<p>21</p> <p>22</p> <p>23</p> <p>24</p>	<p>21</p> <p>22</p> <p>23</p> <p>24</p>

Page 6			Page 8		
			EXHIBITS		
	NO.	DESCRIPTION	PAGE		
1	Amerisource Bergen - Zimmerman				
2	Exhibit-10 ABDCMDL 00000099-100	283			
3	Amerisource Bergen - Zimmerman				
4	Exhibit-11 CAH MDL PRIORPROD -				
5	DEA 07 00880890-92 303 -				
6	Amerisource Bergen - Zimmerman				
7	Exhibit-12 MNKT1_0000291614-1620	328			
8	Amerisource Bergen - Zimmerman				
9	Exhibit-13 ABDCMDL 00278212	362			
10	Amerisource Bergen - Zimmerman				
11	Exhibit-14 ABDCMDL 00000124-147	380			
12	Amerisource Bergen - Zimmerman				
13	Exhibit-15 No Bates				
14	March 2017 AmerisourceBergen Code				
15	of Ethics and Business Conduct	439			
16	Amerisource Bergen - Zimmerman				
17	Exhibit-16 No Bates West Virginia Case				
18	Document, Organization Charts	443			
19	Amerisource Bergen - Zimmerman				
20	Exhibit-17 ABDCMDL 00251392-94	451			
21	Amerisource Bergen - Zimmerman				
22	Exhibit-18 ABDCMDL 00002325-2334	453			
23	Amerisource Bergen - Zimmerman				
24	Exhibit-19 ABDCMDL 00002405-2418	459			
Page 7			Page 9		
			DEPOSITION SUPPORT INDEX		
	NO.	DESCRIPTION	PAGE		
1	Amerisource Bergen - Zimmerman				
2	Exhibit-1 Notice of Deposition	13			
3	Amerisource Bergen - Zimmerman				
4	Exhibit-2 *Skipped*				
5	Amerisource Bergen - Zimmerman				
6	Exhibit-3 Notice of 30(b)(6)				
7	Deposition	19			
8	Amerisource Bergen - Zimmerman				
9	Exhibit-4 2001 Chemical Handler's Notebook	131			
10	Amerisource Bergen - Zimmerman				
11	Exhibit-5 ABDCMDL 00279854-65	137			
12	Amerisource Bergen - Zimmerman				
13	Exhibit-6 ABDCMDL 00269683-694	145			
14	Amerisource Bergen - Zimmerman				
15	Exhibit-7 ABDCMDL 00000101-122	170			
16	Amerisource Bergen - Zimmerman				
17	Exhibit-8 ABDCMDL 00270533	248			
18	Amerisource Bergen - Zimmerman				
19	Exhibit-9 ABDCMDL 00273425	251			
20	Amerisource Bergen - Zimmerman				
21	Exhibit-10 1				
22	Amerisource Bergen - Zimmerman				
23	Exhibit-11 Question Marked				
24	Exhibit-12 Page Line Page Line Page Line				
25	Exhibit-13 None				
26	Amerisource Bergen - Zimmerman				
27	Exhibit-14 Stipulations				
28	Exhibit-15 Page Line Page Line Page Line				
29	Exhibit-16 10				
30	Amerisource Bergen - Zimmerman				
31	Exhibit-17 Question Marked				
32	Exhibit-18 Page Line Page Line Page Line				
33	Exhibit-19 None				
34	Amerisource Bergen - Zimmerman				
35	Exhibit-20 Stipulations				
36	Exhibit-21 Page Line Page Line Page Line				
37	Exhibit-22 10				
38	Amerisource Bergen - Zimmerman				
39	Exhibit-23 Question Marked				
40	Exhibit-24 Page Line Page Line Page Line				
41	Exhibit-25 None				
42	Amerisource Bergen - Zimmerman				
43	Exhibit-26 Stipulations				
44	Exhibit-27 Page Line Page Line Page Line				
45	Exhibit-28 10				
46	Amerisource Bergen - Zimmerman				
47	Exhibit-29 Question Marked				
48	Exhibit-30 Page Line Page Line Page Line				
49	Exhibit-31 None				
50	Amerisource Bergen - Zimmerman				
51	Exhibit-32 Stipulations				
52	Exhibit-33 Page Line Page Line Page Line				
53	Exhibit-34 10				
54	Amerisource Bergen - Zimmerman				
55	Exhibit-35 Question Marked				
56	Exhibit-36 Page Line Page Line Page Line				
57	Exhibit-37 None				
58	Amerisource Bergen - Zimmerman				
59	Exhibit-38 Stipulations				
60	Exhibit-39 Page Line Page Line Page Line				
61	Exhibit-40 10				
62	Amerisource Bergen - Zimmerman				
63	Exhibit-41 Question Marked				
64	Exhibit-42 Page Line Page Line Page Line				
65	Exhibit-43 None				
66	Amerisource Bergen - Zimmerman				
67	Exhibit-44 Stipulations				
68	Exhibit-45 Page Line Page Line Page Line				
69	Exhibit-46 10				
70	Amerisource Bergen - Zimmerman				
71	Exhibit-47 Question Marked				
72	Exhibit-48 Page Line Page Line Page Line				
73	Exhibit-49 None				
74	Amerisource Bergen - Zimmerman				
75	Exhibit-50 Stipulations				
76	Exhibit-51 Page Line Page Line Page Line				
77	Exhibit-52 10				
78	Amerisource Bergen - Zimmerman				
79	Exhibit-53 Question Marked				
80	Exhibit-54 Page Line Page Line Page Line				
81	Exhibit-55 None				
82	Amerisource Bergen - Zimmerman				
83	Exhibit-56 Stipulations				
84	Exhibit-57 Page Line Page Line Page Line				
85	Exhibit-58 10				
86	Amerisource Bergen - Zimmerman				
87	Exhibit-59 Question Marked				
88	Exhibit-60 Page Line Page Line Page Line				
89	Exhibit-61 None				
90	Amerisource Bergen - Zimmerman				
91	Exhibit-62 Stipulations				
92	Exhibit-63 Page Line Page Line Page Line				
93	Exhibit-64 10				
94	Amerisource Bergen - Zimmerman				
95	Exhibit-65 Question Marked				
96	Exhibit-66 Page Line Page Line Page Line				
97	Exhibit-67 None				
98	Amerisource Bergen - Zimmerman				
99	Exhibit-68 Stipulations				
100	Exhibit-69 Page Line Page Line Page Line				
101	Exhibit-70 10				
102	Amerisource Bergen - Zimmerman				
103	Exhibit-71 Question Marked				
104	Exhibit-72 Page Line Page Line Page Line				
105	Exhibit-73 None				
106	Amerisource Bergen - Zimmerman				
107	Exhibit-74 Stipulations				
108	Exhibit-75 Page Line Page Line Page Line				
109	Exhibit-76 10				
110	Amerisource Bergen - Zimmerman				
111	Exhibit-77 Question Marked				
112	Exhibit-78 Page Line Page Line Page Line				
113	Exhibit-79 None				
114	Amerisource Bergen - Zimmerman				
115	Exhibit-80 Stipulations				
116	Exhibit-81 Page Line Page Line Page Line				
117	Exhibit-82 10				
118	Amerisource Bergen - Zimmerman				
119	Exhibit-83 Question Marked				
120	Exhibit-84 Page Line Page Line Page Line				
121	Exhibit-85 None				
122	Amerisource Bergen - Zimmerman				
123	Exhibit-86 Stipulations				
124	Exhibit-87 Page Line Page Line Page Line				
125	Exhibit-88 10				
126	Amerisource Bergen - Zimmerman				
127	Exhibit-89 Question Marked				
128	Exhibit-90 Page Line Page Line Page Line				
129	Exhibit-91 None				
130	Amerisource Bergen - Zimmerman				
131	Exhibit-92 Stipulations				
132	Exhibit-93 Page Line Page Line Page Line				
133	Exhibit-94 10				
134	Amerisource Bergen - Zimmerman				
135	Exhibit-95 Question Marked				
136	Exhibit-96 Page Line Page Line Page Line				
137	Exhibit-97 None				
138	Amerisource Bergen - Zimmerman				
139	Exhibit-98 Stipulations				
140	Exhibit-99 Page Line Page Line Page Line				
141	Exhibit-100 10				
142	Amerisource Bergen - Zimmerman				
143	Exhibit-101 Question Marked				
144	Exhibit-102 Page Line Page Line Page Line				
145	Exhibit-103 None				
146	Amerisource Bergen - Zimmerman				
147	Exhibit-104 Stipulations				
148	Exhibit-105 Page Line Page Line Page Line				
149	Exhibit-106 10				
150	Amerisource Bergen - Zimmerman				
151	Exhibit-107 Question Marked				
152	Exhibit-108 Page Line Page Line Page Line				
153	Exhibit-109 None				
154	Amerisource Bergen - Zimmerman				
155	Exhibit-110 Stipulations				
156	Exhibit-111 Page Line Page Line Page Line				
157	Exhibit-112 10				
158	Amerisource Bergen - Zimmerman				
159	Exhibit-113 Question Marked				
160	Exhibit-114 Page Line Page Line Page Line				
161	Exhibit-115 None				
162	Amerisource Bergen - Zimmerman				
163	Exhibit-116 Stipulations				
164	Exhibit-117 Page Line Page Line Page Line				
165	Exhibit-118 10				
166	Amerisource Bergen - Zimmerman				
167	Exhibit-119 Question Marked				
168	Exhibit-120 Page Line Page Line Page Line				
169	Exhibit-121 None				
170	Amerisource Bergen - Zimmerman				
171	Exhibit-122 Stipulations				
172	Exhibit-123 Page Line Page Line Page Line				
173	Exhibit-124 10				
174	Amerisource Bergen - Zimmerman				
175	Exhibit-125 Question Marked				
176	Exhibit-126 Page Line Page Line Page Line				
177	Exhibit-127 None				
178	Amerisource Bergen - Zimmerman				
179	Exhibit-128 Stipulations				
180	Exhibit-129 Page Line Page Line Page Line				
181	Exhibit-130 10				
182	Amerisource Bergen - Zimmerman				
183	Exhibit-131 Question Marked				
184	Exhibit-132 Page Line Page Line Page Line				
185	Exhibit-133 None				
186	Amerisource Bergen - Zimmerman				
187	Exhibit-134 Stipulations				
188	Exhibit-135 Page Line Page Line Page Line				
189	Exhibit-136 10				
190	Amerisource Bergen - Zimmerman				
191	Exhibit-137 Question Marked				
192	Exhibit-138 Page Line Page Line Page Line				
193	Exhibit-139 None				
194	Amerisource Bergen - Zimmerman				
195	Exhibit-140 Stipulations				
196	Exhibit-141 Page Line Page Line Page Line				
197	Exhibit-142 10				
198	Amerisource Bergen - Zimmerman				
199	Exhibit-143 Question Marked				
200	Exhibit-144 Page Line Page Line Page Line				
201	Exhibit-145 None				
202	Amerisource Bergen - Zimmerman				
203	Exhibit-146 Stipulations				
204	Exhibit-147 Page Line Page Line Page Line				
205	Exhibit-148 10				
206	Amerisource Bergen - Zimmerman				
207	Exhibit-149 Question Marked				
208	Exhibit-150 Page Line Page Line Page Line				
209	Exhibit-151 None				
210	Amerisource Bergen - Zimmerman				
211	Exhibit-152 Stipulations				
212	Exhibit-153 Page Line Page Line Page Line				
213	Exhibit-154 10				
214	Amerisource Bergen - Zimmerman				
215	Exhibit-155 Question Marked				
216	Exhibit-156 Page Line Page Line Page Line				
217	Exhibit-157 None				
218	Amerisource Bergen - Zimmerman				
219	Exhibit-158 Stipulations				
220	Exhibit-159 Page Line Page Line Page Line				
221	Exhibit-160 10				
222	Amerisource Bergen - Zimmerman				
223	Exhibit-161 Question Marked				
224	Exhibit-162 Page Line Page Line Page Line				
225	Exhibit-163 None				
226	Amerisource Bergen - Zimmerman				
227	Exhibit-164 Stipulations				
228	Exhibit-165 Page Line Page Line Page Line				
229	Exhibit-166 10				
230	Amerisource Bergen - Zimmerman				
231	Exhibit-167 Question Marked				
232	Exhibit-168 Page Line Page Line Page Line				
233	Exhibit-169 None				
234	Amerisource Bergen - Zimmerman				
235	Exhibit-170 Stipulations				
236	Exhibit-171 Page Line Page Line Page Line				
237	Exhibit-172 10				
238	Amerisource Bergen - Zimmerman				
239	Exhibit-173 Question Marked				
240	Exhibit-174 Page Line Page Line Page Line				
241	Exhibit-175 None				
242	Amerisource Bergen - Zimmerman				
243	Exhibit-176 Stipulations				
244	Exhibit-177 Page Line Page Line Page Line				
245	Exhibit-178 10				
246	Amerisource Bergen - Zimmerman				
247	Exhibit-179 Question Marked				
248	Exhibit-180 Page Line Page Line Page Line				
249	Exhibit-181 None				
250	Amerisource Bergen - Zimmerman				
251	Exhibit-182 Stipulations				
252	Exhibit-183 Page Line Page Line Page Line				
253	Exhibit-184 10				
254	Amerisource Bergen - Zimmerman				
255	Exhibit-185 Question Marked				
256	Exhibit-186 Page Line Page Line Page Line				
257	Exhibit-187 None				
258	Amerisource Bergen - Zimmerman				
259	Exhibit-188 Stipulations				

Page 10	Page 12
<p>1 - - -</p> <p>2 (It is hereby stipulated and 3 agreed by and among counsel that 4 sealing, filing and certification 5 are waived; and that all 6 objections, except as to the form 7 of the question, will be reserved 8 until the time of trial.)</p> <p>9 - - -</p> <p>10 VIDEO TECHNICIAN: We are 11 now on the record. My name is 12 David Lane, videographer for 13 Golkow Litigation Services. 14 Today's date is August 3rd, 2018. 15 Our time is 9:23 a.m.</p> <p>16 This deposition is taking 17 place in Philadelphia, 18 Pennsylvania, in the matter of 19 National Prescription Opiate 20 Litigation. Our deponent today is 21 Chris Zimmerman. Our counsel will 22 be noted on the stenographic 23 record.</p> <p>24 The court reporter is Amanda</p>	<p>1 your testimony here is under penalty of 2 perjury?</p> <p>3 A. Yes.</p> <p>4 Q. And that means that if you 5 are untruthful or dishonest in any way 6 you could be subject to penalties from 7 the court.</p> <p>8 Do you understand that?</p> <p>9 A. Yes.</p> <p>10 Q. Do you intend to provide 11 cooperative testimony today?</p> <p>12 A. I do.</p> <p>13 Q. From time to time, 14 Amerisource's counsel might assert 15 objections. Unless he instructs you not 16 to answer, I'm still entitled to an 17 answer.</p> <p>18 Do you understand that?</p> <p>19 A. Yes.</p> <p>20 Q. We can take breaks -- I'm 21 sure that you went over all this in the 22 prep session with your lawyers. We can 23 take breaks. The only thing is unless 24 your counsel is going to be conferring</p>
<p>1 Miller and will now swear in the 2 witness.</p> <p>3 - - -</p> <p>4 CHRISTOPHER ZIMMERMAN, after 5 having been duly sworn, was 6 examined and testified as follows:</p> <p>7 - - -</p> <p>8 VIDEO TECHNICIAN: Please 9 begin.</p> <p>10 - - -</p> <p>11 EXAMINATION</p> <p>12 - - -</p> <p>13 BY MR. PIFKO:</p> <p>14 Q. Good morning, Mr. Zimmerman. 15 My name is Mark Pifko, I'm counsel for 16 plaintiffs in this matter. Just met a 17 few moments ago for the first time, off 18 the record.</p> <p>19 You understand that you are 20 here as the company's designated witness 21 for certain topics?</p> <p>22 A. Correct.</p> <p>23 Q. The court reporter just 24 swore you in. So you understand that</p>	<p>1 with you about a privilege, we can't take 2 a break while a question is pending.</p> <p>3 Do you agree to that?</p> <p>4 A. Yes.</p> <p>5 MR. PIFKO: Let's start by 6 handing him the 30(b)(6) notice 7 for Number 1.</p> <p>8 BY MR. PIFKO:</p> <p>9 Q. While he's getting that, are 10 you under any medications or undergoing 11 any treatment of any kind that would 12 inhibit your ability to provide truthful 13 and accurate testimony today?</p> <p>14 A. No.</p> <p>15 Q. Is there any reason that you 16 can state why your deposition should not 17 go forward today?</p> <p>18 A. No.</p> <p>19 - - -</p> <p>20 (Whereupon, Amerisource 21 Bergen-Zimmerman Exhibit-1, Notice 22 of Deposition, was marked for 23 identification.)</p> <p>24 - - -</p>

<p>1 BY MR. PIFKO:</p> <p>2 Q. I've just handed you what's</p> <p>3 marked as Exhibit-1, which is a first</p> <p>4 notice of deposition under Rule 30(b)(6).</p> <p>5 It's got some topics on</p> <p>6 here, there are page numbers under there.</p> <p>7 The topics start on the bottom of the</p> <p>8 page, Page 6.</p> <p>9 Do you see that?</p> <p>10 A. Yes.</p> <p>11 Q. Have you seen this document</p> <p>12 before?</p> <p>13 A. I don't believe so.</p> <p>14 Q. Have you seen these topics</p> <p>15 before?</p> <p>16 A. Let me take a quick look at</p> <p>17 them.</p> <p>18 Q. Sorry?</p> <p>19 A. I'm reading through these</p> <p>20 real quickly.</p> <p>21 Q. Just for housekeeping, we</p> <p>22 didn't go over that, but there are,</p> <p>23 again, I'm sure your counsel told you</p> <p>24 some of these things in preparing for the</p>	<p>Page 14</p> <p>1 A. A couple of weeks ago,</p> <p>2 maybe.</p> <p>3 Q. And are you prepared to</p> <p>4 provide testimony on behalf of the</p> <p>5 company with respect to these topics?</p> <p>6 A. Within a certain time frame,</p> <p>7 yes.</p> <p>8 Q. I understand the time frame</p> <p>9 goes from -- up until the end of 2014; is</p> <p>10 that correct?</p> <p>11 A. Correct.</p> <p>12 MR. NICHOLAS: Just for the</p> <p>13 record, just one of these topics,</p> <p>14 Topic O, is one which I believe</p> <p>15 there's an agreement among counsel</p> <p>16 that we will respond to in writing</p> <p>17 as opposed to in testimony here</p> <p>18 today.</p> <p>19 MR. PIFKO: Well, we can</p> <p>20 meet and confer, but I don't</p> <p>21 intend to take testimony on that</p> <p>22 topic today in any event.</p> <p>23 MR. NICHOLAS: Well, just to</p> <p>24 be clear, though, I think there's</p>
<p>1 depo, but there's a couple of ground</p> <p>2 rules that we have to remember because</p> <p>3 we're on the record here. Try to</p> <p>4 annunciate clearly if you're providing an</p> <p>5 answer, give an audible response and</p> <p>6 don't say words like uh-huh and uh-uh</p> <p>7 because when you read it on the</p> <p>8 transcript, you can't tell if it's a yes</p> <p>9 or no.</p> <p>10 Understood?</p> <p>11 A. Yes.</p> <p>12 Q. So you're reviewing the</p> <p>13 document right now?</p> <p>14 A. Yes.</p> <p>15 Q. To be clear, my question was</p> <p>16 if you had seen these topics before,</p> <p>17 which start on Page 6, and they're</p> <p>18 lettered A through O.</p> <p>19 A. Yes.</p> <p>20 Q. You have seen these topics</p> <p>21 before?</p> <p>22 A. I have.</p> <p>23 Q. Okay. When was the first</p> <p>24 time you saw these?</p>	<p>Page 15</p> <p>1 an agreement that we're responding</p> <p>2 to this in writing.</p> <p>3 MR. PIFKO: I'm not aware of</p> <p>4 such an agreement. I'm not</p> <p>5 disputing -- or I'm not taking a</p> <p>6 position.</p> <p>7 MR. NICHOLAS: Okay.</p> <p>8 MR. PIFKO: But we can be</p> <p>9 clear that that's not part of the</p> <p>10 deposition today, however we end</p> <p>11 up handling it.</p> <p>12 MR. NICHOLAS: Okay.</p> <p>13 BY MR. PIFKO:</p> <p>14 Q. And so you understand that</p> <p>15 you're also being deposed here in your</p> <p>16 individual capacity as well.</p> <p>17 Do you understand that?</p> <p>18 A. Yes.</p> <p>19 Q. For the most part, you can</p> <p>20 imagine, the company is made up of many</p> <p>21 individuals, and so it's hard to have</p> <p>22 someone speak for the company.</p> <p>23 So what we do in these</p> <p>24 situations is we have these topics and</p>

Page 18	Page 20
<p>1 you, right now sitting in that chair for 2 the purpose of this case, are 3 AmerisourceBergen with respect to these 4 topics.</p> <p>5 Do you understand that?</p> <p>6 MR. NICHOLAS: Object to the 7 form.</p> <p>8 You can answer.</p> <p>9 THE WITNESS: Yes, I'm going 10 to be speaking on these topics.</p> <p>11 BY MR. PIFKO:</p> <p>12 Q. And from time to time, I 13 might be asking, does AmerisourceBergen 14 do this or that? And you'll be 15 answering, you know, so long as it's 16 within the scope of these topics, you'll 17 be answering on behalf of the company.</p> <p>18 Do you understand that?</p> <p>19 MR. NICHOLAS: Same 20 objection.</p> <p>21 But go ahead.</p> <p>22 THE WITNESS: Yes, I'll be 23 answering questions.</p> <p>24 BY MR. PIFKO:</p>	<p>1 for identification.) 2 - - - 3 BY MR. PIFKO: 4 Q. It's marked as Exhibit-3, 5 which is the notice that calls us here 6 today. 7 And it also, in addition to 8 calling for your 30(b)(6) testimony, it 9 calls for your individual testimony as 10 well. 11 A. Okay. 12 Q. Are you familiar with The 13 Controlled Substances Act? 14 A. Yes. 15 Q. How long have you been 16 working at AmerisourceBergen? 17 A. Since January 1990. 18 Q. And you are currently senior 19 vice president, chief compliance officer? 20 A. Correct. 21 Q. And you're also senior vice 22 president in charge of the -- what's your 23 exact title for the aspect of the company 24 that deals with compliance with the CSA?</p>
<p>1 Q. And you understand that 2 you'll be answering them on behalf of the 3 company? That's what I'm trying to get 4 at.</p> <p>5 MR. NICHOLAS: Same 6 objection.</p> <p>7 You can answer.</p> <p>8 THE WITNESS: It depends on 9 whether it's as I'm representing 10 the company. You also indicated 11 I'll be answering questions for 12 myself.</p> <p>13 BY MR. PIFKO:</p> <p>14 Q. But with respect to these 15 topics, you understand that for the date 16 range we discussed, you'll be answering 17 on behalf of the company?</p> <p>18 A. Yes.</p> <p>19 Q. Okay. And then I just 20 handed you what's marked as Exhibit-2.</p> <p>21 - - -</p> <p>22 (Whereupon, Amerisource 23 Bergen-Zimmerman Exhibit-3, Notice 24 of 30(b)(6) Deposition, was marked</p>	<p>1 A. So I'm senior vice president 2 of corporate security and regulatory 3 affairs. 4 Q. And you guys called that 5 CSRA within your company? 6 A. That's the abbreviation, 7 yes. 8 Q. So if I use the term "CSRA," 9 you understand what that means? 10 A. Yes. 11 Q. AmerisourceBergen is a 12 registrant under The Controlled 13 Substances Act, correct? 14 A. We are a DEA registrant, 15 correct. 16 Q. Have you ever heard the 17 term, I think -- I'm from California, we 18 drive a lot there, there's a phrase they 19 use that says, driving is a privilege, 20 not a right. 21 Have you ever heard that 22 kind of a phrase before? 23 A. Not really. 24 Q. AmerisourceBergen sells</p>
Page 19	Page 21

<p style="text-align: right;">Page 22</p> <p>1 drugs, correct?</p> <p>2 A. Correct.</p> <p>3 Q. Included among those drugs</p> <p>4 are controlled substances, correct?</p> <p>5 A. Yes.</p> <p>6 Q. And it's AmerisourceBergen's</p> <p>7 position as a registrant that allows the</p> <p>8 company to sell controlled substances,</p> <p>9 correct?</p> <p>10 MR. NICHOLAS: Object to the</p> <p>11 form.</p> <p>12 THE WITNESS: We have a</p> <p>13 controlled substance registration</p> <p>14 that allows us to distribute.</p> <p>15 BY MR. PIFKO:</p> <p>16 Q. And absent that</p> <p>17 registration, it's not legal for</p> <p>18 AmerisourceBergen to sell controlled</p> <p>19 substances, correct?</p> <p>20 A. Correct.</p> <p>21 Q. So do you understand that</p> <p>22 along with the privilege and the right</p> <p>23 to -- the ability to sell controlled</p> <p>24 substances, certain duties are attached</p>	<p style="text-align: right;">Page 24</p> <p>1 THE WITNESS: Can you say</p> <p>2 your question one more time?</p> <p>3 BY MR. PIFKO:</p> <p>4 Q. The ability to sell</p> <p>5 controlled substances also comes with</p> <p>6 certain obligations that you must follow,</p> <p>7 correct?</p> <p>8 MR. NICHOLAS: Same</p> <p>9 objection.</p> <p>10 THE WITNESS: It's the</p> <p>11 obligations of the requirements of</p> <p>12 the Code of Federal Regulations.</p> <p>13 BY MR. PIFKO:</p> <p>14 Q. And specifically, that's The</p> <p>15 Controlled Substances Act, correct?</p> <p>16 A. The regulations from the</p> <p>17 act, correct.</p> <p>18 Q. So The Controlled Substances</p> <p>19 Act and the regulations that follow,</p> <p>20 correct?</p> <p>21 A. Yes.</p> <p>22 Q. Do you know what a duty to</p> <p>23 maintain effective controls is?</p> <p>24 MR. NICHOLAS: Object to the</p>
<p style="text-align: right;">Page 23</p> <p>1 to that as well.</p> <p>2 Do you understand that?</p> <p>3 MR. NICHOLAS: Object to the</p> <p>4 form.</p> <p>5 THE WITNESS: I'm not sure</p> <p>6 what you're referring to as</p> <p>7 "duties."</p> <p>8 BY MR. PIFKO:</p> <p>9 Q. Okay. You understand there</p> <p>10 are restrictions on what you can do as an</p> <p>11 entity selling controlled substances,</p> <p>12 correct?</p> <p>13 A. There's requirements that we</p> <p>14 follow. I don't know if I'd refer to</p> <p>15 them as restrictions, but there's</p> <p>16 regulatory requirements that we have to</p> <p>17 adhere to.</p> <p>18 Q. Right. So my question is,</p> <p>19 the ability to sell controlled substances</p> <p>20 also comes with certain obligations,</p> <p>21 correct?</p> <p>22 MR. NICHOLAS: Object to the</p> <p>23 form.</p> <p>24 Go ahead.</p>	<p style="text-align: right;">Page 25</p> <p>1 form.</p> <p>2 THE WITNESS: I'm not sure</p> <p>3 what your question is. We -- I'm</p> <p>4 not sure what your question is.</p> <p>5 BY MR. PIFKO:</p> <p>6 Q. Have you heard the phrase,</p> <p>7 "duty to maintain effective controls"?</p> <p>8 A. No.</p> <p>9 Q. You've never heard that term</p> <p>10 before?</p> <p>11 A. No.</p> <p>12 Q. Do you have an understanding</p> <p>13 that under The Controlled Substances Act,</p> <p>14 AmerisourceBergen has a duty to maintain</p> <p>15 effective controls to prevent diversion</p> <p>16 of certain substances?</p> <p>17 A. Yes. We have to maintain</p> <p>18 effective controls from diversion. I</p> <p>19 just don't know duty was included in that</p> <p>20 or not.</p> <p>21 Q. I'll represent to you that</p> <p>22 the word "duty" is in there.</p> <p>23 So you do understand that</p> <p>24 you have an obligation to maintain</p>

<p>1 effective controls as part of your 2 serving as a registrant and selling 3 controlled substances? 4 A. Yes, we have an 5 obligation -- there's a regulatory 6 responsibility to have effective controls 7 to prevent diversion. 8 Q. What's your understanding of 9 what that means? 10 MR. NICHOLAS: Object to the 11 form. I object to the question. 12 It's too big. 13 THE WITNESS: I guess -- 14 that's an overarching statement. 15 If you can clarify what 16 instances within the Code of 17 Federal Regulations you're 18 referring to with the effective 19 controls, there's several 20 different areas in there. 21 MR. PIFKO: We're going to 22 have to not have any speaking 23 objections. Saying "too big" is 24 not an objection, and it's</p>	<p>Page 26</p> <p>1 MR. PIFKO: Well, if you 2 tell the witness the question is 3 too big and then he responds, I 4 don't know how to answer it, it's 5 too big, then we've got a problem 6 here because you're telling him 7 what to say. 8 Do you understand? 9 MR. NICHOLAS: No, I'm not 10 telling him what to say. I'm 11 making an objection. So why don't 12 you just go ahead? 13 MR. PIFKO: I hope that we 14 can have compliance with the rules 15 here. And understanding that 16 we're going to be doing that, I'm 17 going to proceed. 18 BY MR. PIFKO: 19 Q. You have a duty to maintain 20 effective controls to prevent against 21 diversion, correct? 22 A. Correct. 23 Q. Do you understand what that 24 means?</p>
<p>1 obviously influencing the 2 witness's testimony. 3 So you can state your 4 objection with clarity. You can 5 state form or foundation. But 6 that's all you can do, okay? 7 MR. NICHOLAS: Mark, I 8 appreciate the instruction, but 9 I'm going to have to handle my own 10 objections the way I see fit. 11 MR. PIFKO: If you're going 12 to be coaching the witness 13 throughout the day, we're going to 14 stop the deposition, we're going 15 to seek sanctions and we're going 16 come back here. 17 Do you understand that? 18 MR. NICHOLAS: You can do 19 whatever you think you need to do. 20 I'm not coaching the witness. I'm 21 stating what I think are 22 appropriate objections in the 23 appropriate manner. And you can 24 proceed.</p>	<p>Page 27</p> <p>1 A. Yes, I understand what that 2 means. 3 Q. What is your understanding 4 of what that means? 5 A. We have to have effective 6 controls to prevent diversion, both on 7 the physical security operational side, 8 as well as ensuring we only distribute to 9 licensed entities, and a duty to report 10 suspicious orders. 11 Q. You mentioned there, "duty 12 to report suspicious orders." 13 If I refer to that as the 14 "reporting requirement," do you have an 15 understanding of that? 16 A. If you are referring to the 17 regulation that we have to design and 18 operate a system to identify suspicious 19 orders and report those suspicious orders 20 to DEA, yes. 21 Q. Okay. So at various points 22 today we might refer to that as the 23 "reporting requirement." 24 Will you understand that?</p>

Page 30	Page 32
<p>1 A. Yes. If that's the 2 definition we're going to go with, yes. 3 Q. Okay. There's also a 4 requirement to provide records of all 5 your shipments through the ARCOS system. 6 Are you familiar with that? 7 A. Only certain drugs are 8 within the -- are considered ARCOS 9 products. So not all controlled 10 substances are reported through ARCOS. 11 Q. Fair enough. 12 But to the extent a 13 substance is under the requirement to 14 report to ARCOS, you understand that 15 there's an obligation to do so, correct? 16 A. Yes. 17 Q. Okay. You understand that 18 the reporting to ARCOS is different than 19 the reporting of a suspicious order, 20 correct? 21 A. Yes. 22 Q. So complying with the ARCOS 23 requirement does not equate to compliance 24 with the suspicious order reporting</p>	<p>1 well? 2 A. I don't -- I don't think 3 there's a requirement not to ship. We do 4 not ship suspicious orders. 5 Q. So it's your position that 6 there's no requirement under the law to 7 not ship a suspicious order? 8 A. Not that I know of. 9 Q. You testified in the West 10 Virginia Attorney General litigation in 11 2016, correct? 12 A. Yes. 13 Q. Let's back up for a second. 14 When we talk about this idea 15 to prevent diversion, do you have an 16 understanding of why there is such a 17 requirement? 18 MR. NICHOLAS: Object to the 19 form. 20 THE WITNESS: There's 21 certain -- as a distributor, the 22 DEA outlines certain requirements 23 that distributors -- I'll speak as 24 for a distributor -- has to adhere</p>
<p>1 requirement. 2 Do you understand that? 3 A. Yes. 4 Q. Have you heard of the 5 shipping requirement? 6 A. No. 7 Q. Are you familiar with the 8 Masters Pharmaceutical case? 9 A. I've seen it, yes. 10 Q. Are you aware that that case 11 discusses something called the shipping 12 requirement? 13 A. I've seen that reference to 14 shipping requirement. 15 Q. Do you know what that is? 16 A. No. 17 Q. You have no understanding of 18 what the shipping requirement is? 19 A. I've never seen it in the 20 Code of Federal Regulations. 21 Q. Do you understand that in 22 addition to reporting a suspicious order 23 to the DEA, AmerisourceBergen is required 24 to -- not to ship a suspicious order as</p>	<p>1 to in order to maintain effective 2 controls to prevent diversion. 3 And those are the -- those 4 are the regulations that our 5 company follows, and those are the 6 ones we have implemented in order 7 to maintain our registration. 8 BY MR. PIFKO: 9 Q. Right. So what I'm trying 10 to understand is, do you have an 11 understanding about what the purpose is 12 of those rules? 13 MR. NICHOLAS: Object to the 14 form. 15 THE WITNESS: The purpose is 16 to maintain effective controls 17 within the distribution center. 18 BY MR. PIFKO: 19 Q. And why do we want to do 20 that? 21 MR. NICHOLAS: Object to the 22 form. 23 THE WITNESS: Because those 24 are the requirements of the</p>

1 regulations. 2 BY MR. PIFKO: 3 Q. Do you have an understanding 4 about why those are the requirements of 5 the regulations? 6 MR. NICHOLAS: Object to the 7 form. 8 THE WITNESS: Those are the 9 regulations that we have to follow 10 in order to keep our registration. 11 To be a distributor, you have to 12 meet those requirements in the 13 regulations. 14 BY MR. PIFKO: 15 Q. Are you familiar with the 16 scheduling system of controlled 17 substances? 18 A. I understand that there's 19 Schedules 1 through IV, yes. 20 Q. Do you know what a Schedule 21 I substance is? 22 A. I believe -- I don't know 23 the official, but it's no -- I believe it 24 references there's no medical purpose.	Page 34 1 Schedule II substance has a high 2 potential for abuse? 3 MR. NICHOLAS: Object to the 4 form. 5 THE WITNESS: I don't know 6 that. But it's a Schedule II. 7 BY MR. PIFKO: 8 Q. What do you mean by, "I 9 don't know that but it's a Schedule II"?
1 Q. How about Schedule II, do 2 you know what a Schedule II substance is? 3 A. It's a Schedule II 4 controlled substance, yes. 5 Q. But what's -- what are 6 attributes of a Schedule II substance -- 7 MR. NICHOLAS: Object. 8 BY MR. PIFKO: 9 Q. -- based on your 10 understanding? 11 MR. NICHOLAS: Object to the 12 form. 13 Go ahead. 14 THE WITNESS: The Schedule 15 II, III, IV, V are all scheduled 16 as to their potential for abuse. 17 BY MR. PIFKO: 18 Q. Do you understand that a 19 Schedule II substance has a high 20 potential for abuse? 21 A. It's higher than III and IV 22 and V. 23 Q. Do you understand that the 24 United States government has said that a	Page 36 1 Schedule II substance has a high 2 potential for abuse? 3 MR. NICHOLAS: Object to the 4 form. 5 THE WITNESS: I don't know 6 that. But it's a Schedule II. 7 BY MR. PIFKO: 8 A. You asked if I knew whether 9 the government stated -- I don't know if 10 the government stated that. But I know, 11 by it being a Schedule II, it has a high 12 potential of abuse. 13 Q. So you do know that a 14 Schedule II substance has a high 15 potential for abuse, correct? 16 A. That's why it's a Schedule 17 II. 18 Q. And you know that this case 19 primarily concerns Schedule II 20 substances? 21 A. I don't know -- I don't know 22 that. Page 35 1 Q. We'll get into that. 2 A. Okay. 3 Q. Do you know what a Schedule 4 III substance is? 5 A. It's a controlled substance 6 that has a -- that has a potential of 7 abuse but not as high as a Schedule II. 8 Q. So a Schedule I -- Schedule 9 II substance has a high potential for 10 abuse and a Schedule III substance has a 11 potential for abuse but may be less high 12 than Schedule II, correct? 13 A. Correct. 14 Q. You understand that this 15 case concerns opioid products, correct? 16 A. Correct. 17 Q. Do you know what an opioid 18 product is? 19 A. A product that contains 20 opioid. 21 Q. Do you know what the word 22 "opioid" means? 23 A. I believe that's the active 24 ingredient in the drug.

Page 38	Page 40
<p>1 Q. Do you know what the active 2 ingredient in morphine is?</p> <p>3 A. I don't know.</p> <p>4 Q. The word "opiate," it 5 derives from opium. 6 Do you understand that?</p> <p>7 A. Yes.</p> <p>8 Q. Opium comes from a poppy 9 flower. 10 Do you understand that?</p> <p>11 A. I understand that, yes.</p> <p>12 Q. So a product that is an 13 opioid is derived from the opium. 14 Do you have an understanding 15 of that?</p> <p>16 MR. NICHOLAS: Objection.</p> <p>17 THE WITNESS: I don't know 18 the medical makeup and how -- of 19 how an opioid is manufactured. I 20 don't know that.</p> <p>21 BY MR. PIFKO:</p> <p>22 Q. But you understand that the 23 active ingredient is derived from some 24 opiate-like substance?</p>	<p>1 A. Yes.</p> <p>2 Q. When we use the word 3 "diversion," do you have an understanding 4 about what that means?</p> <p>5 A. It depends on the context.</p> <p>6 Q. In the context of The 7 Controlled Substances Act.</p> <p>8 MR. NICHOLAS: Object to the 9 form.</p> <p>10 THE WITNESS: So diversion 11 is that a drug that's -- well, 12 again, it depends. Even with 13 controlled substances, it could 14 be -- it could have several 15 different meanings. So if it's 16 diverted from theft, it could be a 17 diversion because of a bad 18 prescription.</p> <p>19 It's when a drug -- I've 20 seen it referenced as a drug that 21 leaves the normal distribution 22 channels.</p> <p>23 BY MR. PIFKO:</p> <p>24 Q. Okay. What's the normal</p>
<p>1 MR. NICHOLAS: Objection. 2 Asked and answered.</p> <p>3 THE WITNESS: I know it's an 4 opioid. I don't know the 5 derivatives.</p> <p>6 BY MR. PIFKO:</p> <p>7 Q. Can you name any substances 8 that you understand to be classified as 9 an opioid?</p> <p>10 A. Oxycodone, hydrocodone are 11 the two major ones.</p> <p>12 Q. Any others?</p> <p>13 A. I know those for sure. I 14 don't want to speculate on some of the 15 others.</p> <p>16 Q. Do you have an understanding 17 that at certain relevant time periods in 18 this case certain hydrocodone combination 19 products were classified as Schedule III 20 substances?</p> <p>21 A. Yes.</p> <p>22 Q. And they were later 23 reclassified as a Schedule II substance. 24 Do you understand that?</p>	<p>1 distribution channel?</p> <p>2 A. That -- the closed system of 3 manufacture to DEA registrant distributor 4 to DEA registrant dispenser.</p> <p>5 Q. Do you have an understanding 6 about what the closed system is?</p> <p>7 MR. NICHOLAS: Object to the 8 form.</p> <p>9 THE WITNESS: The closed 10 system as it pertains to?</p> <p>11 BY MR. PIFKO:</p> <p>12 Q. Well, you just used it in 13 your answer, so I want to know what you 14 were referring to.</p> <p>15 A. The closed system of 16 controlled substances? I just want to 17 make sure I understand your question.</p> <p>18 Q. You talked about a drug 19 leaving the normal channels within the 20 closed system. So I'm trying to 21 understand what you meant by "closed 22 system."</p> <p>23 A. I said distribution channel, 24 I didn't say closed system.</p>

	Page 42	Page 44
<p>1 Q. I think you said within the 2 closed system, or something to that 3 effect.</p> <p>4 A. I thought I said 5 distribution channel.</p> <p>6 Q. We don't need to fight about 7 what you said or didn't say.</p> <p>8 What I just want to know, 9 your -- do you have an understanding 10 about what the closed system is under The 11 Controlled Substances Act?</p> <p>12 MR. NICHOLAS: Object to the 13 form.</p> <p>14 THE WITNESS: The closed 15 system, as I've heard it referred 16 to, is that the DEA sets the 17 quotas of how much product can be 18 produced, then manufactured; those 19 products are transferred to the 20 distributor through ARCOS, which 21 is maintained -- transferred to 22 the distributor.</p> <p>23 And then the distributor 24 transfers to the pharmacy or the</p>		<p>1 BY MR. PIFKO: 2 Q. Well, you said that that's 3 the legitimate one, the one you just 4 described, correct? 5 A. That's the -- you asked me 6 what the closed distribution was, and 7 that's what the closed distribution is. 8 Q. And you understand that your 9 duty to prevent diversion is to prevent 10 applicable controlled substances from 11 exiting that system? 12 MR. NICHOLAS: Object to the 13 form.</p> <p>14 THE WITNESS: Our 15 responsibility is to ensure that 16 we distribute FDA-approved drugs 17 from the -- that we maintain in 18 our distribution centers to 19 licensed entities.</p> <p>20 BY MR. PIFKO: 21 Q. And what do you mean by 22 "licensed entities"?</p> <p>23 A. Pharmacies, hospitals, DEA 24 registrants and State Board of Pharmacy</p>
<p>1 dispenser with an ARCOS 2 transaction, which closes the 3 distribution, as far as DEA 4 tracking goes.</p> <p>5 BY MR. PIFKO: 6 Q. So there are legitimate 7 channels of distribution within that 8 system, correct?</p> <p>9 MR. NICHOLAS: Object to the 10 form.</p> <p>11 THE WITNESS: That is the -- 12 that is the legitimate 13 distribution channel.</p> <p>14 BY MR. PIFKO: 15 Q. Okay. And then there could 16 be -- a channel of distribution outside 17 of that system, that would be 18 illegitimate, correct?</p> <p>19 MR. NICHOLAS: Object to the 20 form.</p> <p>21 THE WITNESS: I can't say 22 what type of other distribution. 23 I can only comment on our 24 distribution system.</p>	Page 43	Page 45
		<p>1 registrants. 2 Q. And you understand that 3 those registrants also have duties to 4 maintain effective controls as well? 5 MR. NICHOLAS: Object to the 6 form.</p> <p>7 THE WITNESS: They have 8 their own regulations that they 9 must follow, correct.</p> <p>10 BY MR. PIFKO: 11 Q. So the idea of preventing 12 diversion is to prevent substances from 13 getting into illegal hands, correct? 14 MR. NICHOLAS: Object to the 15 form.</p> <p>16 THE WITNESS: Each 17 registrant has its 18 responsibilities to maintain 19 effective controls to prevent 20 diversion. We maintain those 21 within our registrant's capacity, 22 correct.</p> <p>23 BY MR. PIFKO: 24 Q. Can you give me an example</p>

<p>1 of diversion?</p> <p>2 MR. NICHOLAS: Objection.</p> <p>3 Object to the form.</p> <p>4 THE WITNESS: As I stated,</p> <p>5 diversion can be many different</p> <p>6 things. So I need some more</p> <p>7 clarification of what type of</p> <p>8 diversion you're talking about.</p> <p>9 BY MR. PIFKO:</p> <p>10 Q. Let's make it specific to</p> <p>11 the issues in this case.</p> <p>12 So, again, you understand</p> <p>13 this case concerns opioid products,</p> <p>14 correct?</p> <p>15 A. Correct.</p> <p>16 Q. And those are, for the most</p> <p>17 part, Schedule II substances under The</p> <p>18 Controlled Substances Act, correct?</p> <p>19 A. Correct.</p> <p>20 Q. Okay. Can you give me an</p> <p>21 example of what it means to have an</p> <p>22 opioid product diverted, as we were</p> <p>23 talking about this under The Controlled</p> <p>24 Substances Act?</p>	<p>Page 46</p> <p>1 Q. Well, it's your -- among the</p> <p>2 responsibilities you have with the</p> <p>3 company, one of them is to manage the</p> <p>4 company's efforts to maintain effective</p> <p>5 controls against diversion, correct?</p> <p>6 A. Correct.</p> <p>7 Q. And so I understand that</p> <p>8 maybe there might be several examples,</p> <p>9 but I'd like to get your understanding of</p> <p>10 the types of situations we're talking</p> <p>11 about here.</p> <p>12 So you talked about sale to</p> <p>13 an unlicensed --</p> <p>14 MR. NICHOLAS: I'm going</p> <p>15 to -- I want to interpose an</p> <p>16 objection. This is not coaching,</p> <p>17 but the question is tremendously</p> <p>18 broad.</p> <p>19 MR. PIFKO: You can say</p> <p>20 broad as an objection.</p> <p>21 "Tremendously" is not necessary.</p> <p>22 That's -- we're good here.</p> <p>23 MR. NICHOLAS: Okay. Broad.</p> <p>24 So I would ask you to narrow it.</p>
<p>Page 47</p> <p>1 MR. NICHOLAS: Object to the</p> <p>2 form.</p> <p>3 THE WITNESS: There's a lot</p> <p>4 of different ways drugs can be</p> <p>5 diverted from our distribution</p> <p>6 center. Diversion could be if</p> <p>7 we -- if we, not ABC -- but if a</p> <p>8 company diverted product to an</p> <p>9 unlicensed location, a</p> <p>10 nonregistered location, that could</p> <p>11 be diversion.</p> <p>12 BY MR. PIFKO:</p> <p>13 Q. Any other --</p> <p>14 MR. NICHOLAS: Object to the</p> <p>15 form.</p> <p>16 THE WITNESS: I'm not going</p> <p>17 to sit here and try to list all</p> <p>18 the areas that could be -- where</p> <p>19 diversion could occur, because we</p> <p>20 could be here for a long time.</p> <p>21 And that's why you have</p> <p>22 effective controls to prevent</p> <p>23 diversion.</p> <p>24 BY MR. PIFKO:</p>	<p>Page 49</p> <p>1 MR. PIFKO: Your objection</p> <p>2 is noted.</p> <p>3 MR. NICHOLAS: The witness</p> <p>4 has asked you to narrow it.</p> <p>5 BY MR. PIFKO:</p> <p>6 Q. So you're the person from</p> <p>7 AmerisourceBergen who is responsible for</p> <p>8 ensuring compliance with The Controlled</p> <p>9 Substances Act requirement to maintain</p> <p>10 effective controls against diversion,</p> <p>11 correct?</p> <p>12 A. Yes.</p> <p>13 Q. And so I'd like an example,</p> <p>14 a bunch of examples, of what diversion</p> <p>15 is, from you.</p> <p>16 MR. NICHOLAS: Same</p> <p>17 objection.</p> <p>18 Go ahead.</p> <p>19 THE WITNESS: So what we do</p> <p>20 to prevent diversion is --</p> <p>21 BY MR. PIFKO:</p> <p>22 Q. I'm not asking what you do</p> <p>23 to prevent diversion --</p> <p>24 MR. NICHOLAS: Hold on.</p>

	Page 50		Page 52
1 BY MR. PIFKO:		1 and I'll rephrase it. And we'll work	
2 Q. -- just an example of what		2 through it. But I would appreciate your	
3 diversion is.		3 testimony in responding to exactly the	
4 MR. NICHOLAS: Hold on.		4 questions that I ask.	
5 Let's stay on the record.		5 Do we have an agreement	
6 You can't interrupt him when		6 about that?	
7 he's answering the question.		7 MR. NICHOLAS: Objection.	
8 MR. PIFKO: He needs to		8 Because he's been doing that.	
9 answer the question asked. I		9 THE WITNESS: I'm trying to	
10 don't -- we're not going to have		10 answer your question, but you	
11 speeches where he talks about		11 won't let me give my -- I did	
12 things that aren't asked.		12 state that there's a lot of	
13 MR. NICHOLAS: You didn't		13 different areas where diversion	
14 hear his answer. He said five		14 could occur.	
15 words, and you interrupted him.		15 And you asked for a list of	
16 MR. PIFKO: He said what we		16 them. I'm going to tell you how	
17 do to prevent diversion. And		17 we prevent diversion and then from	
18 that's not what I asked. I asked		18 that area, anywhere in there, a	
19 what diversion is.		19 diversion can occur.	
20 MR. NICHOLAS: Those were		20 And that's how I was going	
21 his first five words. You're		21 to answer the question.	
22 going to have to let him answer		22 So we first have physical	
23 the question.		23 security controls to prevent	
24 You're going to have to		24 diversion; we have cages and	
	Page 51		Page 53
1 let -- you ask a question, the		1 vaults that are required by the	
2 witness is then entitled to say		2 CFR.	
3 what he wants in answering the		3 We have -- we do background	
4 question.		4 checks on our employees. We do	
5 MR. PIFKO: He's not		5 due diligence of our customers to	
6 entitled to say anything he wants,		6 ensure that they're licensed and	
7 he's entitled to answer the		7 in good standing with the DEA and	
8 question.		8 Boards of Pharmacy.	
9 MR. NICHOLAS: No, he's		9 So there's a whole host of	
10 entitled to say what he wants --		10 things that we do within the -- as	
11 what he believes is answering the		11 a licensed distributor, to prevent	
12 question, and then you can ask		12 diversion.	
13 another question. So don't		13 If we weren't doing those	
14 interrupt him again, please.		14 things, diversion could occur at	
15 BY MR. PIFKO:		15 any one of those steps. So if we	
16 Q. I'm sure that in preparing		16 didn't --	
17 for this deposition, your counsel told		17 BY MR. PIFKO:	
18 you to listen to the question. So I want		18 Q. That's not the question I	
19 you to be very careful and listen to the		19 asked. I asked you to give examples of	
20 questions that I ask, okay?		20 diversion. You're giving me examples of	
21 Do you understand that?		21 prevention of diversion and that's not	
22 A. Yes.		22 the question that was asked.	
23 Q. And so, again, if you don't		23 MR. NICHOLAS: I object.	
24 understand a question, you let me know,		24 BY MR. PIFKO:	

<p style="text-align: right;">Page 54</p> <p>1 Q. We'll go through it -- we'll 2 go through it again. 3 So let's talk about 4 diversion of a Schedule II controlled 5 substance at a pharmacy. 6 Can you explain what 7 potential areas of diversion are in that 8 context?</p> <p>9 MR. NICHOLAS: Object to the 10 form.</p> <p>11 THE WITNESS: I'm not 12 responsible for the diversion that 13 occurs within a pharmacy. If a 14 pharmacy has -- is filling 15 prescriptions that are invalid or 16 if a pharmacy is selling 17 prescriptions -- not 18 prescriptions -- or diverting 19 drugs out the back door, you know, 20 I have no eyes to that.</p> <p>21 BY MR. PIFKO:</p> <p>22 Q. Okay. But those are some 23 examples of a pharmacy filling 24 prescriptions or selling controlled</p>	<p style="text-align: right;">Page 56</p> <p>1 the pharmacy. 2 BY MR. PIFKO: 3 Q. Do you understand why we 4 want to prevent these diversion 5 activities to occur? 6 MR. NICHOLAS: Object to the 7 form. Asked and answered. 8 THE WITNESS: When you say 9 "we," I'm not understanding your 10 question of who is the "we." 11 BY MR. PIFKO: 12 Q. We're all Americans here, 13 and the law is a law of the American 14 jurisprudence, and it's requiring that. 15 And so when I say "we," I mean the people 16 of the United States. 17 So the question is, do you 18 understand why, when enacting that law, 19 we want to prevent diversion in the way 20 we just described? 21 MR. NICHOLAS: Well, I'll 22 object to the form of that 23 question. 24 THE WITNESS: That's why</p>
<p style="text-align: right;">Page 55</p> <p>1 substances without a valid prescription, 2 that would be a diversion, correct? 3 A. As it stands -- is my 4 understanding, yes. 5 Q. And if -- you said if 6 there's -- the pills are flowing out the 7 back door without being sold to anyone or 8 theft, or something like that, that would 9 be diversion, correct? 10 A. That could be a type of 11 diversion, yes. 12 Q. What about a prescription 13 that's written by a doctor who doesn't 14 have a valid DEA registration, is that -- 15 if someone sells pills to somebody who 16 has that kind of a prescription, is that 17 diversion? 18 MR. NICHOLAS: Object to the 19 form. 20 THE WITNESS: That would be 21 the responsibility of the 22 pharmacy. I mean, the distributor 23 has no line of sight on the doctor 24 who is writing prescriptions to</p>	<p style="text-align: right;">Page 57</p> <p>1 there's DEA regulations, because 2 of the -- to prevent diversion. 3 BY MR. PIFKO: 4 Q. And is diversion a good 5 thing? 6 MR. NICHOLAS: Object to the 7 form. 8 THE WITNESS: Is diversion a 9 good thing? I don't think so. 10 BY MR. PIFKO: 11 Q. Why not? 12 MR. NICHOLAS: Objection. 13 Object to the form. 14 THE WITNESS: In the context 15 of -- in the context of diversion 16 from a licensed entity, that's -- 17 that's not good. 18 BY MR. PIFKO: 19 Q. And why not? 20 A. Because it's in violation of 21 the regulation. 22 Q. Is there -- other than it 23 violating the regulation, is there any 24 impact of diversion?</p>

<p style="text-align: right;">Page 58</p> <p>1 MR. NICHOLAS: Object to the 2 form. 3 THE WITNESS: I'm -- I'm not 4 understanding your question. 5 If there's diversion of the 6 product, that's -- as I indicated, 7 that's against the regulations. 8 That's a bad thing. 9 BY MR. PIFKO: 10 Q. What I'm trying to 11 understand is, these are situations that 12 the regulations are designed to prevent 13 from occurring, correct? 14 A. Yes. 15 Q. And I'm trying to understand 16 why is it that we would have regulations 17 to prevent these things from occurring. 18 Do you have an understanding 19 of that? 20 MR. NICHOLAS: I'll object 21 to the form. 22 THE WITNESS: It's the same 23 reason why we have regulations for 24 the approval of the drugs, of how</p>	<p style="text-align: right;">Page 60</p> <p>1 Q. I'm going to give you an 2 opportunity to speak. 3 But what I'm hearing -- and 4 so you correct me if I'm wrong, but what 5 I'm hearing from you is that 6 AmerisourceBergen Corporation has zero 7 understanding of why we should stop 8 diversion under The Controlled Substances 9 Act? 10 MR. NICHOLAS: I'll object 11 to the form of the question. 12 That's a false statement. 13 THE WITNESS: That's not 14 what I'm saying. 15 BY MR. PIFKO: 16 Q. The jury is watching the 17 video and that's what they're seeing, 18 because that's what I'm seeing. 19 MR. NICHOLAS: You don't 20 need to grandstand with references 21 to the jury -- 22 MR. PIFKO: And I -- 23 MR. NICHOLAS: -- just ask 24 the questions.</p>
<p style="text-align: right;">Page 59</p> <p>1 you store and manage the drugs and 2 how -- you know, that's the basis 3 of our system. 4 BY MR. PIFKO: 5 Q. And what is the reason for 6 that? 7 MR. NICHOLAS: This has been 8 asked and answered about seven or 9 eight times now. I will object. 10 THE WITNESS: The reason is 11 to have effective controls to 12 prevent diversion. I think I've 13 said that several times. 14 BY MR. PIFKO: 15 Q. And why do we want to 16 prevent diversion? 17 MR. NICHOLAS: Objection. 18 Asked and answered. You're asking 19 the same question again and again. 20 And he's answering it again and 21 again. 22 THE WITNESS: What's the 23 question one more time? I mean -- 24 BY MR. PIFKO:</p>	<p style="text-align: right;">Page 61</p> <p>1 BY MR. PIFKO: 2 Q. I genuinely would like a 3 response. And I'm sure that you can 4 provide an answer. I'm trying to get 5 that from you. 6 MR. NICHOLAS: The witness 7 has been providing an answer. 8 You can go ahead. 9 THE WITNESS: And what was 10 that, I mean, your last statement, 11 that AmerisourceBergen has -- 12 BY MR. PIFKO: 13 Q. So I've asked you, why do we 14 want to prevent diversion? And what I'm 15 hearing back is, that's what the rule is. 16 And I'm trying to 17 understand, is it AmerisourceBergen's 18 position in this litigation that other 19 than following the rules, there's no 20 reason, it has no understanding of why 21 we're trying to prevent diversion? 22 MR. NICHOLAS: Object to the 23 form of the question. 24 THE WITNESS: I think I've</p>

Page 62	Page 64
<p>1 answered the question, and I -- 2 your understanding or your 3 statement that we don't have any 4 other intent other than following 5 the regulations is incorrect.</p> <p>6 I mean, there's rules and 7 regulations in place for the 8 proper manufacture, distribution, 9 dispensing of, in this case, 10 controlled substances.</p> <p>11 And that's because these 12 items, the opioids, you said, have 13 a potential for abuse. So you 14 have to have additional 15 requirements to make sure you're 16 handling them properly.</p> <p>17 And each registrant in the 18 channel has a responsibility. ABC 19 has our responsibilities. We take 20 them very seriously. We make sure 21 we only buy them from 22 manufacturers. We store them 23 properly. We make sure they're 24 checked, double-checked,</p>	<p>1 Q. We'll establish -- 2 MR. NICHOLAS: Hold on. 3 BY MR. PIFKO: 4 -- we're going to establish 5 that later.</p> <p>6 MR. NICHOLAS: I'm going to 7 object to that and move to strike 8 the mischaracterization and the 9 inappropriate characterization 10 slander in the testimony.</p> <p>11 Proceed, but please don't -- 12 MR. PIFKO: I -- 13 MR. NICHOLAS: Please don't 14 tell him he's making false 15 statements.</p> <p>16 BY MR. PIFKO: 17 Q. I think we were getting 18 closer there when you said we want to 19 prevent diversion because these drugs 20 have a potential for high abuse. 21 You said that, correct? 22 MR. NICHOLAS: Object to the 23 form. 24 Go ahead.</p>
<p>1 triple-checked. We make sure 2 they're stored appropriately in 3 cages and vaults. We vet our 4 employees. We train our 5 employees. We vet our customers. 6 And we take it very 7 seriously. So we only distribute 8 products to those pharmacies and 9 dispensers and hospitals that are 10 in good standing with DEA and the 11 Board of Pharmacy. So we adhere 12 to our requirements. 13 Those drugs aren't diverted 14 while they're under our control. 15 I don't know how much more clearly 16 I can state that.</p> <p>17 BY MR. PIFKO: 18 Q. We'll get into that later. 19 There's a lot of misstatements in your 20 thing, but we don't have to argue about 21 that.</p> <p>22 MR. NICHOLAS: I'll object 23 to that and --</p> <p>24 BY MR. PIFKO:</p>	<p>1 THE WITNESS: Again, I 2 don't -- we, as distributors, 3 don't -- don't identify what drugs 4 are -- have high abuse. That's 5 done by DEA and FDA. 6 We have a -- we are a 7 distributor, we have our 8 requirements that we must follow 9 to protect those drugs while 10 they're under our control. And we 11 take that very seriously and we do 12 that. 13 I'm not understanding what 14 more you want from me, other than 15 our regulatory and our obligations 16 to protect and ensure those drugs 17 are not diverted while under our 18 control.</p> <p>19 BY MR. PIFKO: 20 Q. And you want to ensure that 21 they're not diverted while they're under 22 your control because they have a high 23 potential -- whether you said it or 24 not -- because they have a high potential</p>

<p style="text-align: right;">Page 66</p> <p>1 for abuse under the system; is that 2 correct?</p> <p>3 MR. NICHOLAS: Object to the 4 form of the question.</p> <p>5 THE WITNESS: Because they 6 are a controlled substance and 7 because they're a prescription 8 product.</p> <p>9 We treat our prescription 10 drugs with the same manner as the 11 opioids. I mean, we have 12 additional controls, depending 13 upon whether it's Schedule II or 14 III through IV, whether they're in 15 a vault or a cage.</p> <p>16 But we protect all the 17 product, we prevent diversion from 18 all products.</p> <p>19 BY MR. PIFKO:</p> <p>20 Q. Do you have an understanding 21 that we want to prevent the unlawful 22 distribution of opioids to protect the 23 public health?</p> <p>24 MR. NICHOLAS: Objection.</p>	<p style="text-align: right;">Page 68</p> <p>1 have an understanding that you're 2 required to prevent diversion of opioid 3 products to protect the public health?</p> <p>4 MR. NICHOLAS: Objection.</p> <p>5 The witness is not required to 6 answer yes or no. And he has 7 answered the question.</p> <p>8 THE WITNESS: And I -- I -- 9 I think I stated what our 10 obligations are under the 11 requirements.</p> <p>12 BY MR. PIFKO:</p> <p>13 Q. I'm not asking what your 14 obligations are under the requirements. 15 I'm asking you if the 16 company understands that the reason for 17 preventing diversion of opioid products 18 is, in part, to protect public health?</p> <p>19 MR. NICHOLAS: I'll object 20 to the form of the question. And 21 add as a basis at this point that 22 I don't believe any of this is 23 covered in any of the topics of 24 your 30(b)(6) notice.</p>
<p style="text-align: right;">Page 67</p> <p>1 Object to the form.</p> <p>2 THE WITNESS: Can you state 3 that question again, please?</p> <p>4 BY MR. PIFKO:</p> <p>5 Q. Do you have an understanding 6 that you're required to prevent diversion 7 of opioid products to protect the public 8 health?</p> <p>9 MR. NICHOLAS: Object to the 10 form.</p> <p>11 THE WITNESS: I understand 12 that we have an obligation to have 13 effective controls to prevent 14 diversion because of our 15 regulatory responsibilities and 16 duties. And that's what we 17 implement.</p> <p>18 I'm not here to comment 19 on --</p> <p>20 BY MR. PIFKO:</p> <p>21 Q. That's not -- you can answer 22 yes or no. That wasn't an answer to my 23 question.</p> <p>24 So my question is, do you</p>	<p style="text-align: right;">Page 69</p> <p>1 So we're way far afield 2 here.</p> <p>3 THE WITNESS: And I'm not -- 4 I don't want to comment on what 5 our duty is to public health.</p> <p>6 BY MR. PIFKO:</p> <p>7 Q. So you have no comment about 8 whether you have a duty to protect public 9 health? Is that your answer?</p> <p>10 A. We have a duty to have 11 effective controls to prevent diversion 12 as the products are within our 13 distribution channel.</p> <p>14 And we have a duty to ensure 15 that we only sell products to licensed 16 pharmacies and dispensers and hospitals. 17 And that is our duty.</p> <p>18 Q. In carrying out your duty to 19 prevent diversion, does AmerisourceBergen 20 consider the impact on the public?</p> <p>21 MR. NICHOLAS: Object to the 22 form of the question. This is not 23 in your notice. You're way far 24 afield. You've asked this</p>

<p style="text-align: right;">Page 70</p> <p>1 question many, many times. And 2 it's been answered.</p> <p>3 THE WITNESS: I think I said 4 what I feel our duty is, to ensure 5 we have proper controls to prevent 6 diversion while the drugs are 7 within our control.</p> <p>8 BY MR. PIFKO:</p> <p>9 Q. You're not answering the 10 question. I didn't ask you what your 11 duty was.</p> <p>12 I asked you if, in carrying 13 out your duty, does AmerisourceBergen 14 consider the impact on the public?</p> <p>15 MR. NICHOLAS: Object to the 16 form of the question. He has been 17 answering the question a number of 18 times. I suggest that we move on.</p> <p>19 THE WITNESS: I think I've 20 answered the question.</p> <p>21 BY MR. PIFKO:</p> <p>22 Q. You haven't. It's very 23 clear, you have not answered the 24 question.</p>	<p style="text-align: right;">Page 72</p> <p>1 answer to a question that's not being 2 asked. Let's start over here. 3 I'm trying to ask, does 4 AmerisourceBergen consider public health 5 when it's carrying out its duty to 6 prevent diversion?</p> <p>7 MR. NICHOLAS: Object to the 8 form of the question. Asked and 9 answered. Outside the scope of 10 the notice.</p> <p>11 THE WITNESS: We consider 12 our responsibilities that we're 13 obligated to follow to ensure that 14 products are handled 15 appropriately, safely and securely 16 within the supply channel under 17 our control.</p> <p>18 BY MR. PIFKO:</p> <p>19 Q. Is public health one of 20 those considerations?</p> <p>21 MR. NICHOLAS: Object to the 22 form of the question. Come on.</p> <p>23 THE WITNESS: It's not 24 something that -- our</p>
<p style="text-align: right;">Page 71</p> <p>1 MR. NICHOLAS: Object. 2 That's just a statement. There's 3 nothing for you to say right now.</p> <p>4 MR. PIFKO: Yeah, there is. 5 I've --</p> <p>6 MR. NICHOLAS: There's no 7 question pending.</p> <p>8 MR. PIFKO: -- I've asked 9 the question and we haven't had an 10 answer. I've been trying to ask 11 it for the last ten minutes.</p> <p>12 THE WITNESS: And I've 13 answered --</p> <p>14 MR. PIFKO: And I still 15 haven't gotten an answer --</p> <p>16 THE WITNESS: -- the 17 question of what our 18 responsibilities are.</p> <p>19 BY MR. PIFKO:</p> <p>20 Q. I'm not asking you -- but 21 that's not what the question is.</p> <p>22 A. That's my answer.</p> <p>23 Q. You're not answering the 24 question. You can't just make up an</p>	<p style="text-align: right;">Page 73</p> <p>1 consideration is how we -- who we 2 purchase the products from, how we 3 store the products and who we 4 distribute those products to. 5 We don't have any effect on 6 the public health through 7 prescriptions that are being 8 written, the pharmacies that are 9 filling them. We have no control 10 over that.</p> <p>11 Our responsibility is, in 12 the supply chain, is to ensure 13 that we buy FDA-approved drugs, we 14 keep them securely and we give 15 them to those that dispense those 16 drugs.</p> <p>17 And the duty that they have, 18 I'm not going to comment on it.</p> <p>19 And I think I've answered 20 what our responsibility is within 21 the supply chain.</p> <p>22 BY MR. PIFKO:</p> <p>23 Q. And I'm not trying to put 24 answers in your mouth. I'm trying to</p>

Page 74	Page 76
<p>1 understand what your answer is. 2 A. But that's my answer. 3 Q. But my question is, is 4 public health one of those 5 considerations? Is it or isn't it? 6 You just tell me. I'm 7 not -- you say whatever answer you want 8 to say.</p> <p>9 MR. NICHOLAS: He's answered 10 the question many, many times. 11 You keep asking him the same 12 question over and over.</p> <p>13 MR. PIFKO: He's not 14 answering the question.</p> <p>15 MR. NICHOLAS: I'll object.</p> <p>16 MR. PIFKO: You can object, 17 but he's not answering.</p> <p>18 MR. NICHOLAS: I'm 19 objecting. You're saying he's not 20 answering the question and I'm 21 saying he is and he says he is.</p> <p>22 THE WITNESS: I mean, I can 23 restate that again.</p> <p>24 BY MR. PIFKO:</p>	<p>1 selling to the public. 2 So, again, you're asking me 3 a question that doesn't apply on 4 the distribution side, because 5 we're selling it --</p> <p>6 BY MR. PIFKO:</p> <p>7 Q. I'm not asking about 8 compliance.</p> <p>9 MR. NICHOLAS: You're 10 interrupting the witness.</p> <p>11 THE WITNESS: We're buying 12 it from the manufacturer and we're 13 selling it -- we're selling it to 14 a pharmacy or hospital that has 15 obligations of who they dispense 16 those to and what prescriptions 17 they fill.</p> <p>18 We're in the middle of the 19 chain. The public health, we 20 don't deal with the public health.</p> <p>21 BY MR. PIFKO:</p> <p>22 Q. So you don't think about the 23 public health in carrying out your role 24 in the distribution chain, correct?</p>
<p>1 Q. Well, I'll represent to you, 2 you haven't said the word "public health" 3 once when you've talked about what 4 considerations come into 5 AmerisourceBergen's factors when they're 6 complying with the statutes.</p> <p>7 So I understand from that 8 that public health is not one of those 9 considerations. Is my understanding 10 correct?</p> <p>11 MR. NICHOLAS: Objection. 12 Object to the form of the 13 question. You're just bullying 14 the witness.</p> <p>15 THE WITNESS: Our role 16 within the supply chain is from 17 the manufacturer to 18 the dispenser --</p> <p>19 BY MR. PIFKO:</p> <p>20 Q. I'm not asking what your 21 role is.</p> <p>22 MR. NICHOLAS: Don't 23 interrupt him, please.</p> <p>24 THE WITNESS: We're not</p>	<p>1 Page 75</p> <p>1 MR. NICHOLAS: Object to the 2 form of the question.</p> <p>3 THE WITNESS: I've answered 4 the question several times. I 5 think I've made it clear what our 6 role is in the distribution --</p> <p>7 BY MR. PIFKO:</p> <p>8 Q. I didn't ask you what your 9 role is. That's not the question.</p> <p>10 You've got to answer the question.</p> <p>11 A. I did answer the question.</p> <p>12 Q. Do you consider public 13 health when you're carrying out your 14 duties under the statute, under The 15 Controlled Substances Act?</p> <p>16 MR. NICHOLAS: Objection. 17 I'm going to suggest that the 18 witness does not have to answer 19 this question for the millionth 20 time.</p> <p>21 MR. PIFKO: He's not. This 22 is a yes-or-no question.</p> <p>23 MR. NICHOLAS: No, it's not 24 a yes-or-no question.</p>

<p>1 MR. PIFKO: It is.</p> <p>2 MR. NICHOLAS: He does not 3 have to answer any question yes or 4 no. He's answering the question 5 the way he sees fit.</p> <p>6 BY MR. PIFKO:</p> <p>7 Q. Do you consider public 8 health when you're carrying out your 9 duties under The Controlled Substances 10 Act?</p> <p>11 MR. NICHOLAS: Asked and 12 answered. Same objections.</p> <p>13 THE WITNESS: I mean, I 14 am --</p> <p>15 BY MR. PIFKO:</p> <p>16 Q. It's a yes-or-no question.</p> <p>17 A. It's not a yes-or-no 18 question.</p> <p>19 Q. It is.</p> <p>20 A. I've explained it to you, 21 and we can go through it again, of where 22 we fit in the supply channel.</p> <p>23 Q. I didn't ask where you fit 24 in the supply channel.</p>	<p>Page 78</p> <p>1 question. We can -- I guess we can go 2 back-and-forth here for a while, but we 3 aren't -- we do not distribute to the 4 public. We distribute --</p> <p>5 Q. I didn't ask you if you 6 distribute to the public.</p> <p>7 A. I know. I'm explaining --</p> <p>8 MR. NICHOLAS: You're asking 9 about public health. He's 10 describing the public.</p> <p>11 THE WITNESS: I'm 12 explaining -- we don't sell -- the 13 public health -- we don't sell to 14 the public. We sell to the 15 pharmacies who dispense 16 prescriptions written by doctors. 17 And we buy from manufacturers.</p> <p>18 We aren't -- we do not 19 distribute to the public health. 20 And you're asking me a question --</p> <p>21 BY MR. PIFKO:</p> <p>22 Q. I didn't ask you if you 23 distribute to the public health.</p> <p>24 When you carry out your</p>	<p>Page 80</p>
<p>1 A. I know, but --</p> <p>2 MR. PIFKO: We're going to 3 call Cohen, because this is pure 4 gamesmanship.</p> <p>5 You know, sir, I asked him, 6 is public health a consideration 7 in your compliance with the 8 statute? And he won't answer. 9 He's telling me what his duties 10 are. I'm not asking. It's a 11 yes-or-no question.</p> <p>12 MR. NICHOLAS: He's answered 13 many, many times.</p> <p>14 MR. PIFKO: The court is not 15 going to appreciate answers like 16 this, okay? It's a 17 plain-and-simple situation.</p> <p>18 BY MR. PIFKO:</p> <p>19 Q. I'm asking you, does public 20 health play into your considerations when 21 you're carrying out your duties under The 22 Controlled Substances Act?</p> <p>23 It's a yes-or-no question.</p> <p>24 A. It's not a yes-or-no</p>	<p>Page 79</p> <p>1 duties to maintain effective controls, 2 I'm asking if you consider the impact of 3 them on public health when you carry out 4 your duties?</p> <p>5 A. We consider the duties and 6 we ensure that we follow those duties. 7 And that's what we consider.</p> <p>8 However you want to phrase 9 it, we can -- again, we can discuss this 10 for however long you want to spend on 11 this. But I think I'm being responsive 12 to your question. I think I've explained 13 it clearly. And it's not the answer you 14 might want.</p> <p>15 But I'm just trying to --</p> <p>16 Q. But you're not answering --</p> <p>17 I don't care. You can say yes or no. I 18 don't care what your answer is.</p> <p>19 You've just -- you've got to 20 say whether public health is a 21 consideration of the company when it's 22 carrying out its duties under The 23 Controlled Substances Act. That's all 24 I'm asking you.</p>	<p>Page 81</p>

<p style="text-align: right;">Page 82</p> <p>1 A. And I answered the question. 2 Q. You didn't. 3 A. I did answer the question. 4 Q. You never once said that 5 AmerisourceBergen considers public 6 health -- 7 A. And I explained -- 8 Q. -- when carrying out its 9 duties. 10 A. I explained our process and 11 I explained what we take into 12 consideration, where we are within the 13 supply chain. 14 Q. And you agree that public 15 health isn't one of those things? 16 MR. NICHOLAS: That is not 17 what he said. But you're just 18 arguing. I mean, why are you 19 arguing? Why don't you just ask 20 him -- 21 MR. PIFKO: I'm trying to 22 get your answer to the question. 23 MR. NICHOLAS: You have a 24 30(b)(6) notice with topics.</p>	<p style="text-align: right;">Page 84</p> <p>1 MR. NICHOLAS: I agree time 2 is being wasted by you. 3 BY MR. PIFKO: 4 Q. -- for clarity, the question 5 being asked to you: In carrying out its 6 duties to prevent diversion of Control II 7 substances under the controlled schedules 8 act -- under The Controlled Substances 9 Act, does AmerisourceBergen consider the 10 impact on the public health? 11 MR. NICHOLAS: Object to the 12 form. All my same objections. 13 THE WITNESS: Again, we 14 ensure that we have products that 15 we distribute to the pharmacies 16 that are made available to the 17 pharmacies to be able to dispense 18 to the public. 19 I'm not sure -- you're 20 asking me a question that I've 21 answered several times, given 22 where we fit in the supply 23 channel, given our 24 responsibilities. And as the head</p>
<p style="text-align: right;">Page 83</p> <p>1 MR. PIFKO: And he's burning 2 the time. We've burned 20 minutes 3 here. 4 MR. NICHOLAS: You're 5 burning the time. It's Topics A 6 through N. You haven't started on 7 a single topic. And you haven't 8 asked him -- shown him a single 9 document. 10 So who is burning the time? 11 MR. PIFKO: I'm going to ask 12 the question one more time. And 13 if I don't get an answer, we're 14 going to go and we're going to 15 call the court and we're going to 16 discuss your evasive answers here. 17 Because we're not going to be 18 doing this all day. And this 19 whole last 20 minutes does not 20 count towards my time on this 21 deposition, because you're just 22 wasting everyone's time here. 23 BY MR. PIFKO: 24 Q. So again for clarity --</p>	<p style="text-align: right;">Page 85</p> <p>1 of that department, my job is -- 2 my -- what we consider is we 3 consider that those products are 4 handled appropriately and 5 distributed in an appropriate 6 manner to the licensed entities 7 that we sell to. 8 And, you know -- 9 BY MR. PIFKO: 10 Q. Is the impact -- 11 A. That's the answer. 12 Q. -- on the public health one 13 of those considerations? 14 MR. NICHOLAS: Object to the 15 form. 16 THE WITNESS: The impact on 17 the public health is -- is the 18 whole supply channel. 19 You're asking me a question 20 that we don't interface with the 21 public. You're asking me that -- 22 we interface with the pharmacy and 23 the dispenser and we only have our 24 obligations. And our</p>

Page 86	Page 88
<p>1 understanding and our part in the 2 supply channel is in that -- in 3 that realm.</p> <p>4 We aren't in the realm of 5 the patient that's coming in or 6 the doctor writing the 7 prescription or what 8 considerations they take before 9 they write a prescription. We 10 aren't involved in any of that, 11 and nor should we be.</p> <p>12 We're responsible for making 13 sure the product gets from the 14 manufacturer to the pharmacy. And 15 we have an obligation, if there's 16 a suspicious order, to report it.</p> <p>17 We're not -- we don't have 18 an obligation to vet doctors and 19 understand patient/doctor 20 relationships and all these other 21 areas. That's not our role in the 22 supply chain.</p> <p>23 BY MR. PIFKO:</p> <p>24 Q. So you don't consider public</p>	<p>1 A. I did. We consider -- 2 Q. Am I correct that 3 AmerisourceBergen does not consider the 4 public health when carrying out its 5 duties to prevent diversion under The 6 Controlled Substances Act?</p> <p>7 MR. NICHOLAS: Object to the 8 form.</p> <p>9 THE WITNESS: We consider 10 the -- we consider that pharmacies 11 have product accessible to fill 12 the patients' prescriptions. 13 However you want to interpret 14 that, that's up to you.</p> <p>15 But that is -- the answer 16 is, our consideration is making 17 sure drugs are available. If that 18 means taking into consideration 19 the public safety -- or whatever 20 the -- what you're hammering on 21 here, what is the question?</p> <p>22 BY MR. PIFKO:</p> <p>23 Q. Public health.</p> <p>24 A. Public health.</p>
Page 87	Page 89
<p>1 health when you're carrying out your role 2 in the supply chain; is that correct?</p> <p>3 MR. NICHOLAS: Object to the 4 form of the question. You're 5 mischaracterizing -- 6 mischaracterizing testimony.</p> <p>7 THE WITNESS: I think I've 8 answered the question.</p> <p>9 BY MR. PIFKO:</p> <p>10 Q. I asked you a question.</p> <p>11 You don't consider public 12 health when you're carrying out your role 13 in the supply chain; is that correct?</p> <p>14 MR. NICHOLAS: Object to the 15 form of the question. All the 16 same reasons.</p> <p>17 THE WITNESS: I think I've 18 answered -- I've answered the 19 question. I mean --</p> <p>20 BY MR. PIFKO:</p> <p>21 Q. Answer that question, 22 please.</p> <p>23 A. I did answer that question.</p> <p>24 Q. You have not.</p>	<p>1 We make sure we have 2 products available that are safe and 3 secure to supply to the pharmacies. If 4 that means that's considering public 5 health, then that's your interpretation.</p> <p>6 But to say that we don't 7 have any -- that I haven't answered the 8 question, I don't think that's correct.</p> <p>9 Q. How about, you're talking 10 about supplying a prescription, a valid 11 prescription.</p> <p>12 How about, does 13 AmerisourceBergen consider the public 14 health when trying to prevent Control II 15 substances from getting into illegal 16 hands?</p> <p>17 MR. NICHOLAS: Same 18 objection.</p> <p>19 THE WITNESS: It's the same 20 question. It's the same answer as 21 the last question.</p> <p>22 BY MR. PIFKO:</p> <p>23 Q. What's your answer?</p> <p>24 MR. NICHOLAS: Same</p>

Page 90	Page 92
<p>1 objection.</p> <p>2 THE WITNESS: We adhere to</p> <p>3 our regulatory requirements within</p> <p>4 the confines of a distributor.</p> <p>5 And whether that's the</p> <p>6 consideration of our</p> <p>7 requirements -- I mean, that's --</p> <p>8 that is our role. And that is</p> <p>9 what we consider.</p> <p>10 We want to make sure that we</p> <p>11 only buy from appropriate sources,</p> <p>12 store correctly, and we only sell</p> <p>13 to legitimate sources.</p> <p>14 BY MR. PIFKO:</p> <p>15 Q. We talked about how Schedule</p> <p>16 II substances have a high potential for</p> <p>17 abuse, correct?</p> <p>18 A. They are Schedule II drugs,</p> <p>19 yes.</p> <p>20 Q. And the statute says that</p> <p>21 Schedule II substances have a high</p> <p>22 potential for abuse, correct?</p> <p>23 A. That's why they're Schedule</p> <p>24 II, correct.</p>	<p>1 regulatory responsibilities of who</p> <p>2 we distribute products to.</p> <p>3 We can only control what we</p> <p>4 can control. We can only control</p> <p>5 who we sell drugs to. And we</p> <p>6 consider the impact to ensure that</p> <p>7 we only sell to licensed</p> <p>8 registrants. And that's the</p> <p>9 consideration we make and that's</p> <p>10 our obligation under the</p> <p>11 regulations.</p> <p>12 BY MR. PIFKO:</p> <p>13 Q. Does AmerisourceBergen</p> <p>14 believe it has a responsibility to</p> <p>15 protect people in the communities it</p> <p>16 serves from falling victim to abuse of</p> <p>17 Schedule II substances?</p> <p>18 MR. NICHOLAS: Object to the</p> <p>19 form. It is not an appropriate</p> <p>20 question in this deposition. It's</p> <p>21 outside the scope of the 30(b)(6)</p> <p>22 notice.</p> <p>23 THE WITNESS:</p> <p>24 AmerisourceBergen has its</p>
<p>1 Q. Does AmerisourceBergen</p> <p>2 consider the impact on the communities it</p> <p>3 serves if these Schedule II substances</p> <p>4 get into the wrong hands?</p> <p>5 MR. NICHOLAS: Object to the</p> <p>6 form. Outside the scope of the</p> <p>7 30(b)(6) notice as well.</p> <p>8 THE WITNESS: Can you</p> <p>9 restate your question?</p> <p>10 MR. PIFKO: Can you read</p> <p>11 back the question, please?</p> <p>12 - - -</p> <p>13 (Whereupon, the court</p> <p>14 reporter read the following part</p> <p>15 of the record:</p> <p>16 "Question: Does</p> <p>17 AmerisourceBergen consider the</p> <p>18 impact on the communities it</p> <p>19 serves if these Schedule II</p> <p>20 substances get into the wrong</p> <p>21 hands?"")</p> <p>22 - - -</p> <p>23 THE WITNESS: Again, we</p> <p>24 consider who -- we consider our</p>	<p>1 obligation to ensure that -- I</p> <p>2 mean, you're asking the same</p> <p>3 question, and the answer is the</p> <p>4 same.</p> <p>5 We have regulatory</p> <p>6 responsibilities that are imposed</p> <p>7 on the distributor that we must</p> <p>8 adhere to in order to prevent</p> <p>9 diversion, which we do diligently.</p> <p>10 And we ensure that the customers</p> <p>11 that we sell to are appropriately</p> <p>12 licensed and that -- while those</p> <p>13 drugs are under our control.</p> <p>14 That's what we take into</p> <p>15 consideration and that's what we</p> <p>16 do diligently.</p> <p>17 BY MR. PIFKO:</p> <p>18 Q. So does the company consider</p> <p>19 the adverse impacts of substances that it</p> <p>20 sells in the communities that it sells?</p> <p>21 A. Our duty is not to determine</p> <p>22 the types of the products. We only sell</p> <p>23 FDA-approved drugs. We don't approve the</p> <p>24 drugs. We don't schedule the drugs. We</p>

<p style="text-align: right;">Page 94</p> <p>1 don't put them into classifications. We 2 don't prescribe the drugs. And we don't 3 dispense the drugs. 4 All we do is make sure we 5 buy the drugs that are ordered from our 6 licensed customers, FDA and DEA-approved 7 drugs, and we distribute to them and make 8 sure that they have the appropriate 9 schedules.</p> <p>10 We have nothing to do with 11 the approval of drugs. We have -- 12 nowhere in our scope do we have that 13 responsibility, nor should we.</p> <p>14 MR. PIFKO: We're going to 15 take a break.</p> <p>16 VIDEO TECHNICIAN: Going off 17 the record. The time is 10:20 18 a.m.</p> <p>19 - - -</p> <p>20 (Whereupon, a brief recess 21 was taken.)</p> <p>22 - - -</p> <p>23 VIDEO TECHNICIAN: We're 24 back on record. The time is 10:35</p>	<p style="text-align: right;">Page 96</p> <p>1 opioid products at issue in this 2 litigation can be dangerous? 3 MR. NICHOLAS: Object to the 4 form.</p> <p>5 THE WITNESS: They're 6 Schedule -- by Schedule II, they 7 are -- that, by itself, identifies 8 them as such.</p> <p>9 BY MR. PIFKO:</p> <p>10 Q. And because they're highly 11 addictive, right?</p> <p>12 MR. NICHOLAS: Object to the 13 form. This is outside the scope 14 of the 30(b)(6).</p> <p>15 Are you now -- I do want to 16 start making it very clear on the 17 record when we're on -- in 18 30(b)(6) and when we're not. I 19 understand he's also testifying as 20 an individual.</p> <p>21 Can we be clear that this 22 line of questioning, for example, 23 is outside the scope of the 24 30(b)(6) notice?</p>
<p style="text-align: right;">Page 95</p> <p>1 a.m.</p> <p>2 BY MR. PIFKO:</p> <p>3 Q. One little housekeeping 4 thing we forgot to talk about, although 5 I'm sure your counsel discussed it with 6 you before your -- when you were 7 preparing for the deposition.</p> <p>8 But one of the rules of the 9 jurisdiction where we're in is that 10 you're not allowed to confer about the 11 substance of your testimony during our 12 breaks.</p> <p>13 Do you understand that?</p> <p>14 A. Yes.</p> <p>15 Q. During the last break, did 16 you confer with your counsel about the 17 substance of your testimony?</p> <p>18 A. No.</p> <p>19 Q. Do we have an agreement that 20 going forward, you're not going to be 21 doing that during any break?</p> <p>22 A. Yes.</p> <p>23 Q. Okay. Great.</p> <p>24 Do you understand that the</p>	<p style="text-align: right;">Page 97</p> <p>1 MR. PIFKO: You can object 2 to scope, and we can fight about 3 it later. I don't think we're 4 going to agree on the record about 5 what's part of it or not.</p> <p>6 MR. NICHOLAS: Well, okay. 7 Then I'll just have to keep saying 8 the objection all the time.</p> <p>9 Object to the scope.</p> <p>10 Would you mind if I ask 11 you --</p> <p>12 MR. PIFKO: Let's just ask 13 the question over again.</p> <p>14 MR. NICHOLAS: -- can you 15 identify the section?</p> <p>16 MR. PIFKO: I'm not going to 17 get into that right now.</p> <p>18 BY MR. PIFKO:</p> <p>19 Q. I'm going to ask you the 20 question again, sir, so we have a clear 21 record.</p> <p>22 MR. NICHOLAS: Well, just 23 since we're making a clear record, 24 for the record, I would ask that</p>

Page 98	Page 100
<p>1 you identify, if you consider this 2 to be within the 30(b)(6) notice, 3 tell us which topic we're within.</p> <p>4 MR. PIFKO: Understood. We 5 can meet and confer about that 6 after the deposition.</p> <p>7 MR. NICHOLAS: After the 8 deposition is too late. The 9 deposition will be over. But, 10 okay. I've made my request for 11 the record.</p> <p>12 BY MR. PIFKO:</p> <p>13 Q. So sorry. Let's start over 14 with that.</p> <p>15 You testified that the 16 controlled substances at issue in this 17 litigation, the opioid products, are -- 18 can be potentially dangerous because 19 they're Schedule II and they are highly 20 addictive, correct?</p> <p>21 MR. NICHOLAS: Object to the 22 form.</p> <p>23 Go ahead.</p> <p>24 THE WITNESS: They are</p>	<p>1 is. 2 BY MR. PIFKO: 3 Q. We agree that they're 4 Schedule II? 5 A. Correct. 6 Q. And we agree that a Schedule 7 II product has been classified by the 8 United States government as highly 9 addictive, agreed? 10 A. High potential of abuse. I 11 don't know -- you're saying "addictive." 12 I know the regulatory requirement is 13 abuse. 14 Q. Do you have an understanding 15 that a product that has a high potential 16 for abuse can be dangerous to people 17 taking it? 18 MR. NICHOLAS: Object to the 19 form. Outside the scope of the 20 notice. 21 THE WITNESS: I'm not -- I'm 22 not a medical doctor. I can't 23 comment on that. 24 BY MR. PIFKO:</p>
<p>1 Schedule II because there's a 2 potential for abuse.</p> <p>3 BY MR. PIFKO:</p> <p>4 Q. And because there's a 5 potential for abuse, that makes -- 6 there's a potential danger associated 7 with them, correct?</p> <p>8 MR. NICHOLAS: Object to the 9 form. Outside the scope of the 10 30(b)(6).</p> <p>11 THE WITNESS: It's their 12 potential for abuse that makes 13 them a Schedule II and they have 14 additional security requirements.</p> <p>15 BY MR. PIFKO:</p> <p>16 Q. So you don't have any 17 understanding about -- beyond the fact 18 that they're Schedule II, about what that 19 means for these products?</p> <p>20 MR. NICHOLAS: Object to the 21 form. Outside the scope of the 22 30(b)(6).</p> <p>23 THE WITNESS: I'm not 24 understanding what your question</p>	<p>1 Q. So you have no 2 understanding? 3 MR. NICHOLAS: Object to the 4 form. Outside the scope. 5 THE WITNESS: I have no 6 understanding of -- that they have 7 a high abuse potential, yes, I do 8 have an understanding of that. If 9 that correlates to dangerous, I 10 mean, if that's your correlation. 11 BY MR. PIFKO: 12 Q. I'm not making -- I'm just 13 asking for your answer. You can give me 14 whatever answer you'd like, as far as -- 15 as long as you answer the question. 16 But my question just was, do 17 you have an understanding that if -- 18 because the pills have a high potential 19 for abuse, that they could cause 20 potential danger to people? 21 MR. NICHOLAS: Objection. 22 Outside the scope. 23 THE WITNESS: I don't know 24 that for sure.</p>
Page 99	Page 101

Page 102	Page 104
<p>1 BY MR. PIFKO:</p> <p>2 Q. Do you have an understanding</p> <p>3 that a drug that has a high potential for</p> <p>4 abuse could cause death to people who</p> <p>5 consume that drug?</p> <p>6 MR. NICHOLAS: Objection.</p> <p>7 Outside the scope.</p> <p>8 THE WITNESS: I don't know.</p> <p>9 I don't know.</p> <p>10 I mean, drugs -- people can</p> <p>11 overdose on drugs, and I'm aware</p> <p>12 of that, yes.</p> <p>13 BY MR. PIFKO:</p> <p>14 Q. Do you have an understanding</p> <p>15 that someone is more likely to suffer</p> <p>16 harm from a Schedule II drug than a drug</p> <p>17 that's not a Schedule II drug?</p> <p>18 MR. NICHOLAS: Objection.</p> <p>19 Outside the scope.</p> <p>20 THE WITNESS: I don't know</p> <p>21 that.</p> <p>22 BY MR. PIFKO:</p> <p>23 Q. Let's go back to our duties</p> <p>24 to prevent diversion.</p>	<p>1 Outside the scope.</p> <p>2 THE WITNESS: It calls for a</p> <p>3 conclusion. I don't know that.</p> <p>4 BY MR. PIFKO:</p> <p>5 Q. You don't know either way?</p> <p>6 A. I don't know --</p> <p>7 Q. If AmerisourceBergen does</p> <p>8 not maintain effective controls to</p> <p>9 prevent diversion of Schedule II</p> <p>10 substances, they can be diverted,</p> <p>11 correct?</p> <p>12 MR. NICHOLAS: Object to the</p> <p>13 form. Outside the scope.</p> <p>14 THE WITNESS: Again, if we</p> <p>15 don't adhere to our effective</p> <p>16 controls to prevent diversion,</p> <p>17 yes, diversion could occur.</p> <p>18 BY MR. PIFKO:</p> <p>19 Q. Let's discuss some of the</p> <p>20 company's policies and procedures with</p> <p>21 respect to diversion.</p> <p>22 Before we do that, do you</p> <p>23 agree that the laws and regulations with</p> <p>24 respect to preventing diversion remain --</p>
<p>1 You recall discussing that?</p> <p>2 MR. NICHOLAS: Object to the</p> <p>3 form.</p> <p>4 THE WITNESS: Yes.</p> <p>5 BY MR. PIFKO:</p> <p>6 Q. You agree that</p> <p>7 AmerisourceBergen has a duty to prevent</p> <p>8 diversion of controlled -- I keep messing</p> <p>9 that up.</p> <p>10 You agree that</p> <p>11 AmerisourceBergen has a duty to prevent</p> <p>12 diversion of Schedule II substances?</p> <p>13 MR. NICHOLAS: Object to the</p> <p>14 form. I'm not sure it's within</p> <p>15 the scope either. But I</p> <p>16 definitely object to the form.</p> <p>17 THE WITNESS: We have a duty</p> <p>18 to -- we have an obligation to</p> <p>19 prevent diversion while the drugs</p> <p>20 are under our control.</p> <p>21 BY MR. PIFKO:</p> <p>22 Q. And if you don't carry out</p> <p>23 that duty, diversion can occur, correct?</p> <p>24 MR. NICHOLAS: Objection.</p>	<p>1 have remained unchanged for the last 45</p> <p>2 years?</p> <p>3 MR. NICHOLAS: Object to the</p> <p>4 form. Outside -- definitely</p> <p>5 outside the scope.</p> <p>6 THE WITNESS: The CSA was</p> <p>7 passed in 1970 and in -- the</p> <p>8 federal regulations that regulate</p> <p>9 our responsibilities have not</p> <p>10 changed.</p> <p>11 BY MR. PIFKO:</p> <p>12 Q. So it's your understanding</p> <p>13 that there haven't been changes with</p> <p>14 respect to the duties to prevent</p> <p>15 diversion since the passage of the</p> <p>16 statute?</p> <p>17 MR. NICHOLAS: Object to the</p> <p>18 form. Outside the scope. You're</p> <p>19 asking him a legal question.</p> <p>20 THE WITNESS: The</p> <p>21 regulatory -- the regulations have</p> <p>22 not changed.</p> <p>23 BY MR. PIFKO:</p> <p>24 Q. So AmerisourceBergen has the</p>
Page 103	Page 105

Page 106	Page 108
<p>1 same duty under the regulations today as 2 it did in 1990, correct?</p> <p>3 MR. NICHOLAS: Object to the 4 form. You're asking him a legal 5 question. Outside the scope.</p> <p>6 THE WITNESS: We have a 7 requirement to have effective 8 controls to prevent diversion.</p> <p>9 BY MR. PIFKO:</p> <p>10 Q. And that requirement hasn't 11 changed since the passage of The 12 Controlled Substances Act, correct?</p> <p>13 MR. NICHOLAS: Object to the 14 form. Calls for a legal 15 conclusion. Outside the scope.</p> <p>16 THE WITNESS: I'm not aware 17 if the regulations have changed.</p> <p>18 BY MR. PIFKO:</p> <p>19 Q. You're familiar with the -- 20 AmerisourceBergen's practices and 21 procedures under The Controlled 22 Substances Act going back to the '80s, 23 correct?</p> <p>24 A. The '90s.</p>	<p>1 Q. Sorry, I'm not quite as 2 organized as I want to be. 3 From the time you started 4 with AmerisourceBergen -- let's back up. 5 You started working for 6 AmerisourceBergen in the 1990s?</p> <p>7 A. January, correct.</p> <p>8 Q. Do you remember the exact 9 date and year?</p> <p>10 A. January 2nd, 1990.</p> <p>11 Q. Okay. From the time that 12 you started with AmerisourceBergen until 13 about 1998, AmerisourceBergen's 14 monitoring protocol was that every order 15 that exceeded the threshold was deemed to 16 be suspicious, correct?</p> <p>17 MR. NICHOLAS: Object to the 18 form. Outside the scope.</p> <p>19 THE WITNESS: So when I 20 started with the company, the 21 process was a two-step process. 22 It was an excessive order report 23 that was produced monthly to send 24 to DEA, and then we also had a</p>
Page 107	Page 109
<p>1 Q. Okay. The '90s. 2 And you testified about the 3 company's practices with respect to 4 preventing diversion dating back to the 5 '90s in connection with the West Virginia 6 litigation, correct?</p> <p>7 MR. NICHOLAS: Objection. 8 Outside the scope. 9 Go ahead.</p> <p>10 THE WITNESS: I don't 11 remember, but --</p> <p>12 BY MR. PIFKO:</p> <p>13 Q. You testified in 2006, 14 correct?</p> <p>15 A. 2006?</p> <p>16 Q. '16, sorry.</p> <p>17 A. Yes.</p> <p>18 Q. In preparing for this 19 deposition, did you review your 20 transcript of that proceeding?</p> <p>21 A. I looked at it, yes.</p> <p>22 Q. When was the last time you 23 looked at it?</p> <p>24 A. A couple of weeks ago.</p>	<p>1 manual process at the distribution 2 centers where the order fillers 3 would identify suspicious orders 4 and report those.</p> <p>5 BY MR. PIFKO:</p> <p>6 Q. And the orders were reported 7 after they were shipped, correct?</p> <p>8 MR. NICHOLAS: Object to the 9 form. Outside the scope.</p> <p>10 THE WITNESS: Correct.</p> <p>11 BY MR. PIFKO:</p> <p>12 Q. Prior to 2007, 13 AmerisourceBergen's system shipped all 14 orders at night and reported any orders 15 that it deemed to be suspicious the next 16 day, correct?</p> <p>17 MR. NICHOLAS: Objection. 18 Outside the scope.</p> <p>19 THE WITNESS: That was the 20 program that we developed in 21 conjunction with DEA over a 22 two-year process, that we tested a 23 new -- a process of reporting 24 suspicious orders that we</p>

Page 110	Page 112
1 developed with DEA and then worked 2 with them for two years testing 3 the program until they approved 4 the program in '98. 5 BY MR. PIFKO: 6 Q. I'm not asking for 7 approvals, or I didn't ask you the 8 formulation for the policy. I just asked 9 if that was a correct statement about 10 what the practice was. 11 So I'll just -- let's get a 12 clear answer to the question. 13 A. That was the practice that 14 we did in conjunction with DEA's 15 guidance. 16 Q. Just so we have a clear 17 record, the practice was to ship the 18 orders at night, and then the next day 19 any orders that were identified as 20 suspicious were then reported to the DEA; 21 is that correct? 22 A. Correct. 23 Q. Are you familiar with the 24 term "threshold"?	1 to identify an order of interest 2 for further review. 3 BY MR. PIFKO: 4 Q. And so the threshold is the 5 first step in the suspicious order 6 monitoring program, correct? 7 MR. NICHOLAS: Object to the 8 form. 9 THE WITNESS: It is a step. 10 BY MR. PIFKO: 11 Q. Is there a step before the 12 threshold? 13 A. We train our employees at 14 the distribution centers also to be aware 15 of, and train them on suspicious orders. 16 And if they identify a suspicious order, 17 they're to report it. 18 Q. The threshold is a key 19 factor that's used to identify 20 potentially suspicious orders, correct? 21 MR. NICHOLAS: Object to the 22 form. 23 THE WITNESS: It's an 24 identifier that we use
Page 111	Page 113
1 A. Yes. 2 Q. That's an attribute of your 3 suspicious order monitoring system, 4 correct? 5 MR. NICHOLAS: Object to the 6 form. 7 THE WITNESS: You need to 8 put it into context of time, 9 because the program has been 10 enhanced over the years. 11 BY MR. PIFKO: 12 Q. Well, for the time period 13 for which you're here to testify, which 14 ends in 2014, at all times there's been 15 some threshold requirement in the system, 16 correct? 17 A. Correct. 18 Q. Can you tell me what a 19 threshold is? 20 MR. NICHOLAS: Object to the 21 form. 22 THE WITNESS: A threshold is 23 the -- is a trigger that we have 24 put into the program to create --	1 systematically to trigger a 2 potential order of interest. [REDACTED]

Page 114

Page 116

Page 115

Page 117



	Page 122	Page 124
<p>1 A. The product?</p> <p>2 Q. Yes.</p> <p>3 A. Yes.</p> <p>4 Q. After 1998, what was the</p> <p>5 practice with respect to calculating</p> <p>6 thresholds?</p> <p>7 MR. NICHOLAS: Same</p> <p>8 objection. Outside the scope.</p> <p>9 THE WITNESS: So in 1996, we</p> <p>10 worked with DEA, for two years,</p> <p>11 on -- in order to provide DEA with</p> <p>12 more -- we feel, more accurate</p> <p>13 information, that we worked on a</p> <p>14 project to where we would identify</p> <p>15 a customer based upon its own</p> <p>16 purchase history versus all</p> <p>17 pharmacies in one big bucket.</p> <p>18 And then we calculated a</p> <p>19 rolling four-month average of that</p> <p>20 pharmacy's purchases. And then</p> <p>21 created a multiplier of three to</p> <p>22 identify a trigger that would</p> <p>23 identify a suspicious order.</p> <p>24 BY MR. PIFKO:</p>		<p>1 that two-year period.</p> <p>2 We continued to make changes</p> <p>3 in the program, and that was the final</p> <p>4 calculation that we came up with.</p> <p>5 Q. And that calculation was</p> <p>6 used from 1998 to 2007?</p> <p>7 A. Yes.</p> <p>8 Q. Something happened in 2007,</p> <p>9 correct?</p> <p>10 A. Yes.</p> <p>11 Q. You had an enforcement</p> <p>12 action brought against you by the DEA,</p> <p>13 correct?</p> <p>14 A. Correct.</p> <p>15 Q. The three times multiplier,</p> <p>16 where does that come from? Scratch that</p> <p>17 question for a second.</p> <p>18 You agree that throughout</p> <p>19 the time period we just discussed, from</p> <p>20 the 1990s to 2007, there was always a</p> <p>21 three times multiplier used in connection</p> <p>22 with calculating the threshold, correct?</p> <p>23 A. So for -- so from 1990 to</p> <p>24 '98, the excessive report for ARCOS</p>
<p>1 Q. That practice was in place</p> <p>2 from 1998 to when?</p> <p>3 MR. NICHOLAS: Object to</p> <p>4 the -- objection. Scope. Same</p> <p>5 objection as I've been stating.</p> <p>6 THE WITNESS: So that -- so</p> <p>7 once we got approval from DEA to</p> <p>8 enact that program nationally, we</p> <p>9 tested it for -- with one DEA</p> <p>10 office and then several, and then</p> <p>11 Washington, D.C. approved it for</p> <p>12 national use throughout in 1998.</p> <p>13 And that was the practice</p> <p>14 until 2007.</p> <p>15 BY MR. PIFKO:</p> <p>16 Q. So to be clear, from 2007 --</p> <p>17 I'm sorry, from 1998 to 2007, the</p> <p>18 practice was to take a specific</p> <p>19 customer's order history over the prior</p> <p>20 four-month period and then average the</p> <p>21 order history and multiply that by three,</p> <p>22 and that would be its threshold, correct?</p> <p>23 A. That was the agreed-upon</p> <p>24 process through our testing with DEA over</p>	Page 123	<p>1 items, which would be your Schedule II</p> <p>2 and reportable IIIIs had a three times</p> <p>3 multiplier. Non-ARCOS items, I think it</p> <p>4 might have been six; it might have been a</p> <p>5 higher multiplier.</p> <p>6 Our program that we</p> <p>7 implemented in '98 set them all at three.</p> <p>8 Q. And do you know what the</p> <p>9 methodology was in calculating that three</p> <p>10 times multiplier?</p> <p>11 MR. NICHOLAS: Object to the</p> <p>12 form. And same objection, as to</p> <p>13 outside -- as to the scope here of</p> <p>14 all these questions.</p> <p>15 THE WITNESS: So the three</p> <p>16 times multiplier had been in place</p> <p>17 when I came on board in 1990. And</p> <p>18 that was the program that we were</p> <p>19 submitting and working with DEA in</p> <p>20 1990 all the way up to '96.</p> <p>21 And then when we started to</p> <p>22 work on the new program in</p> <p>23 conjunction with DEA and testing</p> <p>24 it and refining it for that</p>

Page 126	Page 128
<p>1 two-year period, the three times 2 multiplier was the multiplier that 3 we -- that, in conjunction with 4 the DEA, decided to use.</p> <p>5 BY MR. PIFKO:</p> <p>6 Q. So you don't know where it 7 came from, because it was already in 8 place when you started at the company?</p> <p>9 MR. NICHOLAS: Object to the 10 form. Outside the scope.</p> <p>11 THE WITNESS: It was -- 12 correct, it was in place.</p> <p>13 And then in '96, '7, '8, 14 right in that time period, the 15 Methamphetamine Control Act was 16 passed. And part of that act 17 required the -- it didn't require, 18 it mandated a Suspicious Order 19 Task Force to come up with a 20 process to identify suspicious 21 orders and report it to DEA.</p> <p>22 I participated on that task 23 force, and that was what came up. 24 And it was with enforcement,</p>	<p>1 And then in '96, when we 2 started working with DEA, we came 3 up and we mutually decided on a 4 three times multiplier.</p> <p>5 And then the Suspicious 6 Order Task Force was assembled 7 and, again, through their meetings 8 with enforcement agencies and 9 regulators and industry, they came 10 up with a process to identify 11 systematic -- a systematic 12 approach for reporting suspicious 13 orders, and that was a three times 14 multiplier as well.</p> <p>15 BY MR. PIFKO:</p> <p>16 Q. This three times multiplier 17 that you relied on through this task 18 force, was there any written 19 documentation establishing that?</p> <p>20 A. It was in the chemical 21 handling handbook published by the DEA.</p> <p>22 Q. And that's a document that 23 you relied on for the three times 24 multiplier?</p>
<p>1 state, federal and industry. And 2 we met quarterly. And the 3 Suspicious Order Task Force 4 mandated by the Methamphetamine 5 Control Act came up with the same 6 process with the three times 7 multiplier. And that's the same 8 one we used, which kind of is in 9 line with what we used in '90, 10 what we used in '98, and what we 11 implemented in 2007.</p> <p>12 BY MR. PIFKO:</p> <p>13 Q. And so your three times 14 multiplier came from being involved with 15 the task force on -- what did you say?</p> <p>16 The Methamphetamine Act?</p> <p>17 A. The three time --</p> <p>18 MR. NICHOLAS: Object to the 19 form. Scope.</p> <p>20 Go ahead.</p> <p>21 THE WITNESS: So the three 22 times multiplier was already in 23 place in 1990, and those were the 24 reports we were submitting to DEA.</p>	<p>1 A. That was --</p> <p>2 MR. NICHOLAS: Same 3 objection. Objections to the form 4 and outside the scope.</p> <p>5 Go ahead.</p> <p>6 THE WITNESS: Again, what 7 time frame are you talking about?</p> <p>8 When we worked with DEA, we 9 relied on our negotiations with 10 DEA. And then in 2007, when we 11 were implementing a new enhanced 12 program, again, in conjunction 13 with DEA, we came up with the 14 three times multiplier. Referring 15 back to the handling manual that 16 was published by DEA, has -- 17 identifying a suspicious order 18 systematically, it was three times 19 multiplier.</p> <p>20 BY MR. PIFKO:</p> <p>21 Q. So what I'm asking you is, 22 the three times multiplier that you're 23 relying on with respect to the handling 24 manual that was published by DEA,</p>
Page 127	Page 129

Page 130	Page 132
<p>1 that's -- what that's called?</p> <p>2 A. Your question is what the</p> <p>3 manual is called? Chemical handling</p> <p>4 guide, I believe. I can't -- I don't</p> <p>5 know the exact name. It was also on the</p> <p>6 DEA's website for some time.</p> <p>7 Q. Did you produce a copy of</p> <p>8 that guide, to your knowledge?</p> <p>9 MR. NICHOLAS: Who are you</p> <p>10 talking about? Are you talking</p> <p>11 about --</p> <p>12 MR. PIFKO: The company.</p> <p>13 MR. NICHOLAS: -- in this</p> <p>14 litigation?</p> <p>15 MR. PIFKO: Yes.</p> <p>16 THE WITNESS: In this --</p> <p>17 MR. NICHOLAS: Objection.</p> <p>18 BY MR. PIFKO:</p> <p>19 Q. If you know.</p> <p>20 A. I don't know.</p> <p>21 MR. NICHOLAS: For the</p> <p>22 record, since the implication is</p> <p>23 that maybe we were supposed to</p> <p>24 produce the document or</p>	<p>1 Q. I'll represent to you that</p> <p>2 this is the 2001 version.</p> <p>3 A. Okay.</p> <p>4 Q. Do you believe you've seen</p> <p>5 this before?</p> <p>6 A. I've seen -- I don't know if</p> <p>7 I've seen this version, but I've seen it.</p> <p>8 Q. And when you refer to the</p> <p>9 Chemical Handler's Manual, this is what</p> <p>10 you're referring to?</p> <p>11 A. Yes. And, again, it was</p> <p>12 also on the website as well.</p> <p>13 Q. When you talk about the</p> <p>14 three times multiplier -- there's page</p> <p>15 numbers on the bottom here, Page 43.</p> <p>16 They are side-by-side columns, Appendix</p> <p>17 E-3.</p> <p>18 Can you turn to that?</p> <p>19 A. Uh-huh.</p> <p>20 Q. Are you there?</p> <p>21 A. Yes.</p> <p>22 Q. On Page 43, the page on the</p> <p>23 right, you see there it says, Suspicious</p> <p>24 order reporting system for use in</p>
<p>1 something --</p> <p>2 MR. PIFKO: No accusations.</p> <p>3 Just asking.</p> <p>4 MR. NICHOLAS: Good. It's a</p> <p>5 DEA document prior to 2006.</p> <p>6 - - -</p> <p>7 (Whereupon, Amerisource</p> <p>8 Bergen-Zimmerman Exhibit-4, 2001</p> <p>9 Chemical Handler's Notebook, was</p> <p>10 marked for identification.)</p> <p>11 - - -</p> <p>12 BY MR. PIFKO:</p> <p>13 Q. I'm handing you what's</p> <p>14 marked as Exhibit-4.</p> <p>15 A. Thank you.</p> <p>16 Q. Do you have Exhibit-4 in</p> <p>17 front of you?</p> <p>18 A. Uh-huh.</p> <p>19 Q. Are you reviewing Exhibit-4?</p> <p>20 A. Yes.</p> <p>21 Q. Have you seen this document</p> <p>22 before?</p> <p>23 A. I've seen a version of it.</p> <p>24 I'm not sure what version this is.</p>	<p>1 automated tracking systems.</p> <p>2 Do you see that?</p> <p>3 A. What page are you on?</p> <p>4 Q. It's 43 on the very bottom.</p> <p>5 A. Okay.</p> <p>6 Q. Are you there?</p> <p>7 A. Yes.</p> <p>8 Q. Appendix E-3.</p> <p>9 Do you see that at the top</p> <p>10 of that page? Is that the page you're</p> <p>11 looking at?</p> <p>12 A. Yes.</p> <p>13 Q. And it says, Suspicious</p> <p>14 order reporting system for use in</p> <p>15 automated tracking systems.</p> <p>16 Do you see that?</p> <p>17 A. Yes.</p> <p>18 Q. Okay. Is this where the</p> <p>19 three times multiplier that you were</p> <p>20 talking about comes from?</p> <p>21 A. This is -- yeah, the basis</p> <p>22 of it.</p> <p>23 Q. And it says there -- there's</p> <p>24 terms and definitions and then it's got</p>

Page 134	Page 136
<p>1 these numbers, 1, 2, 3, 4. And then it 2 has, Note. 3 Do you see that? 4 A. Yes. 5 Q. And it says, Factor equals 6 3. 7 Do you see that? 8 A. Yes. 9 Q. Is that what you were 10 talking about? 11 A. Yes. 12 Q. And you worked with the task 13 force that was responsible for coming up 14 with this manual? 15 A. I participated on it. I 16 wasn't the -- the industry could have one 17 member, but there was a group of people 18 within the industry. 19 Q. Did you help in drafting any 20 of the language that was in the manual? 21 A. I don't recall. 22 Q. Do you recall if the DEA 23 asked you for comment on the final 24 version of the manual?</p>	<p>1 A. There was a designee of one 2 person. It wasn't me. I wasn't the 3 one-person designee. 4 Q. Do you know who that was? 5 A. I don't. 6 Q. Do you know what company 7 they worked for? 8 A. I want to say it was 9 Cardinal or McKesson, but I'm not sure. 10 It wasn't ABC. 11 Q. Did you work with anyone 12 from Cardinal or McKesson -- so I asked 13 you who the designated person was, and 14 you said maybe it was Cardinal or 15 McKesson. 16 Setting aside who the 17 designated person was, when you were 18 involved with this task force, did you 19 work with anyone from McKesson or 20 Cardinal on the task force? 21 MR. NICHOLAS: Object to the 22 form. Scope. 23 Go ahead. 24 THE WITNESS: I can't</p>
<p>1 A. I don't. 2 Q. Your work on this task force 3 was through the Healthcare Distribution 4 Alliance, which I guess was under a 5 different name at that time? 6 A. They had the -- yeah, there 7 was -- I think there was one member, one 8 slot on the task force for the 9 wholesaler. It was through the HDMA at 10 the time, I believe it was called. 11 Q. And so the DEA said that the 12 HDMA could have a member participate on 13 the task force, and you were the selected 14 member; is that correct? 15 A. No. 16 MR. NICHOLAS: Objection to 17 the form. 18 Go ahead. 19 THE WITNESS: No. No, I was 20 not. I said I participated. The 21 group -- 22 BY MR. PIFKO: 23 Q. There was someone else who 24 was the HDMA member?</p>	<p>1 remember who specifically was 2 involved. 3 BY MR. PIFKO: 4 Q. But you generally feel like 5 maybe McKesson or Cardinal was involved? 6 MR. NICHOLAS: Object to the 7 form. 8 THE WITNESS: Again, I don't 9 know exactly who was involved. I 10 wouldn't be comfortable saying who 11 exactly that would be. 12 BY MR. PIFKO: 13 Q. In 2007, there was a DEA 14 enforcement action against 15 AmerisourceBergen, correct? 16 A. Yes. 17 - - - 18 (Whereupon, Amerisource 19 Bergen-Zimmerman Exhibit-5, 20 ABDCMDL 00279854-54, was marked 21 for identification.) 22 - - - 23 BY MR. PIFKO: 24 Q. I'm handing you what is</p>

Page 138	Page 140
<p>1 marked as Exhibit-5. This is a document 2 Bates labeled ABDCMDL 00279854 to 65. 3 Have you seen this document 4 before?</p> <p>5 A. Yes.</p> <p>6 Q. Can you tell me what this 7 is?</p> <p>8 A. This is our settlement and 9 release agreement with the DEA for 10 Orlando distribution center.</p> <p>11 Q. So as a result of the 12 enforcement action with the DEA, this was 13 the agreement that was reached between 14 AmerisourceBergen and the DEA, correct?</p> <p>15 MR. NICHOLAS: Object to the 16 form.</p> <p>17 THE WITNESS: This is the 18 agreement, yes, that was made 19 after the order to show cause.</p> <p>20 BY MR. PIFKO:</p> <p>21 Q. Was there any money paid, 22 under this agreement, from 23 AmerisourceBergen to the United States 24 government?</p>	<p>1 And they also wanted us to 2 modify our suspicious order 3 monitoring program to stop orders 4 that we believed -- stop orders 5 that could possibly be suspicious 6 and then to any suspicious -- any 7 order we deem suspicious should 8 not be shipped.</p> <p>9 BY MR. PIFKO:</p> <p>10 Q. Did AmerisourceBergen agree 11 to do that?</p> <p>12 A. We modified our program per 13 this agreement, correct.</p> <p>14 Q. Can we refer to this 15 agreement as the shipping requirement?</p> <p>16 MR. NICHOLAS: Object to the 17 form.</p> <p>18 BY MR. PIFKO:</p> <p>19 Q. If I say "shipping 20 requirement," can we have an 21 understanding that I'm referring to the 22 idea that you're not supposed to ship an 23 order that's deemed to be suspicious?</p> <p>24 MR. NICHOLAS: I'll object</p>
<p>1 A. No.</p> <p>2 Q. But as a result of this 3 agreement, AmerisourceBergen changed its 4 suspicious order monitoring program, 5 correct?</p> <p>6 MR. NICHOLAS: Object to the 7 form.</p> <p>8 Go ahead.</p> <p>9 THE WITNESS: It modified 10 the existing program, yes.</p> <p>11 BY MR. PIFKO:</p> <p>12 Q. Can you tell me how the 13 agreement modified the existing program?</p> <p>14 MR. NICHOLAS: Object to the 15 form.</p> <p>16 THE WITNESS: So through 17 negotiations with DEA and in 18 enhancing our existing order 19 monitoring program that we had in 20 place at the time, DEA wanted us 21 to include a more in-depth due 22 diligence process in addition to 23 ensuring that we only distribute 24 products to licensed individuals.</p>	<p>1 to the form.</p> <p>2 I want to understand, are 3 you asking the witness if 4 heretofore we can refer to this 5 agreement as the shipping 6 requirement? Because if so, I'd 7 object to that.</p> <p>8 BY MR. PIFKO:</p> <p>9 Q. Do you understand the 10 question?</p> <p>11 A. Do you want to repeat it?</p> <p>12 Q. All I'm asking is if, for 13 ease of reference, going forward, we can 14 refer to the idea that you don't ship an 15 order that's been identified as 16 suspicious as the shipping requirement?</p> <p>17 MR. NICHOLAS: I'll object 18 to the form. And the language.</p> <p>19 THE WITNESS: We never -- 20 the shipping requirement was never 21 discussed in this document and is 22 not a term that we had used in 23 presentations or requirements.</p> <p>24 We chose, through our work</p>

Page 142	Page 144
<p>1 with the DEA, that if we 2 defined -- ABC defined an order as 3 suspicious, that we would report 4 it and would not ship it.</p> <p>5 BY MR. PIFKO:</p> <p>6 Q. Did DEA ever tell you that 7 there was a -- prior to entering into 8 this agreement, did DEA ever tell you 9 that an order that's suspicious should 10 not be shipped?</p> <p>11 MR. NICHOLAS: Object to the 12 form.</p> <p>13 THE WITNESS: Did DEA ever 14 tell us? No.</p> <p>15 BY MR. PIFKO:</p> <p>16 Q. We talked about this 17 Chemical Handler's Manual and how it 18 provided guidance on the three times 19 threshold requirement, correct?</p> <p>20 A. Yes.</p> <p>21 Q. Did you take any guidance 22 from that manual about the idea of not 23 shipping an order that's deemed to be 24 suspicious?</p>	<p>1 Q. That's good. Thank you. 2 A. Do you want me to read the 3 whole thing? 4 Q. That's all I was asking you 5 to read.</p> <p>6 MR. NICHOLAS: You asked him 7 to read the whole thing.</p> <p>8 MR. PIFKO: You can read to 9 yourself the rest of that 10 paragraph, if you please. But all 11 I wanted you to read for the 12 record was that portion.</p> <p>13 MR. NICHOLAS: You asked 14 him, for the record, to read the 15 whole paragraph. Are you now 16 telling him you don't want him to 17 read the whole paragraph?</p> <p>18 MR. PIFKO: You don't need 19 to read any more.</p> <p>20 BY MR. PIFKO:</p> <p>21 Q. Did you ever consider 22 foregoing some transactions, as a result 23 of reading this document?</p> <p>24 MR. NICHOLAS: Object to the</p>
<p>1 MR. NICHOLAS: Object to the 2 form. Outside the scope.</p> <p>3 THE WITNESS: No.</p> <p>4 BY MR. PIFKO:</p> <p>5 Q. Let's take a look at that 6 manual again. I'd like to direct your 7 attention to Page 21 of that document. 8 Exhibit-4, for the record.</p> <p>9 Looking at the second full 10 paragraph of Page 21, can you read that 11 to me?</p> <p>12 A. On Page 21? You want me to 13 read it out loud?</p> <p>14 Q. Yes, please.</p> <p>15 A. When a regulated person 16 suspects that an order may be intended 17 for illicit purposes, good practice 18 requires that every reasonable effort be 19 made to resolve those suspicions. In 20 addition to making the required reports, 21 the transaction should not be completed 22 until the customer is able to eliminate 23 the suspicions. The distributor may have 24 to forego some transactions.</p>	<p>1 form. Outside the scope.</p> <p>2 THE WITNESS: No.</p> <p>3 - - -</p> <p>4 (Whereupon, Amerisource 5 Bergen-Zimmerman Exhibit-6, 6 ABDCMDL 00269683-694, was marked 7 for identification.)</p> <p>8 - - -</p> <p>9 BY MR. PIFKO:</p> <p>10 Q. I'm handing you what has 11 been marked as Exhibit-6. For the 12 record, these are a series of letters 13 from the Department of Justice, Bates 14 labeled ABDCMDL 00269683 to 694.</p> <p>15 For the record, there's four 16 letters in this packet. This is how they 17 were produced. They are dated -- the one 18 in the back is the earliest, it's on Page 19 ABDCMDL 00269691, and it's dated 20 September 27th, 2006. And there's 21 another one dated February 7th, 2007; 22 another one dated December 27th, 2007; 23 and another one with a stamp on it, June 24 12th, 2012.</p>

Page 146	Page 148
<p>1 Have you seen these before?</p> <p>2 A. I have.</p> <p>3 Q. These are what we refer to</p> <p>4 as the Dear Registrant letters.</p> <p>5 Have you heard that term</p> <p>6 before?</p> <p>7 A. I have, since -- yep. Yes.</p> <p>8 Q. Did AmerisourceBergen</p> <p>9 receive these letters from the Department</p> <p>10 of Justice? Let's start with the first</p> <p>11 one, dated September 27th, 2006, Bates</p> <p>12 label ABDCMDL 00269691.</p> <p>13 Are you there?</p> <p>14 A. Yes.</p> <p>15 Q. Okay. Did AmerisourceBergen</p> <p>16 receive a copy of this letter?</p> <p>17 A. I believe one or more of our</p> <p>18 distribution centers did.</p> <p>19 Q. When you were at the</p> <p>20 company, at that time, did you receive a</p> <p>21 copy of that letter?</p> <p>22 A. I eventually saw a copy of</p> <p>23 the letter. I never received one from</p> <p>24 DEA.</p>	<p>1 just review the letter before you</p> <p>2 ask -- before he's asked questions</p> <p>3 about portions of it?</p> <p>4 MR. PIFKO: You can review</p> <p>5 the letter.</p> <p>6 BY MR. PIFKO:</p> <p>7 Q. Do you believe this a --</p> <p>8 while you're reviewing it, do you believe</p> <p>9 this is a true and correct copy of the</p> <p>10 September 27th, 2006 letter from the</p> <p>11 Department of Justice?</p> <p>12 MR. NICHOLAS: Object to the</p> <p>13 form.</p> <p>14 THE WITNESS: It looks the</p> <p>15 same.</p> <p>16 BY MR. PIFKO:</p> <p>17 Q. And this is something that</p> <p>18 the company would have maintained in its</p> <p>19 files in the ordinary course of business?</p> <p>20 MR. NICHOLAS: Could you let</p> <p>21 him finish reading the letter,</p> <p>22 please, before you ask?</p> <p>23 BY MR. PIFKO:</p> <p>24 Q. I just wanted to ask you</p>
<p>1 Q. But someone in the company</p> <p>2 provided one to you?</p> <p>3 A. Yes.</p> <p>4 Q. And it was on or around the</p> <p>5 time of the letter?</p> <p>6 A. It was some time after. I</p> <p>7 don't recollect how far after.</p> <p>8 Q. Like a month after, or less?</p> <p>9 A. It could have been a month</p> <p>10 or two.</p> <p>11 Q. But not, like, a year later?</p> <p>12 MR. NICHOLAS: Object to the</p> <p>13 form.</p> <p>14 THE WITNESS: Not that I</p> <p>15 recollect.</p> <p>16 BY MR. PIFKO:</p> <p>17 Q. I want to point you to some</p> <p>18 provisions in this letter. There's a</p> <p>19 heading, Background.</p> <p>20 Do you see that?</p> <p>21 A. What page are you on?</p> <p>22 Q. On ABDC 00269691.</p> <p>23 MR. NICHOLAS: Could the</p> <p>24 witness have the opportunity to</p>	<p>1 about a couple of provisions in the</p> <p>2 letter.</p> <p>3 A. Just one second.</p> <p>4 Okay.</p> <p>5 Q. My last question was, is</p> <p>6 this letter something that would have</p> <p>7 been maintained by the company in the</p> <p>8 ordinary course of business?</p> <p>9 A. We would have it.</p> <p>10 Q. So let's go to the first</p> <p>11 page of this letter which, again, for the</p> <p>12 record, is ABDCMDL 00269691.</p> <p>13 Are you there?</p> <p>14 A. Page 1, yes.</p> <p>15 Q. Okay. There's a heading</p> <p>16 here, Background.</p> <p>17 Do you see that?</p> <p>18 A. Oh, yes. At the top. Yes.</p> <p>19 Q. It says, As each of you is</p> <p>20 undoubtedly aware, the abuse (nonmedical</p> <p>21 use) of controlled prescription drugs is</p> <p>22 a serious and growing health problem in</p> <p>23 this country.</p> <p>24 Do you see that?</p>

Page 150	Page 152
<p>1 A. Yes.</p> <p>2 Q. Do you agree that the DEA</p> <p>3 communicated that to AmerisourceBergen on</p> <p>4 September 27th, 2006?</p> <p>5 MR. NICHOLAS: Object to the</p> <p>6 form.</p> <p>7 THE WITNESS: So it states.</p> <p>8 It's stated in the letter.</p> <p>9 BY MR. PIFKO:</p> <p>10 Q. And you agree that the</p> <p>11 Department of Justice communicated that</p> <p>12 to AmerisourceBergen?</p> <p>13 MR. NICHOLAS: Object to the</p> <p>14 form.</p> <p>15 THE WITNESS: We received</p> <p>16 this letter, yes.</p> <p>17 BY MR. PIFKO:</p> <p>18 Q. The letter also says, The</p> <p>19 CSA was designed by Congress to combat</p> <p>20 diversion by providing for a closed</p> <p>21 system of drug distribution in which all</p> <p>22 legitimate handlers of controlled</p> <p>23 substances must obtain a DEA</p> <p>24 registration, and as a condition of</p>	<p>1 Q. It then says, If the closed</p> <p>2 system is to function properly as</p> <p>3 Congress envisioned, distributors must be</p> <p>4 vigilant in deciding whether a</p> <p>5 prospective customer can be trusted to</p> <p>6 deliver controlled substances only for</p> <p>7 lawful purposes.</p> <p>8 Do you see that?</p> <p>9 A. I do.</p> <p>10 Q. Do you agree with that</p> <p>11 statement?</p> <p>12 MR. NICHOLAS: Object to the</p> <p>13 form.</p> <p>14 THE WITNESS: I think -- I</p> <p>15 think there's a lot of inference</p> <p>16 there.</p> <p>17 BY MR. PIFKO:</p> <p>18 Q. In what way?</p> <p>19 A. Congress -- he's indicating</p> <p>20 what Congress envisioned. I'm not sure</p> <p>21 what they're basing -- I'm not sure where</p> <p>22 they're drawing that from.</p> <p>23 Q. So you don't agree with that</p> <p>24 statement?</p>
Page 151	Page 153
<p>1 maintaining such registration, must take</p> <p>2 reasonable steps to ensure that their</p> <p>3 registration is not being utilized as a</p> <p>4 source of diversion.</p> <p>5 Do you see that?</p> <p>6 A. Yes.</p> <p>7 Q. Do you agree with that</p> <p>8 statement?</p> <p>9 MR. NICHOLAS: Object to the</p> <p>10 form.</p> <p>11 THE WITNESS: We have a</p> <p>12 responsibility to make sure we</p> <p>13 have adequate controls to prevent</p> <p>14 diversion, yes.</p> <p>15 BY MR. PIFKO:</p> <p>16 Q. And so you agree with the</p> <p>17 characterization here in this letter?</p> <p>18 MR. NICHOLAS: Object to the</p> <p>19 form. The letter is the letter.</p> <p>20 THE WITNESS: I agree that</p> <p>21 we must adhere to our regulatory</p> <p>22 requirements under the Code of</p> <p>23 Federal Regulations.</p> <p>24 BY MR. PIFKO:</p>	<p>1 MR. NICHOLAS: That's not</p> <p>2 what he said. Objection.</p> <p>3 THE WITNESS: I'm just</p> <p>4 stating that there's a statement</p> <p>5 made in there that Congress</p> <p>6 envisioned what the scope was.</p> <p>7 And I'm not sure what</p> <p>8 they're basing that upon. If I</p> <p>9 could see some documentation of</p> <p>10 what Congress indicated as the --</p> <p>11 you know, of our duty of</p> <p>12 vigilant -- deciding whether a</p> <p>13 customer can be trusted to</p> <p>14 deliver, that's what they</p> <p>15 envision, I'd like to know in what</p> <p>16 context.</p> <p>17 BY MR. PIFKO:</p> <p>18 Q. I'm just asking if -- I'm</p> <p>19 not asking you what DEA meant.</p> <p>20 I'm asking, based on your</p> <p>21 understanding of what that sentence</p> <p>22 means, do you agree with it?</p> <p>23 A. I don't know --</p> <p>24 MR. NICHOLAS: Object to the</p>

Page 154	Page 156
<p>1 form.</p> <p>2 THE WITNESS: I don't know</p> <p>3 what they envisioned. I don't</p> <p>4 know what they're basing that on.</p> <p>5 You're asking me to make a</p> <p>6 conclusion off of something I</p> <p>7 don't have all the facts about.</p> <p>8 BY MR. PIFKO:</p> <p>9 Q. So you don't have an</p> <p>10 understanding either way about whether</p> <p>11 distributors must be vigilant in deciding</p> <p>12 whether a prospective customer can be</p> <p>13 trusted to deliver controlled substances</p> <p>14 only for lawful purposes?</p> <p>15 A. We need --</p> <p>16 MR. NICHOLAS: Object to the</p> <p>17 form.</p> <p>18 Go ahead.</p> <p>19 THE WITNESS: We need to</p> <p>20 ensure that the customers that we</p> <p>21 sell to have been appropriately</p> <p>22 licensed and in good standing with</p> <p>23 DEA and the Boards of Pharmacy. I</p> <p>24 agree with that.</p>	<p>1 on the health and general welfare of the</p> <p>2 American people?</p> <p>3 MR. NICHOLAS: Object to the</p> <p>4 form.</p> <p>5 THE WITNESS: Can you just</p> <p>6 restate that?</p> <p>7 BY MR. PIFKO:</p> <p>8 Q. I said, do you have an</p> <p>9 understanding that in attempting to</p> <p>10 prevent illegal distribution of</p> <p>11 controlled substances, that the company's</p> <p>12 actions can have an impact on the health</p> <p>13 and general welfare of the American</p> <p>14 people?</p> <p>15 MR. NICHOLAS: Object to the</p> <p>16 form.</p> <p>17 THE WITNESS: Yeah, I -- can</p> <p>18 you break it into two or three</p> <p>19 questions? Because you lumped a</p> <p>20 lot in there. Can you --</p> <p>21 BY MR. PIFKO:</p> <p>22 Q. What part is tricking you</p> <p>23 up?</p> <p>24 A. The first part.</p>
<p>1 BY MR. PIFKO:</p> <p>2 Q. It says, Congress has</p> <p>3 expressly declared that the illegal</p> <p>4 distribution of controlled substances has</p> <p>5 a substantial and detrimental effect on</p> <p>6 the health and general welfare of the</p> <p>7 American people.</p> <p>8 Do you see that?</p> <p>9 A. Yes.</p> <p>10 Q. Do you agree with that</p> <p>11 statement?</p> <p>12 MR. NICHOLAS: Object to the</p> <p>13 form.</p> <p>14 BY MR. PIFKO:</p> <p>15 Q. It's cites 21 USC.8012.</p> <p>16 A. If Congress has expressly</p> <p>17 declared that, then I agree that Congress</p> <p>18 expressly declared that there's a</p> <p>19 substantial and detrimental effect to the</p> <p>20 American wellbeing.</p> <p>21 Q. Do you have an understanding</p> <p>22 that in attempting to prevent illegal</p> <p>23 distribution of controlled substances,</p> <p>24 the company's actions can have an impact</p>	<p>1 Page 155</p> <p>1 Q. We agree that</p> <p>2 AmerisourceBergen has a duty to take</p> <p>3 actions to prevent illegal distribution</p> <p>4 of controlled substances, agree?</p> <p>5 MR. NICHOLAS: Object to the</p> <p>6 form.</p> <p>7 THE WITNESS: We have a duty</p> <p>8 to make sure that we follow our</p> <p>9 regulatory responsibilities to</p> <p>10 prevent diversion, I agree.</p> <p>11 BY MR. PIFKO:</p> <p>12 Q. And then the question is, in</p> <p>13 carrying out that role, do you believe</p> <p>14 that AmerisourceBergen's actions can have</p> <p>15 an impact on the health and general</p> <p>16 welfare of the American people?</p> <p>17 MR. NICHOLAS: Object to the</p> <p>18 form.</p> <p>19 THE WITNESS: Again, we go</p> <p>20 back to what we were talking about</p> <p>21 before, is that, yes, we have to</p> <p>22 follow our policy and procedure to</p> <p>23 ensure that we have effective</p> <p>24 controls to prevent diversion.</p>

Page 158	Page 160
<p>1 And I'm not sure what more 2 we can say. We have an obligation 3 to ensure that we get medications 4 to the pharmacies in need. And, 5 yes, we do have an obligation to 6 help with providing access for 7 medications to the patients that 8 need them, which I guess would be 9 the public.</p> <p>10 BY MR. PIFKO:</p> <p>11 Q. How about in preventing 12 illegal substances from being 13 distributed, do you believe that 14 AmerisourceBergen's actions can have an 15 impact on the health and general welfare 16 of the American people?</p> <p>17 MR. NICHOLAS: Object to the 18 form.</p> <p>19 THE WITNESS: As long as 20 we -- again, this implies chain 21 under our control, we can do what 22 we can under our control and our 23 responsibilities and we do that 24 diligently.</p>	<p>1 need to dispense them to their 2 patients and that there's access 3 to patients that have been issued 4 a prescription and fill it at the 5 pharmacy, which would have an 6 impact on the health and safety of 7 the public.</p> <p>8 BY MR. PIFKO:</p> <p>9 Q. So you said by not having a 10 diversion occurring within the 11 distribution center, then that's how we 12 impact the health and welfare of the 13 public.</p> <p>14 MR. NICHOLAS: Object to the 15 form.</p> <p>16 BY MR. PIFKO:</p> <p>17 Q. Do you recall saying that?</p> <p>18 MR. NICHOLAS: Object to the 19 form. Are you asking what he said 20 a minute ago and just reading the 21 transcript? Is that what you're 22 doing?</p> <p>23 THE WITNESS: We have an 24 obligation to maintain -- I -- I</p>
Page 159	Page 161
<p>1 And, you know, that's -- and 2 by not having a diversion 3 occurring within the distribution 4 centers, then that's how we impact 5 the health and welfare of the 6 public, by not having that occur 7 within our distribution centers.</p> <p>8 BY MR. PIFKO:</p> <p>9 Q. Okay. And if it does occur, 10 it could have an adverse impact on the 11 health and general welfare of the 12 American public, correct?</p> <p>13 MR. NICHOLAS: Object to the 14 form.</p> <p>15 THE WITNESS: I don't know 16 that. Again, we can go 17 back-and-forth again. I think we 18 covered this ground.</p> <p>19 But we have an obligation to 20 have effective controls to prevent 21 diversion, which we follow. And 22 we also have an obligation to 23 ensure that we get FDA-approved 24 medications to the pharmacies that</p>	<p>1 don't understand what you mean by 2 that.</p> <p>3 BY MR. PIFKO:</p> <p>4 Q. All I'm asking is, you just 5 said: By not having diversion occurring 6 within the distribution centers, then 7 that's how we impact the health and 8 general welfare of the public.</p> <p>9 A. That's a --</p> <p>10 Q. That's a quote I just read 11 from the transcript.</p> <p>12 A. Then that's --</p> <p>13 Q. Okay. Do you agree to 14 having said that?</p> <p>15 A. -- what I stated.</p> <p>16 Again, it goes back to the 17 same issue that you have been asking me, 18 and I've answered it several times, of 19 what our role in the supply channel is, 20 how we -- what things we have in place to 21 prevent diversion. And that is our role 22 and responsibility.</p> <p>23 We don't touch the patient.</p> <p>24 Q. I haven't asked you a</p>

Page 162	Page 164
<p>1 question.</p> <p>2 A. I know you haven't. But you</p> <p>3 continue --</p> <p>4 MR. NICHOLAS: Let him</p> <p>5 finish.</p> <p>6 BY MR. PIFKO:</p> <p>7 Q. You're giving a speech.</p> <p>8 All I asked you --</p> <p>9 A. Well, you're reading back</p> <p>10 what I just said.</p> <p>11 Q. The question I asked is what</p> <p>12 you said. Did you say that? And you're</p> <p>13 giving a speech.</p> <p>14 MR. NICHOLAS: Hold on.</p> <p>15 Hold on. If you're going to go</p> <p>16 back and read him a portion of</p> <p>17 what he just said a minute ago --</p> <p>18 MR. PIFKO: I didn't ask him</p> <p>19 to give a speech.</p> <p>20 MR. NICHOLAS: I think you</p> <p>21 then can also let him answer your</p> <p>22 question.</p> <p>23 MR. PIFKO: No. I just</p> <p>24 said, did you say that? That's</p>	<p>1 question, sir. I don't want a speech to</p> <p>2 questions I'm not asking.</p> <p>3 All I asked you was if I had</p> <p>4 read that portion correctly?</p> <p>5 MR. NICHOLAS: You know</p> <p>6 what, you don't tell him that you</p> <p>7 don't want a speech or you do want</p> <p>8 a speech. Let him answer your</p> <p>9 questions. Don't lecture him.</p> <p>10 MR. PIFKO: We're going to</p> <p>11 have to have this transcript</p> <p>12 evaluated by the court for your</p> <p>13 lack of cooperation and we're</p> <p>14 going to seek appropriate remedies</p> <p>15 at the appropriate time.</p> <p>16 MR. NICHOLAS: That's fine.</p> <p>17 Do whatever you want. Let him</p> <p>18 answer your questions.</p> <p>19 MR. PIFKO: I'm trying to</p> <p>20 ask him, but he's not letting me</p> <p>21 ask questions, because he's</p> <p>22 talking about and giving speeches.</p> <p>23 MR. NICHOLAS: He's not</p> <p>24 letting you answer questions</p>
<p style="text-align: center;">Page 163</p> <p>1 all the question was. And he goes</p> <p>2 on a five-minute speech.</p> <p>3 That's not what the question</p> <p>4 was.</p> <p>5 MR. NICHOLAS: First of all,</p> <p>6 it's been about 20 seconds that</p> <p>7 he's talking. If he wanted to</p> <p>8 talk for an hour, he could. But</p> <p>9 he's not doing that. He's trying</p> <p>10 to answer your questions.</p> <p>11 MR. PIFKO: All my question</p> <p>12 was, was did I read it right?</p> <p>13 MR. NICHOLAS: You're just</p> <p>14 arguing with him.</p> <p>15 MR. PIFKO: No, my question</p> <p>16 was --</p> <p>17 MR. NICHOLAS: You're just</p> <p>18 arguing.</p> <p>19 MR. PIFKO: You're wasting</p> <p>20 our time, okay?</p> <p>21 MR. NICHOLAS: Just ask him</p> <p>22 questions. Yeah --</p> <p>23 BY MR. PIFKO:</p> <p>24 Q. I'm trying to ask you a</p>	<p>1 because he is answering questions.</p> <p>2 MR. PIFKO: He's talking</p> <p>3 about things I'm not asking him.</p> <p>4 MR. NICHOLAS: You're just</p> <p>5 arguing. Go ahead.</p> <p>6 BY MR. PIFKO:</p> <p>7 Q. You said -- I'm reading from</p> <p>8 the transcript -- By not having diversion</p> <p>9 occurring within the distribution center,</p> <p>10 then that's how we impact the health and</p> <p>11 general welfare of the public.</p> <p>12 Agreed?</p> <p>13 A. That's what I said.</p> <p>14 Q. Okay. And so my question</p> <p>15 is, if diversion does occur, then that</p> <p>16 could have an adverse impact on the</p> <p>17 health and welfare of the public.</p> <p>18 Do you agree?</p> <p>19 MR. NICHOLAS: Object to the</p> <p>20 form. You really are arguing.</p> <p>21 Go ahead.</p> <p>22 THE WITNESS: If there's</p> <p>23 diversion occurring -- I mean,</p> <p>24 that's the reason why we have</p>

Page 166	Page 168
<p>1 controls in place, to protect and 2 to guard against diversion. 3 If a diversion occurs, then 4 that would have an impact.</p> <p>5 BY MR. PIFKO:</p> <p>6 Q. Thank you.</p> <p>7 Let's go to the second page 8 of the letter, ABDCMDL 00269692.</p> <p>9 Are you on that page?</p> <p>10 A. Yes.</p> <p>11 Q. I want to read you a section 12 from the second paragraph there; second 13 paragraph, second sentence.</p> <p>14 Moreover, all registrants, 15 manufacturers, distributors, pharmacies 16 and practitioners share responsibility 17 for maintaining appropriate safeguards 18 against diversion.</p> <p>19 Do you agree with that 20 statement?</p> <p>21 A. Yes.</p> <p>22 Q. It says, a little bit 23 further down, Given the extent of 24 prescription drug abuse in the United</p>	<p>1 orders that might be diverted into 2 other-than-legitimate medical, 3 scientific, and industrial channels. 4 Do you see that?</p> <p>5 A. I do.</p> <p>6 Q. Do you agree with that 7 statement?</p> <p>8 MR. NICHOLAS: Object to the 9 form.</p> <p>10 THE WITNESS: Given the -- 11 no, I don't agree.</p> <p>12 BY MR. PIFKO:</p> <p>13 Q. And what's the basis for 14 your disagreement?</p> <p>15 A. Because up until this 16 letter, all of our interactions with DEA 17 and our consultations and meetings and 18 presentations, there had never been any 19 indication, up until this time, that we 20 were to avoid filling suspicious orders. 21 It's the first time I've seen that 22 statement.</p> <p>23 Q. Let's go to the third page, 24 ABDCMDL 00269693. Tell me when you're</p>
Page 167	Page 169
<p>1 States, along with the dangerous and 2 potentially lethal consequences of such 3 abuse, even just one distributor that 4 uses its DEA registration to facilitate 5 diversion can cause enormous harm. 6 Do you agree with that 7 statement?</p> <p>8 MR. NICHOLAS: I'll object 9 to the form. And ask if you're 10 going to read portions of this 11 paragraph, that you read the first 12 sentence of the paragraph as well. 13 THE WITNESS: I don't know 14 the answer to your question. 15 Because -- I don't know.</p> <p>16 BY MR. PIFKO:</p> <p>17 Q. Let's go down a little bit 18 further toward the third-to-last 19 paragraph. 20 In addition -- it says, 21 Thus, in addition to reporting all 22 suspicious orders, a distributor has a 23 statutory responsibility to exercise due 24 diligence to avoid filling suspicious</p>	<p>1 there. 2 A. Yes.</p> <p>3 Q. Do you see the heading at 4 the top is, Circumstances That Might Be 5 Indicative of Diversion? 6 Do you see that?</p> <p>7 A. Yes.</p> <p>8 Q. It's got a list of four 9 items. 10 Do you see that?</p> <p>11 A. Yes.</p> <p>12 Q. Do you believe that the DEA 13 communicated this information to you? 14 MR. NICHOLAS: Object to the 15 form.</p> <p>16 THE WITNESS: In this 17 letter? We received this letter, 18 yes.</p> <p>19 BY MR. PIFKO:</p> <p>20 Q. And then there's another 21 paragraph with ten items. 22 Do you see that?</p> <p>23 A. Yes.</p> <p>24 Q. Do you believe that the DEA</p>

Page 170	Page 172
<p>1 communicated this information to you?</p> <p>2 MR. NICHOLAS: Object to the</p> <p>3 form.</p> <p>4 THE WITNESS: In -- with</p> <p>5 this letter, yes.</p> <p>6 - - -</p> <p>7 (Whereupon, Amerisource</p> <p>8 Bergen-Zimmerman Exhibit-7,</p> <p>9 ABDCMDL 00000101-122, was marked</p> <p>10 for identification.)</p> <p>11 - - -</p> <p>12 BY MR. PIFKO:</p> <p>13 Q. I'm handing you what has</p> <p>14 been marked as Exhibit-7.</p> <p>15 Please take a moment to</p> <p>16 review this document and let me know when</p> <p>17 you're done.</p> <p>18 For the record, it's Bates</p> <p>19 labeled ABDCMDL 00000101 through 122.</p> <p>20 Let me know when you're done</p> <p>21 reviewing the document, sir.</p> <p>22 A. Okay.</p> <p>23 Q. Have you seen this document</p> <p>24 before?</p>	<p>1 Q. Do you have any reason to</p> <p>2 dispute that this is a document from</p> <p>3 AmerisourceBergen's files?</p> <p>4 A. No.</p> <p>5 Q. Do you dispute that this is</p> <p>6 a true and correct copy of what was in</p> <p>7 this document?</p> <p>8 A. I don't know that, because</p> <p>9 I'm not familiar with this presentation.</p> <p>10 Q. You just took some time to</p> <p>11 review the presentation, correct?</p> <p>12 A. Yes.</p> <p>13 Q. The title of the</p> <p>14 presentation, on the first page, is, ABC</p> <p>15 Diversion Control Program, Effective June</p> <p>16 25, 2007.</p> <p>17 Do you see that?</p> <p>18 A. Yes.</p> <p>19 Q. You're familiar with the</p> <p>20 changes that AmerisourceBergen made to</p> <p>21 its diversion control program as a result</p> <p>22 of the settlement with the DEA, correct?</p> <p>23 A. Correct.</p> <p>24 Q. Does this reflect changes</p>
Page 171	Page 173
<p>1 A. I don't know if I've seen</p> <p>2 this exact document, but I've seen</p> <p>3 presentations that have this material in</p> <p>4 them.</p> <p>5 Q. When you say that, what do</p> <p>6 you mean by that?</p> <p>7 MR. NICHOLAS: Object to the</p> <p>8 form.</p> <p>9 THE WITNESS: I'm saying</p> <p>10 that many of these slides in here</p> <p>11 look familiar. I don't know if</p> <p>12 I've seen this exact presentation.</p> <p>13 BY MR. PIFKO:</p> <p>14 Q. Okay. You say you've seen</p> <p>15 some of the slides but maybe not all of</p> <p>16 the slides, or do you think you've seen</p> <p>17 all of the slides?</p> <p>18 MR. NICHOLAS: Object to the</p> <p>19 form.</p> <p>20 THE WITNESS: I think</p> <p>21 I've -- I can't say I've seen</p> <p>22 every single slide, but I'm</p> <p>23 familiar with the information.</p> <p>24 BY MR. PIFKO:</p>	<p>1 that were made to the policy as a result</p> <p>2 of that settlement?</p> <p>3 MR. NICHOLAS: Object to the</p> <p>4 form.</p> <p>5 THE WITNESS: Yes, I believe</p> <p>6 so.</p> <p>7 BY MR. PIFKO:</p> <p>8 Q. Having reviewed this</p> <p>9 document, do you believe this document</p> <p>10 discusses the nature of</p> <p>11 AmerisourceBergen's program as of June</p> <p>12 25th, 2007?</p> <p>13 MR. NICHOLAS: Object to the</p> <p>14 form.</p> <p>15 THE WITNESS: I believe so.</p> <p>16 BY MR. PIFKO:</p> <p>17 Q. Do you know who Steve Mays</p> <p>18 is?</p> <p>19 A. Yes.</p> <p>20 Q. Is he someone that works</p> <p>21 under you?</p> <p>22 A. Yes, he does.</p> <p>23 Q. Does he still work at the</p> <p>24 company?</p>

	Page 174	Page 176
	<p>1 A. He does.</p> <p>2 Q. His title at this time is</p> <p>3 senior director, corporate security and</p> <p>4 regulatory affairs.</p> <p>5 Do you see that?</p> <p>6 A. Yes.</p> <p>7 Q. When he was in that title,</p> <p>8 he reported to you?</p> <p>9 A. Yes.</p> <p>10 Q. Was he a direct report to</p> <p>11 you at this time?</p> <p>12 A. He was.</p> <p>13 Q. Did you instruct him to give</p> <p>14 presentations about AmerisourceBergen's</p> <p>15 diversion control program as it was</p> <p>16 changed from the DEA settlement?</p> <p>17 A. He did presentations, yes.</p> <p>18 Q. Do you know to whom he did</p> <p>19 presentations?</p> <p>20 A. I don't know specifically.</p> <p>21 Q. You said you've seen</p> <p>22 versions of this document.</p> <p>23 Do you believe this was</p> <p>24 something that would have been presented</p>	<p>1 statement of the CFR1301.71.</p> <p>2 BY MR. PIFKO:</p> <p>3 Q. It's a statement of</p> <p>4 AmerisourceBergen's regulatory</p> <p>5 responsibility under this provision; is</p> <p>6 that correct?</p> <p>7 MR. NICHOLAS: Object to the</p> <p>8 form.</p> <p>9 THE WITNESS: It's the</p> <p>10 statement of -- for all</p> <p>11 distributors. It's 1301.71(a).</p> <p>12 BY MR. PIFKO:</p> <p>13 Q. I'm not trying to trick you</p> <p>14 into something.</p> <p>15 I'm just asking, is it your</p> <p>16 understanding that 1301.71(a) applies to</p> <p>17 AmerisourceBergen?</p> <p>18 MR. NICHOLAS: Object to the</p> <p>19 form.</p> <p>20 Go ahead.</p> <p>21 THE WITNESS: It does apply</p> <p>22 to AmerisourceBergen as a</p> <p>23 registrant.</p> <p>24 BY MR. PIFKO:</p>
	<p>1 to people inside the company?</p> <p>2 MR. NICHOLAS: Object to the</p> <p>3 form. Mischaracterizes the</p> <p>4 testimony.</p> <p>5 THE WITNESS: It doesn't say</p> <p>6 who this was actually presented</p> <p>7 to. So I don't know.</p> <p>8 BY MR. PIFKO:</p> <p>9 Q. Let's go to the first page</p> <p>10 of the document here. It says,</p> <p>11 Regulatory responsibility.</p> <p>12 Do you see that?</p> <p>13 A. Yes.</p> <p>14 Q. Have you seen this slide</p> <p>15 before?</p> <p>16 A. I understand -- I don't know</p> <p>17 if I've seen this slide. But, yes, I've</p> <p>18 seen a slide that has this information on</p> <p>19 it, yes.</p> <p>20 Q. Can you tell me what this</p> <p>21 is?</p> <p>22 MR. NICHOLAS: Object to the</p> <p>23 form.</p> <p>24 THE WITNESS: It's just a</p>	<p>1 to people inside the company?</p> <p>2 MR. NICHOLAS: Object to the</p> <p>3 form. Mischaracterizes the</p> <p>4 testimony.</p> <p>5 THE WITNESS: It doesn't say</p> <p>6 who this was actually presented</p> <p>7 to. So I don't know.</p> <p>8 BY MR. PIFKO:</p> <p>9 Q. Let's go to the first page</p> <p>10 of the document here. It says,</p> <p>11 Regulatory responsibility.</p> <p>12 Do you see that?</p> <p>13 A. Yes.</p> <p>14 Q. Do you agree that's what it</p> <p>15 says?</p> <p>16 A. That's what it says.</p> <p>17 Q. And you agree that's a</p> <p>18 regulatory responsibility that</p> <p>19 AmerisourceBergen has?</p> <p>20 A. Yes.</p> <p>21 Q. Let's go to the next page.</p> <p>22 It says, How?</p> <p>23 Do you see that?</p> <p>24 A. Yes.</p> <p>THE WITNESS: It's just a</p> <p>statement of the CFR1301.71.</p> <p>BY MR. PIFKO:</p> <p>Q. It's a statement of</p> <p>AmerisourceBergen's regulatory</p> <p>responsibility under this provision; is</p> <p>that correct?</p> <p>MR. NICHOLAS: Object to the</p> <p>form.</p> <p>THE WITNESS: It's the</p> <p>statement of -- for all</p> <p>distributors. It's 1301.71(a).</p> <p>BY MR. PIFKO:</p> <p>Q. I'm not trying to trick you</p> <p>into something.</p> <p>I'm just asking, is it your</p> <p>understanding that 1301.71(a) applies to</p> <p>AmerisourceBergen?</p> <p>MR. NICHOLAS: Object to the</p> <p>form.</p> <p>Go ahead.</p> <p>THE WITNESS: It does apply</p> <p>to AmerisourceBergen as a</p> <p>registrant.</p> <p>BY MR. PIFKO:</p> <p>Q. And it says, All applicants</p> <p>and registrants shall provide effective</p> <p>controls and procedures to guard against</p> <p>theft and diversion of controlled</p> <p>substances.</p> <p>Do you see that?</p> <p>A. Yes.</p> <p>Q. Do you agree that's what it</p> <p>says?</p> <p>A. That's what it says.</p> <p>Q. And you agree that's a</p> <p>regulatory responsibility that</p> <p>AmerisourceBergen has?</p> <p>A. Yes.</p> <p>Q. Let's go to the next page.</p> <p>It says, How?</p> <p>Do you see that?</p> <p>A. Yes.</p> <p>Q. Do you have an</p> <p>understanding, then, this is how</p> <p>AmerisourceBergen is supposed to carry</p> <p>out its responsibility to provide</p> <p>effective controls and procedures to</p> <p>guard against theft and diversion of</p>

Page 178	Page 180
<p>1 controlled substances?</p> <p>2 MR. NICHOLAS: Object to the</p> <p>3 form.</p> <p>4 THE WITNESS: It appears</p> <p>5 that it lists the different</p> <p>6 elements under that section and</p> <p>7 states the relating Code of</p> <p>8 Federal Regulation's section and</p> <p>9 how companies may -- again, I</p> <p>10 don't know who this was to,</p> <p>11 whether it was internally, to</p> <p>12 distributors. I'm not sure who</p> <p>13 the customer was of the</p> <p>14 presentation.</p> <p>15 But it's just reiterating</p> <p>16 items that fall underneath each of</p> <p>17 the CFR sections.</p> <p>18 BY MR. PIFKO:</p> <p>19 Q. Do you believe -- or do you</p> <p>20 have an understanding that</p> <p>21 AmerisourceBergen has a responsibility to</p> <p>22 comply with the CFR sections identified</p> <p>23 here?</p> <p>24 MR. NICHOLAS: Object to the</p>	<p>1 Q. And afterwards it says, No</p> <p>2 problem.</p> <p>3 Let's look at the first one.</p> <p>4 A. Yes.</p> <p>5 Q. Physical security controls.</p> <p>6 No problem.</p> <p>7 Do you see that?</p> <p>8 A. Yes, I see that.</p> <p>9 Q. Records and reports of</p> <p>10 registrants. No problem.</p> <p>11 Do you see that?</p> <p>12 A. Yes.</p> <p>13 Q. Orders for filling -- for</p> <p>14 Schedule I and II controlled substances.</p> <p>15 No problem.</p> <p>16 Do you see that?</p> <p>17 A. Yes.</p> <p>18 Q. Other security controls-make</p> <p>19 a good faith inquiry; report suspicious</p> <p>20 orders; report significant losses. Gray</p> <p>21 area.</p> <p>22 Do you see that?</p> <p>23 A. Yes.</p> <p>24 Q. Do you have an understanding</p>
<p>1 form.</p> <p>2 THE WITNESS: These are</p> <p>3 sections that we -- that fall</p> <p>4 under the distributor</p> <p>5 requirements, yes.</p> <p>6 BY MR. PIFKO:</p> <p>7 Q. And do you believe that they</p> <p>8 apply to AmerisourceBergen?</p> <p>9 A. Yes.</p> <p>10 Q. Under CFR1301.74 -- do you</p> <p>11 see that at the bottom?</p> <p>12 A. Yes.</p> <p>13 Q. It says -- for all the other</p> <p>14 ones above, it says a statement of the</p> <p>15 regulation with a short summary, and it</p> <p>16 says, No problem.</p> <p>17 Do you see that?</p> <p>18 A. I'm sorry, where?</p> <p>19 Q. If you look at each</p> <p>20 regulation, it's got a number, a bold</p> <p>21 heading, a subject of that, and then it</p> <p>22 has a brief summary of it.</p> <p>23 Do you see that?</p> <p>24 A. Yes.</p>	<p>1 about what it means by "gray area"?</p> <p>2 A. I think what they're</p> <p>3 referring to, under these regulations,</p> <p>4 are -- say 1301.72, physical security</p> <p>5 controls, that the DEA has been very</p> <p>6 specific.</p> <p>7 So vaults need to have</p> <p>8 poured-in-place concrete, 8 inches thick,</p> <p>9 half-inch rebar, 6 inches on center. And</p> <p>10 cages have to be developed of 10-gauge</p> <p>11 steel. Openings can't be more than 2.5</p> <p>12 inch diameter across. The structure has</p> <p>13 to be built on 6-inch -- 1-inch posts</p> <p>14 with 6 inches apart. They're very</p> <p>15 specific.</p> <p>16 With regards to reports, it</p> <p>17 explains exactly how often you have to do</p> <p>18 inventories, how to annotate it. It's</p> <p>19 black-and-white.</p> <p>20 And then also with the</p> <p>21 schedule order 222 forms, it states that</p> <p>22 you can't complete a line that has any</p> <p>23 alterations. It's very black-and-white.</p> <p>24 And when it gets to</p>

<p style="text-align: right;">Page 182</p> <p>1 reporting suspicious orders, it's very -- 2 a gray area, because it's not 3 black-and-white. It doesn't say over 4 five or less than four. And with 5 significant losses, there's no 6 definition. Is it a thousand? Is it 7 one? Is it five? Is it 10,000? 8 So that's, I believe, I 9 don't want to speak for Steve Mays, but I 10 believe that's the inference, is that DEA 11 has been very diligent about laying out 12 responsibilities, black-and-white, 13 through all these requirements, and then 14 this one area is -- they're not very 15 specific at all. It's very open-ended. 16 If that makes sense. 17 Q. Let's go to the next page. 18 It's got another CFR section 19 here -- well, actually, the one we were 20 just talking about, part of it. 21 Do you see that? 22 A. Yes. 23 Q. It says, The registrant 24 shall design and operate a system to</p>	<p style="text-align: right;">Page 184</p> <p>1 not relieve the distributor of the 2 responsibility to maintain effective 3 controls to prevent diversion. 4 Do you see that? 5 A. Yes. 6 Q. Do you have an understanding 7 about what that means? 8 MR. NICHOLAS: Object to the 9 form. 10 THE WITNESS: That you can't 11 just have a system that has -- 12 that reports suspicious orders and 13 not have -- not have effective 14 controls in all the other areas we 15 just mentioned. It doesn't 16 relieve your responsibility to 17 maintain effective controls. 18 BY MR. PIFKO: 19 Q. Right. So just reporting a 20 suspicious order doesn't discharge your 21 responsibility under The Controlled 22 Substances Act, correct? 23 A. For recordkeeping, all those 24 other ones we kind of just went through.</p>
<p style="text-align: right;">Page 183</p> <p>1 disclose to the registrant suspicious 2 orders of controlled substances. The 3 registrant shall inform field diversion 4 office of the administration in his area 5 of suspicious orders when covered by the 6 registrant. 7 Do you see that? 8 A. Yes. 9 Q. Do you agree that that's a 10 regulatory responsibility that 11 AmerisourceBergen has? 12 MR. NICHOLAS: Object to the 13 form. 14 But go ahead. 15 THE WITNESS: Yes. 16 BY MR. PIFKO: 17 Q. Let's go to the next page. 18 Are we there? 19 A. Yes. 20 Q. Okay. Again, it says, 21 Regulatory responsibility. It's got 22 three bullet points. 23 The first one says, 24 Reporting suspicious orders to DEA does</p>	<p style="text-align: right;">Page 185</p> <p>1 They are all grouped under the same 2 section, effective controls to prevent 3 diversion, 1301. All of these are in 4 1301. 5 So just doing one of 1301, 6 74, doesn't relieve you of all the other 7 items under 1301.71. 8 Q. The next bullet point says, 9 DEA cannot/will not tell a distributor if 10 an order is or is not legitimate; and/or 11 if the distributor should or should not 12 ship an order. 13 Do you see that? 14 A. Yes. 15 Q. Is that consistent with your 16 understanding of the DEA's position? 17 A. Yes. At the time of this 18 presentation, yes.</p>

Page 186

Page 188

Page 187

Page 189

24 completing transactions?

about



Page 190

Page 192

13 Q. Do you have a copy of that
14 presentation that you believe that DEA
15 made to you in your office somewhere?

16 A. We may have it somewhere,
17 yes.

18 Q. Did you make any attempts to
19 look for it?

20 MR. NICHOLAS: Objection.
21 We're making productions as we're
22 required to do in this case.

23 THE WITNESS: Is there a
24 question?

Page 191

Page 193

¹ BY MR. PIFKO:

2 Q. I asked if you made any
3 attempt to look for that document?

4 A. No, I did not.

5 Q. Is that something -- you
6 said you might have that in your office
7 somewhere?

8 A. I won't have -- no, I don't
9 have that in my office. We may have it
10 on file or in storage or something. It's
11 from years ago.

12 MR. NICHOLAS: Again, just
13 in case there's any implication on
14 the record that we haven't
15 produced something we were
16 supposed to produce.

17 MR. PIFKO: Again, the
18 speaking -- I got it. There's no
19 implication. The record is what
20 it is.

21 MR. NICHOLAS: Good. That's
22 all I want to hear. There's no
23 implication. That's fantastic
24 news.

Page 194	Page 196
<p>1 Go ahead.</p> <p>2 BY MR. PIFKO:</p> <p>3 Q. Was anyone else present at</p> <p>4 this presentation that you're referring</p> <p>5 to?</p> <p>6 A. Steve Mays.</p> <p>7 Q. And who specifically from</p> <p>8 the DEA was there?</p> <p>9 A. I was not there. I</p> <p>10 believe -- I believe Mike Mapes.</p> <p>11 Q. Anyone else?</p> <p>12 A. I don't know, because I</p> <p>13 wasn't there.</p> <p>14 Q. Did you undertake any</p> <p>15 effort, in connection with preparing for</p> <p>16 this deposition, to learn about</p> <p>17 communications with the DEA that might</p> <p>18 have occurred?</p> <p>19 A. In what context?</p> <p>20 Q. Concerning The Controlled</p> <p>21 Substances Act.</p> <p>22 MR. NICHOLAS: Object to the</p> <p>23 form.</p> <p>24 THE WITNESS: I'm not</p>	<p>1 Steve Mays and maybe Mike Mapes from the</p> <p>2 DEA?</p> <p>3 MR. NICHOLAS: If you can</p> <p>4 answer that and it doesn't involve</p> <p>5 attorney-client communications,</p> <p>6 that's fine. If not, please don't</p> <p>7 answer.</p> <p>8 THE WITNESS: I can't</p> <p>9 answer.</p> <p>10 BY MR. PIFKO:</p> <p>11 Q. So the only conversations</p> <p>12 you may have had about this meeting</p> <p>13 were -- involved counsel?</p> <p>14 MR. NICHOLAS: I'm going to</p> <p>15 instruct him not to answer.</p> <p>16 BY MR. PIFKO:</p> <p>17 Q. You're unable to answer any</p> <p>18 questions about inquiries about this</p> <p>19 meeting based on the attorney-client</p> <p>20 privilege; is that correct?</p> <p>21 MR. NICHOLAS: I'll instruct</p> <p>22 him not to answer. I'm</p> <p>23 instructing him not to answer. He</p> <p>24 doesn't have to answer questions</p>
<p>1 understanding your question. I'm</p> <p>2 sorry.</p> <p>3 BY MR. PIFKO:</p> <p>4 Q. I'm just asking if you tried</p> <p>5 to learn about the company's</p> <p>6 communications with the DEA in connection</p> <p>7 with preparing for this deposition.</p> <p>8 A. Yes.</p> <p>9 Q. Did you ask anyone about</p> <p>10 that meeting that we were just talking</p> <p>11 about where Steve Mays and maybe Mike</p> <p>12 Mapes was there?</p> <p>13 A. I think --</p> <p>14 THE WITNESS: Is that a</p> <p>15 legal question?</p> <p>16 MR. NICHOLAS: To the extent</p> <p>17 this question invades the</p> <p>18 attorney-client privilege, don't</p> <p>19 answer it. I'll instruct you not</p> <p>20 to answer it.</p> <p>21 BY MR. PIFKO:</p> <p>22 Q. All I'm asking is if you</p> <p>23 asked anyone other than counsel about</p> <p>24 this meeting where -- in 2005 between</p>	<p>1 about this.</p> <p>2 MR. PIFKO: I'm trying to</p> <p>3 understand the privilege that's</p> <p>4 being asserted here.</p> <p>5 MR. NICHOLAS: It's the</p> <p>6 attorney-client privilege.</p> <p>7 MR. PIFKO: So the witness</p> <p>8 is being instructed not to answer</p> <p>9 any questions about efforts he</p> <p>10 undertook to learn about this</p> <p>11 meeting; is that correct?</p> <p>12 MR. NICHOLAS: No, not at</p> <p>13 all.</p> <p>14 MR. PIFKO: That's what I'm</p> <p>15 trying to understand. So I'm</p> <p>16 asking the witness --</p> <p>17 MR. NICHOLAS: If the</p> <p>18 witness undertook any efforts</p> <p>19 in -- at the direction of or, you</p> <p>20 know, in conjunction with attorney</p> <p>21 communications, then I'm only</p> <p>22 instructing him to answer in that</p> <p>23 respect.</p> <p>24 BY MR. PIFKO:</p>

1 Q. Aside from any efforts at
2 the direction of counsel or in
3 conjunction with an attorney, did you
4 engage in any efforts to learn about this
5 DEA meeting between Steve Mays and Mike
6 Mapes in 2005?

7 A. No.

8 Q. You don't know if anyone
9 else was present besides the two of them?

10 A. I don't know.

11 Q. Let's go to the next page.

12 MR. NICHOLAS: For planning
13 purposes, purely a scheduling
14 thing, after you get through this
15 document --

16 MR. PIFKO: We'll take a
17 break.

18 MR. NICHOLAS: For lunch or
19 a short break, whatever you
20 prefer.

Page 198


Page 200

Page 199

Page 201

Page 202

Page 204



Page 203

Page 205



Page 206

Page 208

Page 207

Page 209



Page 210

Page 212

Page 211

Page 213



Page 214

Page 216

Page 215

Page 217




Page 218

Page 220

Page 219

Page 221



Page 222

Page 224

24 MR. PIFKO: We can take a

Page 223

Page 225

1 break.
2 VIDEO TECHNICIAN: Going off
3 the record. The time is 12:30
4 p.m.

5 - - -
6 (Whereupon, a luncheon
7 recess was taken.)
8 - - -

9 VIDEO TECHNICIAN: We're
10 back on the record. The time is
11 1:19 p.m.

12 BY MR. PIFKO:

13 Q. Let's go back to Exhibit-6,
14 the stack of Dear Registrant letters.

15 Let's go two pages in to the
16 second -- or the Dear Registrant letter
17 dated December 27th, 2007.

18 Do you see that? It's on
19 Bates label ABDCMDL 00269685.

20 Are you there, sir?

21 A. Yes.

22 Q. Did AmerisourceBergen
23 receive this letter?

24 MR. NICHOLAS: Could you

Page 226	Page 228
<p>1 just ask him to take -- give him 2 just a minute to take a quick look 3 at it and make sure he's familiar 4 with the document before he 5 responds to these questions.</p> <p>6 MR. PIFKO: I think we went 7 over these before.</p> <p>8 MR. NICHOLAS: I think you 9 showed him the one and asked him 10 that question. He didn't look at 11 all the letters. He looked at 12 one.</p> <p>13 THE WITNESS: Okay.</p> <p>14 BY MR. PIFKO:</p> <p>15 Q. Are you ready? It's a 16 two-page letter here.</p> <p>17 A. Yes.</p> <p>18 Q. Did AmerisourceBergen 19 receive this letter?</p> <p>20 A. I believe so, at the 21 distribution centers.</p> <p>22 Q. And that would have been on 23 or around the date of this letter, 24 December 27th, 2007?</p>	<p>1 CSA compliance were discussed with DEA. 2 Generally, do you recall 3 that?</p> <p>4 A. We've had ongoing 5 communications with DEA since I started 6 with the company. I referenced our 7 negotiations with them in '96 to '98, 8 with the suspicious order monitoring 9 program, which resulted in an approval 10 letter. And then the negotiations, in 11 2007.</p> <p>12 So we've had ongoing -- and 13 we also provided training for DEA 14 diversion investigators from '99 to 2004 15 or '05. So we've had an open dialogue 16 with DEA since I've been with the 17 company.</p> <p>18 Q. Did anyone at the company 19 discuss this statement with the DEA and 20 how it impacted some of the prior 21 discussions that you may have had with 22 them?</p> <p>23 MR. NICHOLAS: Object to the 24 form.</p>
Page 227	Page 229
<p>1 A. I would assume so.</p> <p>2 Q. Let's go to the second 3 paragraph, last sentence -- or, sorry, 4 second-to-last sentence.</p> <p>5 Accordingly, DEA does not 6 approve or otherwise endorse any specific 7 system for reporting suspicious orders. 8 Past communications with DEA, whether 9 implicit or explicit, that could be 10 construed as approval of a particular 11 system for reporting suspicious orders 12 should no longer be taken to mean that 13 DEA approves a specific system.</p> <p>14 Do you see that?</p> <p>15 A. Yes.</p> <p>16 Q. Were you aware that that was 17 a statement that the DEA had made to 18 AmerisourceBergen at that time?</p> <p>19 A. Yes.</p> <p>20 Q. Did you discuss that with 21 anyone at the company?</p> <p>22 A. No.</p> <p>23 Q. Earlier you testified that 24 certain aspects of AmerisourceBergen's</p>	<p>1 THE WITNESS: No.</p> <p>2 BY MR. PIFKO:</p> <p>3 Q. For example, with respect to 4 the business decision that we talked 5 about in Exhibit-7 that you recalled 6 having been derived from a meeting in 7 2005, did anyone say to the DEA, as a 8 result of this December 27th, 2007 9 letter, we can no longer rely on that?</p> <p>10 MR. NICHOLAS: Object to the 11 form. Only if you're asking about 12 any conversation anyone at the 13 company ever had. I don't know 14 how he can answer that.</p> <p>15 But go ahead.</p> <p>16 THE WITNESS: Can you 17 restate that or paraphrase the 18 question, please?</p> <p>19 BY MR. PIFKO:</p> <p>20 Q. Do you remember that 21 Exhibit-7 talked about the business 22 decision about whether to ship an order?</p> <p>23 A. Yes.</p> <p>24 Q. You remember testifying that</p>

Page 230	Page 232
<p>1 that was derived from a conversation with 2 the DEA in 2005? 3 A. It wasn't derived from a 4 conversation. It was -- it was -- you 5 had asked about the quotations of the 6 business decision, and that was a slide 7 on a DEA slide, not ABC slide.</p> <p>8 Q. From a -- you said from a 9 presentation between Steve Mays and Mike 10 Mapes in 2005?</p> <p>11 A. From a presentation from DEA 12 to Steve Mays.</p> <p>13 Q. Did anyone, at this time, 14 reach out to the DEA and say, we can no 15 longer rely on that presentation?</p> <p>16 MR. NICHOLAS: Object to the 17 form.</p> <p>18 THE WITNESS: No.</p> <p>19 BY MR. PIFKO:</p> <p>20 Q. This letter also says, in 21 the second paragraph, Filling a monthly 22 report -- Filing a monthly report of 23 completed transactions, e.g., excessive 24 purchase report or high unit purchases,</p>	<p>1 agree that its responsibility continued 2 after the filing of a suspicious order 3 report? 4 MR. NICHOLAS: Object to the 5 form. 6 THE WITNESS: I mean, the 7 program we developed, which is 8 pretty much two months, three -- a 9 few months before this letter, is 10 pretty much in line with this 11 letter, in that -- in the way that 12 this is written, I'm not sure if 13 they're referring that an order 14 that hits a -- they're calling it 15 an excessive purchase, meet the 16 requirements of suspicious order, 17 is that an order of interest or a 18 suspicious order? 19 So I'm not really sure of 20 the context of their statement.</p> <p>21 BY MR. PIFKO:</p> <p>22 Q. Well, he's saying, 23 Responsibility does not end merely with 24 the filing of a suspicious order report.</p>
<p>1 does not meet the regulatory requirement 2 to report suspicious orders. Registrants 3 are reminded that their responsibility 4 does not end merely with the filing of a 5 suspicious order report.</p> <p>6 Do you see that?</p> <p>7 A. Are you in the --</p> <p>8 MR. NICHOLAS: Could you 9 highlight it on the screen?</p> <p>10 MR. CLUFF: We're putting it 11 up now. It was actually the third 12 paragraph.</p> <p>13 THE WITNESS: I didn't see 14 that. Sorry.</p> <p>15 What line in the third 16 paragraph? I just want to make 17 sure, if I'm commenting on this.</p> <p>18 And your question? I'm 19 sorry.</p> <p>20 BY MR. PIFKO:</p> <p>21 Q. You see that, first, was the 22 question? You do see it now?</p> <p>23 A. Yes.</p> <p>24 Q. Okay. Did AmerisourceBergen</p>	<p>1 So he's talking about 2 suspicious orders. 3 Do you see that? 4 A. Yes. 5 Q. So my question is, does 6 AmerisourceBergen agree that its 7 responsibility extends beyond the filing 8 of a suspicious order report? 9 MR. NICHOLAS: Object to the 10 form. 11 But go ahead. 12 THE WITNESS: I'm not really 13 sure of the context of -- once we 14 file the suspicious order report, 15 I'm not necessarily saying that 16 there's any additional 17 responsibility we have after the 18 filing of the suspicious order 19 report.</p> <p>20 BY MR. PIFKO:</p> <p>21 Q. So you disagree with that 22 statement, is that what I'm hearing you 23 say? 24 That's fine, whatever you're</p>

Page 234	Page 236
<p>1 saying. I just don't understand your 2 answer.</p> <p>3 MR. NICHOLAS: Object to the 4 form.</p> <p>5 Go ahead.</p> <p>6 THE WITNESS: Yes.</p> <p>7 BY MR. PIFKO:</p> <p>8 Q. Yes, you disagree?</p> <p>9 A. I disagree -- let me read it 10 on the page, so I can make sure that --</p> <p>11 So again, it depends on the 12 context of the sentence. Our registrants 13 are reminded that their responsibility 14 does not end merely with the filing of a 15 suspicious order.</p> <p>16 That's correct. We have 17 other responsibilities to have adequate 18 controls to prevent diversion, other than 19 the filing of a suspicious order. So I'm 20 not sure if their statement is in the 21 context of filing a suspicious order and 22 the totality of the distributor's 23 responsibility.</p> <p>24 Q. Well, let me ask a different</p>	<p>1 form. Outside the scope.</p> <p>2 THE WITNESS: I don't think 3 that is in line with the 4 regulatory responsibilities of a 5 distributor, to define a program 6 to report suspicious orders.</p> <p>7 BY MR. PIFKO:</p> <p>8 Q. Let's go to the last 9 sentence of that paragraph.</p> <p>10 It says, Reporting an order 11 as suspicious will not absolve the 12 registrant of responsibility if the 13 registrant knew or should have known that 14 controlled substances were being 15 diverted.</p> <p>16 Do you see that?</p> <p>17 A. I do see that.</p> <p>18 Q. Do you agree with that 19 statement?</p> <p>20 A. If I had more understanding 21 of what should have -- what they're 22 constituting as should have known.</p> <p>23 Q. Do you believe that if 24 AmerisourceBergen knows that controlled</p>
<p>1 question.</p> <p>2 Regardless of what this 3 letter says or doesn't say, does 4 AmerisourceBergen agree that with respect 5 to a suspicious order, its 6 responsibilities under The Controlled 7 Substances Act don't end by merely filing 8 a suspicious order report?</p> <p>9 MR. NICHOLAS: Object to the 10 form.</p> <p>11 THE WITNESS: I think my 12 last answer is the -- is the same 13 answer.</p> <p>14 That filing a suspicious 15 order does not meet all the 16 requirements of -- to have an 17 effective controls for diversion.</p> <p>18 So my answer is the same.</p> <p>19 BY MR. PIFKO:</p> <p>20 Q. Do you believe that 21 AmerisourceBergen is required to conduct 22 due diligence of a suspicious order even 23 after a suspicious order report is filed?</p> <p>24 MR. NICHOLAS: Object to the</p>	<p>1 substances are being diverted, it has to 2 do more to prevent diversion beyond just 3 reporting it?</p> <p>4 MR. NICHOLAS: Object to the 5 form. Could you be more specific 6 with the question?</p> <p>7 THE WITNESS: It's a 8 hypothetical question, I think.</p> <p>9 BY MR. PIFKO:</p> <p>10 Q. You can't give an answer to 11 the question?</p> <p>12 A. If we -- I think, if a 13 distributor knows that a pharmacy and -- 14 they know that they're diverting, then 15 they have responsibility to react.</p> <p>16 Q. So do you agree that the 17 company has a responsibility to act?</p> <p>18 A. If they have --</p> <p>19 MR. NICHOLAS: Object to the 20 form.</p> <p>21 Go ahead.</p> <p>22 THE WITNESS: If they know 23 there's a pharmacy that's -- that 24 they know is diverting product.</p>

Page 238	Page 240
<p>1 BY MR. PIFKO:</p> <p>2 Q. Okay. So just, again, I'm</p> <p>3 not trying to misstate your testimony, I</p> <p>4 just want to get a clear record.</p> <p>5 So it's my understanding</p> <p>6 that what you just said is if</p> <p>7 AmerisourceBergen knows that a pharmacy</p> <p>8 is diverting product, it has a</p> <p>9 responsibility to act; is that correct?</p> <p>10 MR. NICHOLAS: Object to the</p> <p>11 form.</p> <p>12 THE WITNESS: It depends on</p> <p>13 the circumstances. You asked me a</p> <p>14 hypothetical question.</p> <p>15 So, again, and I'm not sure,</p> <p>16 again, when we put the context of</p> <p>17 diversion, what we're talking</p> <p>18 about.</p> <p>19 If a pharmacy has an</p> <p>20 employee that was arrested for</p> <p>21 diverting product, they put a</p> <p>22 bottle in their pocket, the</p> <p>23 reaction is going to be different.</p> <p>24 So it all depends upon the</p>	<p>1 AmerisourceBergen would know about</p> <p>2 diversion and not be obligated to act?</p> <p>3 MR. NICHOLAS: Object to the</p> <p>4 form. I think you're now just</p> <p>5 arguing.</p> <p>6 THE WITNESS: Again, it all</p> <p>7 depends on the circumstances of</p> <p>8 the case.</p> <p>9 BY MR. PIFKO:</p> <p>10 Q. Well, so, if it depends on</p> <p>11 the circumstances, there must be</p> <p>12 circumstances where AmerisourceBergen</p> <p>13 would know of diversion and you don't</p> <p>14 believe they would be required to act.</p> <p>15 MR. NICHOLAS: Object to the</p> <p>16 form. This isn't --</p> <p>17 MR. PIFKO: You've got to</p> <p>18 stop. You have to stop.</p> <p>19 You can object in a normal</p> <p>20 objection way, you can say form.</p> <p>21 You can say foundation. You can</p> <p>22 state a legal objection.</p> <p>23 But you are coaching the</p> <p>24 witness. You have done</p>
<p>1 totality of the circumstance.</p> <p>2 I can't give you a general</p> <p>3 answer that if there's a pharmacy</p> <p>4 that's diverting, depending upon</p> <p>5 what that type of diversion is,</p> <p>6 what that action will be.</p> <p>7 BY MR. PIFKO:</p> <p>8 Q. But you agree that some</p> <p>9 action may be -- it depends on the nature</p> <p>10 of the diversion -- the action would</p> <p>11 depend on the nature of the diversion,</p> <p>12 but some action would be required?</p> <p>13 MR. NICHOLAS: Object to the</p> <p>14 form.</p> <p>15 THE WITNESS: It depends on</p> <p>16 the circumstances. And, again,</p> <p>17 it's a case-by-case basis,</p> <p>18 depending upon the totality of the</p> <p>19 circumstances, of what the</p> <p>20 reaction would be. There isn't a</p> <p>21 must.</p> <p>22 BY MR. PIFKO:</p> <p>23 Q. So is it your testimony that</p> <p>24 there are circumstances where</p>	<p>1 textbook -- there is case law</p> <p>2 addressing exactly what you're</p> <p>3 doing in this district, and you</p> <p>4 need to stop, okay?</p> <p>5 MR. NICHOLAS: Listen. Now</p> <p>6 you're going to let me speak for a</p> <p>7 minute.</p> <p>8 MR. PIFKO: No, I'm not.</p> <p>9 You need to stop this right now.</p> <p>10 MR. NICHOLAS: I read the</p> <p>11 transcript of your defense of the</p> <p>12 Merrill Gordon.</p> <p>13 MR. PIFKO: We're not</p> <p>14 talking about anything right now.</p> <p>15 And all I did -- and all I did was</p> <p>16 state my objections with clarity</p> <p>17 and specificity. And I did not</p> <p>18 coach the witness at one moment of</p> <p>19 the deposition.</p> <p>20 You are telling -- you said</p> <p>21 things like "if you know." You</p> <p>22 said that before the last break.</p> <p>23 MR. NICHOLAS: Is that so</p> <p>24 horrible?</p>

Page 242	Page 244
<p>1 MR. PIFKO: Because there's 2 case law prohibiting that kind of 3 conduct. That is directing the 4 witness. If you know, that's 5 directing the witness to say I 6 don't know.</p> <p>7 You cannot do that. Just 8 stop.</p> <p>9 MR. NICHOLAS: 10 Unfortunately --</p> <p>11 MR. PIFKO: Am I going to 12 get your agreement that you're 13 going to comply with the law?</p> <p>14 MR. NICHOLAS: I've been 15 complying with the law the entire 16 time.</p> <p>17 I read your deposition.</p> <p>18 MR. PIFKO: You've been 19 coaching the witness.</p> <p>20 MR. NICHOLAS: I have not.</p> <p>21 MR. PIFKO: You have.</p> <p>22 MR. NICHOLAS: I read your 23 transcript of the Merrill 24 Gordon --</p>	<p>1 AmerisourceBergen is aware of diversion, 2 do you believe that beyond reporting it 3 to the DEA, the company has a 4 responsibility to take some action?</p> <p>5 A. It depends on the 6 circumstances. We had an investigation, 7 we were working with DEA, and they had 8 diversion at a pharmacy and we were told 9 to continue servicing them during the 10 course of the investigation.</p> <p>11 There's an instance where we 12 knew of diversion and we didn't take any 13 action because we were working with the 14 DEA.</p> <p>15 Every instance is different. 16 You're asking me to give you a blanket 17 response to situational instances. And I 18 can't. There's -- no two are alike. And 19 I can't give you a single answer to your 20 response, because it depends.</p> <p>21 It depends. If DEA wants us 22 to continue servicing them and there's a 23 diversion, then we would have no action.</p> <p>24 Q. What pharmacy are you</p>
<p>1 MR. PIFKO: I never once 2 said facts --</p> <p>3 MR. NICHOLAS: I never saw 4 anything like it.</p> <p>5 MR. PIFKO: -- in my 6 objections.</p> <p>7 MR. NICHOLAS: It was an 8 incredible thing. I'm like Mother 9 Teresa compared to you in that 10 deposition.</p> <p>11 MR. PIFKO: I disagree.</p> <p>12 MR. NICHOLAS: I'm sure you 13 do disagree.</p> <p>14 MR. PIFKO: We're moving on. 15 You need to stop, okay?</p> <p>16 MR. NICHOLAS: I will 17 continue to do exactly what I 18 think is appropriate in this 19 deposition, as needed.</p> <p>20 BY MR. PIFKO:</p> <p>21 Q. I'm trying to get an answer 22 from you, and I'm just trying to 23 understand what your testimony is, okay?</p> <p>24 So I've asked you if</p>	<p>1 referring to where there was diversion 2 and the DEA told you to continue 3 servicing them?</p> <p>4 MR. NICHOLAS: I'm going to 5 caution the witness that if 6 there's -- for any reason, this is 7 an ongoing investigation and 8 confidential --</p> <p>9 MR. PIFKO: He raised the 10 issue.</p> <p>11 MR. NICHOLAS: I don't care. 12 If it's confidential and he's not 13 supposed to disclose the name of 14 it for legal reasons, then he 15 shouldn't do it.</p> <p>16 THE WITNESS: And it's some 17 time ago and outside the scope.</p> <p>18 MR. PIFKO: You're not 19 allowed to object to outside the 20 scope, sir.</p> <p>21 MR. NICHOLAS: Well, he's 22 not objecting.</p> <p>23 MR. PIFKO: He just said 24 it's outside the scope.</p>

Page 246	Page 248
<p>1 MR. NICHOLAS: I don't know 2 that -- 3 MR. PIFKO: You're a fact 4 witness here as well as a 30(b)(6) 5 witness. You need to answer my 6 questions. 7 THE WITNESS: I don't know 8 the name of the pharmacy, but we 9 received recognition from the DEA 10 for participation in the 11 investigation.</p> <p>12 BY MR. PIFKO:</p> <p>13 Q. When was that?</p> <p>14 A. It was 2002 or 2004, I can't 15 remember the time frame.</p> <p>16 But after the course of the 17 investigation, the prosecution, we 18 received a certificate of recognition 19 from the DEA. That's the case I'm 20 referring to.</p> <p>21 Q. So it was a concluded 22 investigation, correct?</p> <p>23 A. Yes.</p> <p>24 Q. Okay. Where was this</p>	<p>1 individuals. 2 You're asking me as a -- as 3 a -- this gets to the part of am I 4 a 3 -- what is it? 5 MR. NICHOLAS: 30(b)(6). 6 THE WITNESS: 30(b)(6) or me 7 personally.</p> <p>8 BY MR. PIFKO:</p> <p>9 Q. Do you know if that pharmacy 10 in New Jersey was put on the do not ship 11 list?</p> <p>12 MR. NICHOLAS: Object to the 13 form. Outside the scope.</p> <p>14 THE WITNESS: I don't know. 15 I don't know.</p> <p>16 BY MR. PIFKO:</p> <p>17 Q. I'm handing you what is 18 marked as Exhibit-8.</p> <p>19 - - - 20 (Whereupon, Amerisource 21 Bergen-Zimmerman Exhibit-8, 22 ABDCMDL 00270533, was marked for 23 identification.) 24 - - -</p>
Page 247	Page 249
<p>1 pharmacy? What state? 2 A. It was in New Jersey. 3 Q. Okay. What type of pharmacy 4 was it? 5 A. I don't -- I mean, you're 6 talking about something that happened 16 7 years ago. I know we received a 8 recognition for participation in the 9 investigation. And, you know, I don't 10 know the name of the pharmacy. I don't 11 know the -- 12 Q. Can you recall any other 13 pharmacies where the DEA told you to 14 continue shipping to them despite knowing 15 about diversion? 16 A. I don't. 17 Q. So that's only happened, to 18 your knowledge, on one occasion? 19 MR. NICHOLAS: Object to the 20 form. 21 THE WITNESS: That I'm aware 22 of right now. And I'm not saying 23 that that hasn't occurred within 24 my department and with other</p>	<p>1 MR. PIFKO: For the record, 2 it's a single-page document Bates 3 labeled ABDCMDL 00270533. It's 4 dated Monday, August 7th, 2017. 5 BY MR. PIFKO: 6 Q. And I will represent to you 7 that the metadata that accompanied this 8 document says that it came from your 9 files, Mr. Zimmerman. 10 So please take a moment to 11 review it and let me know when you're 12 done. 13 A. Yes. 14 Q. Are you done? 15 A. I am. 16 Q. Okay. Do you recognize this 17 document? 18 A. I don't -- I guess it's a 19 document. 20 Q. Do you recall writing this? 21 A. It was notes, yes. 22 Q. What was it notes for? 23 A. I think I was -- for -- I 24 was probably meeting with somebody, so I</p>

<p>1 was just jotting down some points. 2 Q. BOD, is that board of 3 directors? 4 A. Board of -- where? 5 Q. It's on the subject line. 6 A. I think it was supposed to 7 be -- I'm not sure. I don't know if it 8 should have been BOP or BOD. Board of 9 Pharmacy. I'm not sure. I can't 10 remember. 11 Q. What would CS mean? 12 Controlled substances? 13 A. I don't recall. 14 Q. TPs, does that mean anything 15 to you? 16 A. I'm guessing -- if I had to 17 guess, I would say talking points. 18 Q. So it could be board of 19 directors, controlled substances, talking 20 points? 21 MR. NICHOLAS: Object to the 22 form. 23 THE WITNESS: I'm not sure. 24 - - -</p>	
---	--

Page 250

Page 252

<p>1 (Whereupon, Amerisource 2 Bergen-Zimmerman Exhibit-9, 3 ABDCMDL 00273425, was marked for 4 identification.) 5 - - - 6 BY MR. PIFKO: [REDACTED]</p>	
---	--

Page 251

Page 253

Page 254

Page 256



Page 257

Page 258

Page 260

Page 259

Page 261

3 BY MR. PIFKO:

4 Q. Do you believe that
5 AmerisourceBergen has any duties to
6 prevent diversion outside of the
7 regulations under The Controlled
8 Substances Act?

9 MR. NICHOLAS: Object to the
10 form. Not within the scope of
11 the -- I don't know if you're
12 asking him as an individual or
13 under the 30(b)(6) thing, but it's
14 not covered by 30(b)(6) topics.
15 I'll object to it.

16 THE WITNESS: I think we
17 have a responsibility to comply
18 with the federal regulations and
19 state Board of Pharmacy
20 regulations as it respects to the
21 handling, storage and distribution
22 of controlled substances.

23 BY MR. PIFKO:

24 Q. But do you believe that

Page 262

1 there's any other requirements to prevent
2 diversion outside of The Controlled
3 Substances Act or State Pharmacy Board
4 rules?

5 MR. NICHOLAS: Object to the
6 form. Same objection I just
7 stated.

8 THE WITNESS: I'm not aware
9 of any other requirements.

10 BY MR. PIFKO:

11 Q. Does AmerisourceBergen
12 undertake any actions to prevent
13 diversion for reasons beyond what is
14 required in The Controlled Substances
15 Act?

16 MR. NICHOLAS: Object to the
17 form. Outside the scope. And I
18 don't understand the question.
19 And I don't know if the witness
20 does.

21 THE WITNESS: Can you state
22 that one more time, please?

23 BY MR. PIFKO:

Page 264

Page 263

Page 265

Page 266

Page 268

Page 267

Page 269

7 Q. You're aware that there's an
8 opioid crisis in America, correct?

9 A. Yes.








10 Q. Did AmerisourceBergen ever,
11 at any point, think to itself, could we
12 do more to prevent diversion as a result
13 of the opioid crisis?

14 MR. NICHOLAS: Object to the
15 form. It's outside the scope as
16 well.

17 THE WITNESS: And I'm not
18 sure I understand the time frame
19 you're talking about.

20 We always want to make sure
21 that we're following the
22 appropriate policy and procedures
23 and working with DEA on these
24 issues, you know, whether it's

Page 270	Page 272
<p>1 methamphetamine abuse or any other 2 area.</p> <p>3 And in the past, we had a 4 great working relationship with 5 the DEA to resolve these issues. 6 When it was methamphetamine, they 7 passed a bill, enacted regulations 8 and requirements, as we talked 9 about, with the handling.</p> <p>10 But in the opioid crisis, 11 there's no implementation of 12 bills, there was no -- there was 13 no input from DEA like they had in 14 past crises, for the opioid 15 crisis.</p> <p>16 We worked with DEA in 2007. 17 We felt we built a program that 18 was, again, I think, 19 state-of-the-art in the industry. 20 And that was the program we 21 implemented.</p> <p>22 We shared our program with 23 all the other industry 24 memberships. It wasn't -- we were</p>	<p>1 do that to enhance our program, we 2 do. It's not -- it's not static. 3 We don't just implement it in 2007 4 and there's just no changes. It's 5 a constant.</p> <p>6 BY MR. PIFKO:</p> <p>7 Q. Right. But I'm asking if 8 you had a specific discussion about 9 changing or adding to the program as a 10 result of issues stemming from the opioid 11 crisis?</p> <p>12 MR. NICHOLAS: Object to the 13 form. You're arguing.</p> <p>14 THE WITNESS: I don't know 15 if there was a specific meeting 16 titled exactly how you're stating 17 it. No, I don't know.</p> <p>18 BY MR. PIFKO:</p> <p>19 Q. Okay. I told you I would 20 ask you the question a different way. 21 Now as an individual -- or 22 as the chief compliance officer and the 23 head of the CSRA, are you aware of any 24 conversations, at any time when you</p>
<p>1 open about our process. And, you 2 know, I think that, on itself, 3 shows the efforts of 4 AmerisourceBergen.</p> <p>5 BY MR. PIFKO:</p> <p>6 Q. I'm going to ask this 7 question two different ways. 8 First, from -- for the 9 30(b)(6) period of the deposition, the 10 time period, are you aware of any 11 meetings where the company discussed the 12 opioid crisis and what steps it could 13 take to improve its diversion control 14 measures to address those issues?</p> <p>15 MR. NICHOLAS: Object to the 16 form.</p> <p>17 THE WITNESS: We 18 regularly -- the department 19 regularly meets and discusses our 20 programs and processes and what we 21 do at the distribution centers, 22 but also with this program as 23 well. And it's open dialogue.</p> <p>24 And if there's areas we can</p>	<p>1 worked at the company, where there was 2 discussion of improving diversion control 3 measures specifically in response to the 4 opioid crisis?</p> <p>5 MR. NICHOLAS: Object to the 6 form.</p> <p>7 THE WITNESS: As I 8 previously stated, there is always 9 discussions about our program and 10 our processes, not just with the 11 suspicious order monitoring but 12 how we handled things across the 13 scope of the distribution center 14 and all of our requirements.</p> <p>15 So you're asking me, did 16 have -- can I point to one 17 specific meeting? Not that I'm 18 aware of. But it was a topic that 19 we generally discussed.</p> <p>20 VIDEO TECHNICIAN: Going off 21 the record. 2:01 p.m.</p> <p>22 - - -</p> <p>23 (Whereupon, a brief recess 24 was taken.)</p>

1  	Page 274  
Page 275 	Page 276 
Page 277 	

Page 278

[REDACTED]

Page 280

[REDACTED]

Page 279

[REDACTED]

Page 281

[REDACTED]

Page 282

Page 284

283

Page 285



Page 286

Page 288

287

Page 289



Page 290

Page 292

Page 291


Page 293



Page 294	Page 296
Page 295	Page 297


Page 298

Page 300



Page 299

Page 301



<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>Page 302</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>
	<p>1 e-mail?</p> <p>2 A. I don't.</p> <p>3 Q. Do you have any reason to</p> <p>4 believe this is not a true and correct</p> <p>5 copy of an e-mail that you received?</p> <p>6 A. No, I don't doubt that.</p> <p>7 Q. We did talk about the HDMA a</p> <p>8 little bit earlier.</p> <p>9 Did you serve -- did you</p> <p>10 serve, in any capacity, on any committee</p> <p>11 or board or group within the HDMA?</p> <p>12 A. At some point, I was on the</p> <p>13 regulatory affairs committee. And now</p> <p>14 I'm on the public -- I think they call it</p> <p>15 the public policy committee.</p> <p>16 Q. Do you believe that you were</p> <p>17 on the regulatory affairs committee at</p> <p>18 around the time this e-mail was sent in</p> <p>19 September of 2007?</p> <p>20 A. Could have been, yes.</p> <p>21 Q. Do you recall what your</p> <p>22 responsibilities were as a member of the</p> <p>23 regulatory affairs committee?</p> <p>24 A. As a member, I mean, we</p>
24	- - -
<p>1 (Whereupon, Amerisource</p> <p>2 Bergen-Zimmerman Exhibit-11,</p> <p>3 CAH_MDL_PRIORPROD_DEA_07_00880890-</p> <p>4 92, was marked for</p> <p>5 identification.)</p> <p>6 - - -</p> <p>7 BY MR. PIFKO:</p> <p>8 Q. I'm handing you what is</p> <p>9 marked as Exhibit-11.</p> <p>10 It's a document produced by</p> <p>11 Cardinal Health in this matter, which we,</p> <p>12 under the protective order, obtained</p> <p>13 prior approval to use it in this</p> <p>14 deposition. It's Bates labeled</p> <p>15 CAH_MDL_PRIORPROD_DEA07_00880890 to 92.</p> <p>16 It's an e-mail at the top</p> <p>17 from Steve Reardon, dated September 11,</p> <p>18 2007, to Mr. Zimmerman. The subject is,</p> <p>19 Summary of September 7th meeting with DEA</p> <p>20 and attachments.</p> <p>21 Let me know when you're done</p> <p>22 reviewing it.</p> <p>23 A. Okay.</p> <p>24 Q. Do you recall receiving this</p>	<p>Page 303</p> <p>1 would talk about regulatory issues facing</p> <p>2 wholesalers.</p> <p>3 Q. Regulatory issues concerning</p> <p>4 The Controlled Substances Act; is that</p> <p>5 correct?</p> <p>6 A. It could be a whole host of</p> <p>7 things. It could be destruction. It</p> <p>8 wasn't only for controlled substances.</p> <p>9 Anything involving wholesale distribution</p> <p>10 in the healthcare chain.</p> <p>11 Q. But that could include</p> <p>12 controlled substances?</p> <p>13 A. Yes.</p> <p>14 Q. Okay. How about diversion</p> <p>15 control, would that include that?</p> <p>16 A. Yes.</p> <p>17 Q. Do you recall HDMA setting</p> <p>18 up a meeting with members of the DEA</p> <p>19 around this time in 2007?</p> <p>20 A. I don't.</p> <p>21 Q. This is around the time of</p> <p>22 some of the Dear Registrant letters.</p> <p>23 Do you agree?</p> <p>24 A. Yes. Yes.</p>
	Page 305

Page 306	Page 308
<p>1 Q. Do you recall there being 2 more activity between members of the 3 industry and DEA at that time? 4 A. As I previously stated, I 5 mean, when I started, we met with DEA 6 every six months and it was a regular 7 activity. And then with the training 8 program, we met with them a lot more; 9 there was a lot more communication. 10 In 2007, this came shortly 11 after -- this is probably within weeks 12 after we got our distribution center back 13 and implemented our new program. So 14 there was a lot of activity on this 15 subject matter.</p> <p>16 Q. Do you know why the HDMA 17 would have been having a meeting with the 18 DEA at this time?</p> <p>19 MR. NICHOLAS: Object to the 20 form.</p> <p>21 THE WITNESS: As I 22 indicated, at that time, they 23 would meet regularly with them; if 24 not every six months, every year.</p>	<p>1 one in years. People on my staff attend 2 them.</p> <p>3 Q. When do you recall having 4 last attended one?</p> <p>5 A. It may have been 2009. I am 6 not sure if I attended one in 2011. But 7 I know I haven't attended one for the 8 last, you know, years.</p> <p>9 Q. You've always -- someone 10 from Amerisource has always been sent to 11 one of these conferences?</p> <p>12 A. Usually, yes.</p> <p>13 Q. And do they continue to this 14 day?</p> <p>15 A. Yes.</p> <p>16 Q. Do you know if there was one 17 in 2016?</p> <p>18 A. I don't know if it's 2016 or 19 2017, but they have them every two years.</p> <p>20 Q. Okay. Does anyone take 21 notes at these meetings?</p> <p>22 A. I don't know if HDA as -- 23 does that or not. I don't know.</p> <p>24 Q. Do you direct any of your</p>
<p>1 I don't know if this is a regular 2 meeting that they have to discuss 3 issues with distributors or 4 distributors wanting 5 clarification.</p> <p>6 I'm not really sure what the 7 nexus of this meeting was about.</p> <p>8 BY MR. PIFKO:</p> <p>9 Q. Did you ever attend DEA 10 conferences?</p> <p>11 A. Yes.</p> <p>12 Q. How often does the DEA put 13 on conferences?</p> <p>14 A. I believe every other year 15 for distributors, and then the other 16 years pharmacy practitioners. I'm not 17 positive about that.</p> <p>18 But I know our meetings 19 are -- usually every two years, DEA will 20 have an industry meeting for 21 distributors.</p> <p>22 Q. Do you always attend those?</p> <p>23 A. I attended a lot of them 24 earlier on. I probably haven't attended</p>	<p>1 staff members to take notes of the 2 meetings if you don't attend?</p> <p>3 A. They would -- I would assume 4 they would take notes. DEA usually 5 provides the slides that they produce at 6 the industry conferences. I'm not sure 7 if they put them on their website -- I'm 8 not sure if they put them on their 9 website or not.</p> <p>10 Q. Do you discuss the 11 presentations or the conferences with 12 other members of the HDMA?</p> <p>13 A. Do we discuss the DEA 14 conferences with HDMA members? Most of 15 them are usually there. I shouldn't say 16 all of them, but a lot of the members are 17 there at the DEA conference.</p> <p>18 Q. So you meet with each other 19 while you're at these conferences?</p> <p>20 You're there together?</p> <p>21 A. Yes.</p> <p>22 Q. Do you discuss diversion 23 control while you're at these 24 conferences?</p>

Page 310	Page 312
<p>1 MR. NICHOLAS: I'm going to 2 just object to the questions, only 3 to the extent that the witness 4 said he hasn't been to one of 5 these conferences himself since 6 2009 or maybe 2011.</p> <p>7 So I want to make sure the 8 record is clear that we're, you 9 know -- he's not talking about -- 10 he can only talk about what he can 11 talk about.</p> <p>12 Go ahead.</p> <p>13 THE WITNESS: Years back, 14 yeah, we would talk about 15 regulatory issues or how we do 16 things or, you know, what -- those 17 type of things.</p> <p>18 BY MR. PIFKO:</p> <p>19 Q. Is there a meeting through 20 the HDMA, after these conferences, where 21 the members get together and discuss what 22 was said at the conference and their 23 views on the information that the DEA 24 might have shared at the conference?</p>	<p>1 Q. Do you know if he still 2 works at Cardinal Health?</p> <p>3 A. He does not.</p> <p>4 Q. Does he work for another 5 distributor, do you know?</p> <p>6 A. He's retired.</p> <p>7 Q. How about Anita Ducca, do 8 you know who that is?</p> <p>9 A. I believe -- yes, I do.</p> <p>10 Q. Who is she?</p> <p>11 A. I believe she's vice 12 president of regulatory affairs for HDMA.</p> <p>13 Q. So then Brian sends this to 14 Steve Reardon, and says, Steve, pasted 15 below please find the summary of HDMA's 16 meeting with the DEA last Friday. Please 17 let me know if you need anything else. 18 Do you see that?</p> <p>19 A. Yes.</p> <p>20 Q. And then it's got a summary 21 of the meeting here. 22 It says, Key takeaways from 23 the meeting were -- do you see where that 24 is?</p>
<p>1 MR. NICHOLAS: Same 2 objection for the same reason.</p> <p>3 THE WITNESS: My 4 recollection was that, you know, 5 there would be discussions prior 6 to the meetings if there's 7 questions that we wanted to bring 8 up, as an industry.</p> <p>9 I don't recall if there was 10 a structured debrief or anything 11 like that after.</p> <p>12 BY MR. PIFKO:</p> <p>13 Q. Let's look back at 14 Exhibit-11.</p> <p>15 It says here -- well, first, 16 do you know who Brian Cherico is?</p> <p>17 A. I'm not familiar with Brian.</p> <p>18 Q. How about Steve Reardon?</p> <p>19 A. Yes.</p> <p>20 Q. Who is Steve Reardon?</p> <p>21 A. He was -- I don't know if 22 he's director or senior director or vice 23 president of regulatory. I've known him 24 for quite some time.</p>	<p>1 A. Yes.</p> <p>2 Q. DEA's policy was to expect 3 more than just reporting suspicious 4 orders. If there was a suspicious order, 5 the distributor should either stop the 6 delivery or should evaluate the customer 7 further before delivering it. 8 Do you see that?</p> <p>9 A. Yes.</p> <p>10 Q. Did you have an 11 understanding, at that time, that that 12 was DEA's position?</p> <p>13 A. Yes. This was the program 14 that we had just negotiated.</p> <p>15 Q. It says, Simply complying 16 with the suspicious orders regulatory 17 requirement does not mean, in the 18 agency's view, that the registrant is 19 maintaining an effective program to 20 detect and prevent diversion. 21 Do you see that?</p> <p>22 A. Yes.</p> <p>23 Q. Did you have an 24 understanding that that was the DEA's</p>

<p style="text-align: right;">Page 314</p> <p>1 position at the time?</p> <p>2 A. As I previously indicated, 3 there's many requirements to have 4 adequate controls to prevent diversion, 5 other than just to report a suspicious 6 order, yes.</p> <p>7 Q. It then says, DEA indicated 8 that they did not have the resources to 9 inspect every pharmacy; therefore, it was 10 important for the distributor to, quote, 11 know their customers, end quote.</p> <p>12 Do you see that?</p> <p>13 A. I see that.</p> <p>14 Q. Did you have an 15 understanding that that was the DEA's 16 position at the time?</p> <p>17 A. I've never seen it stated as 18 such, that a lack of resources by DEA 19 imposes a requirement upon a registrant 20 over and above their regulatory 21 responsibilities.</p> <p>22 Q. Well, they sent this e-mail 23 to you saying this in 2007.</p> <p>24 A. Yes.</p>	<p style="text-align: right;">Page 316</p> <p>1 Q. Upon receiving this e-mail, 2 did AmerisourceBergen take any steps to 3 respond to the idea that DEA did not have 4 adequate resources to inspect pharmacies 5 and, therefore, it was important for them 6 to, quote, know their customer?</p> <p>7 MR. NICHOLAS: Object to the 8 form.</p> <p>9 THE WITNESS: No. This 10 is -- like I indicated previously, 11 this is maybe a couple of weeks 12 after we negotiated our program 13 which contained the "know your 14 customer." So there's no use to 15 respond to this. This is our 16 program.</p> <p>17 BY MR. PIFKO:</p> <p>18 Q. Let's go to the next page. 19 It says, DEA provided 20 examples of what a wholesale distributor 21 should do to, quote, know their 22 customers, end quote, and what to look 23 for.</p> <p>24 Do you see that?</p>
<p style="text-align: right;">Page 315</p> <p>1 Q. Do you recall discussing 2 that with anyone?</p> <p>3 A. No.</p> <p>4 Q. Do you recall being shocked 5 that that was a new position of the DEA 6 of which you weren't familiar with?</p> <p>7 A. No.</p> <p>8 Q. Okay. So that's consistent 9 with the DEA's position as far as you 10 knew at the time?</p> <p>11 MR. NICHOLAS: Object to the 12 form.</p> <p>13 THE WITNESS: You had stated 14 that -- in our negotiation, they 15 wanted us to enhance our due 16 diligence process. What I don't 17 recall them saying is that we 18 can't -- we don't have resources 19 to do this, so we want you to do 20 that. I don't recall that.</p> <p>21 I recall them wanting us to 22 enhance our due diligence process, 23 yes.</p> <p>24 BY MR. PIFKO:</p>	<p style="text-align: right;">Page 317</p> <p>1 A. Yes. I see that, yes.</p> <p>2 Q. Do you recall getting 3 guidance from the DEA on what you should 4 do to know your customers?</p> <p>5 MR. NICHOLAS: Object to the 6 form. It seems like you'd want to 7 call his attention to the 8 additional sentences in the 9 paragraph to help answer the 10 question.</p> <p>11 THE WITNESS: As I 12 indicated, we had had these 13 discussions with the DEA in 14 developing our program and the 15 discussions about the form, yes.</p> <p>16 BY MR. PIFKO:</p> <p>17 Q. Did you understand that the 18 DEA wanted you to inspect pharmacies?</p> <p>19 A. Part of our due diligence 20 program was to have a site visit and 21 complete a form, yes.</p> <p>22 Q. This is what -- the new 23 customer onboarding you talked about?</p> <p>24 A. Correct.</p>

Page 318

1 Q. Did you have an
2 understanding that you should inspect
3 customers who are existing customers?

4 A. No.

5 Q. It says, They -- referring
6 to the DEA -- also mentioned such actions
7 as, quote, doing Google searches, end
8 quote, to determine if the pharmacy's
9 name was affiliated with an Internet site
10 and getting information from the state as
11 to the nature and number of prior legal
12 actions against a pharmacy.

13 Do you see that?

14 A. Yes.

Page 320

Page 319

Page 321

Page 322

Page 324

6 BY MR. PIFKO:

7 Q. It says, towards the bottom,
8 second-to-last bullet point, DEA also
9 indicated that they were not going to
10 make a decision for the wholesale
11 distributor as to when an order was
12 suspicious. They feel this is up to the
13 distributor.

14 Do you see that?

15 A. Yes.

16 Q. Did you understand that the
17 determination of whether an order was
18 suspicious was up to you?

19 A. Yes.

20 Q. The last bullet point says,
21 DEA suggested that distributors should
22 check on the pharmacy's prescribing
23 physicians. They pointed to some states
24 having online systems by which a

Page 323

Page 325

1 distributor could check to see if a
2 prescribing physician had a valid DEA
3 registration. DEA suggested that
4 distributors ask who the doctors are that
5 are prescribing, where the pharmacy is
6 geographically with respect to its
7 prescribing doctors, and the patient
8 population.

9 Do you see that?

10 A. Yes.

Page 330	Page 332
<p>1 that's what they're referring to.</p> <p>2 Q. When you were on -- you've</p> <p>3 been -- you've had a role with respect to</p> <p>4 the HDMA for a long time now, right?</p> <p>5 You've had different roles.</p> <p>6 I think -- I forget, but you</p> <p>7 were on one committee and then you're on</p> <p>8 some other committee now, right?</p> <p>9 A. That's correct.</p> <p>10 Q. So you've always had an</p> <p>11 affiliation with the HDMA?</p> <p>12 A. Yes.</p> <p>13 Q. Have you attended this</p> <p>14 conference in the past?</p> <p>15 A. I have.</p> <p>16 Q. Do you believe you attended</p> <p>17 this one?</p> <p>18 A. I may have. It's like with</p> <p>19 the other one, I don't -- I haven't</p> <p>20 attended them the last -- for years. I</p> <p>21 just don't know when -- when I stopped</p> <p>22 attending.</p> <p>23 Q. You see at the top here, it</p> <p>24 says, Attendees included</p>	<p>1 interacted with before?</p> <p>2 A. I have.</p> <p>3 Q. It says she's chief policy</p> <p>4 and liaison, Drug Enforcement</p> <p>5 Administration.</p> <p>6 A. Correct.</p> <p>7 Q. What did she do, as far as</p> <p>8 your interactions with her?</p> <p>9 A. She would be one, if we had</p> <p>10 a policy question or a process question,</p> <p>11 that we would either write to her or call</p> <p>12 her.</p> <p>13 Q. It says here, Cathy gave a</p> <p>14 brief overview of hot topics current</p> <p>15 within the DEA.</p> <p>16 Do you see that?</p> <p>17 A. Yes.</p> <p>18 Q. In conferences -- in HDMA</p> <p>19 conferences you do remember attending, do</p> <p>20 you remember the DEA presenting current</p> <p>21 topics of interest to the members of the</p> <p>22 industry at these conferences?</p> <p>23 A. Yes. There was usually a</p> <p>24 segment that DEA presented at.</p>
<p>1 AmerisourceBergen, Cardinal, H.D. Smith,</p> <p>2 McKesson, Lilly, Johnson & Johnson,</p> <p>3 Purdue, Sanofi, Aventis, AmeriCares and</p> <p>4 many more.</p> <p>5 Do you see that?</p> <p>6 A. Yes.</p> <p>7 Q. So you believe you would</p> <p>8 always send someone to these conferences</p> <p>9 if you didn't attend yourself?</p> <p>10 A. Yes.</p> <p>11 Q. I just want to know, I want</p> <p>12 to ask you about your familiarity with</p> <p>13 some of the topics that were discussed</p> <p>14 here.</p> <p>15 This is -- the notes here</p> <p>16 are about a specific DEA session that</p> <p>17 occurred on March 7th at this conference.</p> <p>18 Do you see that just on the</p> <p>19 first page at the top?</p> <p>20 A. Yes. ^^</p> <p>21 Q. Do you know who Cathy</p> <p>22 Gallagher is?</p> <p>23 A. I do.</p> <p>24 Q. Is that someone you've</p>	<p>1 One of these, if you scroll</p> <p>2 way down to the bottom,</p> <p>3 second-to-the-last bullet point, Increase</p> <p>4 of ER visits are 97 percent contributable</p> <p>5 to pharmaceuticals; opioids are the most</p> <p>6 frequent.</p> <p>7 Do you see that?</p> <p>8 A. Yes.</p> <p>9 Q. Do you recall that being a</p> <p>10 topic of discussion within the industry</p> <p>11 in 2011?</p> <p>12 MR. NICHOLAS: Object to the</p> <p>13 form.</p> <p>14 THE WITNESS: No.</p> <p>15 BY MR. PIFKO:</p> <p>16 Q. Do you recall discussing</p> <p>17 that with anyone at the HDMA at any</p> <p>18 point?</p> <p>19 A. I don't recall discussions</p> <p>20 regarding emergency room visits, no.</p> <p>21 Q. Do you have any reason to</p> <p>22 dispute this fact?</p> <p>23 MR. NICHOLAS: Object to the</p> <p>24 form.</p>

Page 334	Page 336
<p>1 THE WITNESS: I'm assuming 2 that these are bullet points based 3 upon DEA slides. So, I mean, this 4 is what DEA presented.</p> <p>5 BY MR. PIFKO:</p> <p>6 Q. Let's turn to the next page.</p> <p>7 Look at the heading, Rogue 8 Pain Clinics in Florida.</p> <p>9 Do you see that?</p> <p>10 A. Yes.</p> <p>11 Q. It talks about Operation 12 Pill Nation, it looks like some sort of 13 enforcement initiative.</p> <p>14 And then it says, Problem 15 now is migration, in quotes, vast 16 majority of patients are visiting Florida 17 from out of state.</p> <p>18 It mentions various states, 19 including Ohio.</p> <p>20 Do you see that?</p> <p>21 A. Yes.</p> <p>22 Q. Do you recall ever 23 discussing the topic of migration amongst 24 members of the industry or with HDA?</p>	<p>1 attorney-client privilege. 2 Otherwise, you can answer.</p> <p>3 THE WITNESS: No.</p> <p>4 BY MR. PIFKO:</p> <p>5 Q. Aside from communications 6 with the HDMA and this conference, are 7 you familiar with the idea of migration?</p> <p>8 MR. NICHOLAS: Objection. 9 Outside the scope of the 30(b)(6).</p> <p>10 THE WITNESS: I'm not -- in 11 what context?</p> <p>12 BY MR. PIFKO:</p> <p>13 Q. Well, okay, you're the top 14 dog with respect to the CSRA and 15 compliance at the company.</p> <p>16 And I just want to know, in 17 serving in that role at the company, if 18 this idea of out-of-state people going to 19 different states to buy pills and 20 migrating them back to their hometown, if 21 that's something that you are familiar 22 with?</p> <p>23 A. I've seen articles that 24 reference that.</p>
<p>1 MR. NICHOLAS: Objection. 2 Not to the form, but to the fact 3 that I think this is completely 4 outside the scope of the 30(b)(6), 5 unless you can tell me --</p> <p>6 MR. PIFKO: He's the had 7 representative. I believe you 8 designated him for that topic.</p> <p>9 THE WITNESS: I don't 10 recall.</p> <p>11 BY MR. PIFKO:</p> <p>12 Q. Did you undertake any 13 activities, in preparing for this 14 deposition, to familiarize yourself with 15 HDMA presentations?</p> <p>16 A. I did not review any HDMA 17 presentations.</p> <p>18 Q. Did you talk to anybody to 19 familiarize yourself with 20 AmerisourceBergen's role in participating 21 in HDMA-related events?</p> <p>22 MR. NICHOLAS: Hold on. 23 I'll object only to the extent 24 that this may invade the</p>	<p>1 Q. When do you believe you've 2 seen articles about that?</p> <p>3 A. I can't cite specific ones.</p> <p>4 Q. How about general ones?</p> <p>5 A. I can't cite general ones.</p> <p>6 Q. So you can't cite any is 7 what you're saying?</p> <p>8 MR. NICHOLAS: You're asking 9 him to cite an article?</p> <p>10 BY MR. PIFKO:</p> <p>11 Q. You've referenced that 12 you've seen articles, but you can't 13 identify a specific article, correct?</p> <p>14 A. Correct.</p> <p>15 Q. When do you believe you 16 might have first heard of the idea of 17 migration?</p> <p>18 MR. NICHOLAS: Objection. 19 Outside the scope.</p> <p>20 Are you asking him in the 21 30(b)(6) context or otherwise?</p> <p>22 MR. PIFKO: Individually. 23 MR. NICHOLAS: Individually. 24 Go ahead.</p>

Page 338

1 THE WITNESS: Was it ever
2 discussed, the term migration, as
3 you're stating it, of people that
4 were getting prescriptions filled
5 and then -- from out of state? I
6 mean, I had read articles on that
7 and I was aware of it.

8 BY MR. PIFKO:

9 Q. Okay. So migration is not a
10 term that you're familiar with, but you
11 are familiar with the idea of someone
12 traveling to a state and getting a
13 prescription and exporting it back to
14 somewhere else, correct?

15 MR. NICHOLAS: Object to the
16 form.

17 THE WITNESS: The specific
18 information that I had on that, on
19 the articles, was that -- whether
20 they were referring to some
21 arrests that were made by some
22 individuals who had gotten
23 prescriptions filled in another
24 state, and they arrested them in

Page 340

1 another state. If that makes
2 sense.

3 BY MR. PIFKO:

Page 339

Page 341

[REDACTED]	Page 342	Page 344
[REDACTED]	1 question. 2 THE WITNESS: You have to 3 ask the person that's performing 4 that function. 5 BY MR. PIFKO: 6 Q. Who is responsible for 7 performing that function currently? 8 A. David May is the one who 9 oversees that department. 10 Q. So someone under him would 11 be responsible for doing that? 12 A. Yes. 13 Q. Okay. David May joined the 14 company in 2014. 15 Who served in his role prior 16 to him? 17 A. Ed Hazewski. 18 Q. If I wanted to know, for an 19 earlier time period, what the company's 20 practices were with respect to what they 21 look at, with respect to prescribing 22 physicians, would I ask him? 23 A. Yes. 24 Q. And how far back was his	[REDACTED]
[REDACTED]	Page 343	Page 345
[REDACTED]	1 tenure in that position? 2 A. 2008, I believe. Somewhere 3 around there. 4 Q. Is he still with the 5 company? 6 A. Yes. 7 Q. What's his current role? 8 A. He's director diversion 9 control. 10 Q. In obtaining information 11 about a pharmacy, does AmerisourceBergen 12 investigate the type of doctor who is 13 writing prescriptions in comparison to 14 the type of pills he's prescribing, he or 15 she is prescribing? 16 MR. NICHOLAS: Hold on. 17 I'll object to the form. I also 18 would appreciate it if you would 19 put this into some time frame. 20 MR. PIFKO: For the time 21 period for which you're a 22 30(b)(6). 23 BY MR. PIFKO: 24 Q. Let me ask the question,	[REDACTED]

Page 346	Page 348
<p>1 just to get a cleaner record.</p> <p>2 During the time from prior</p> <p>3 to -- from -- prior to 2015, in obtaining</p> <p>4 information about a pharmacy's</p> <p>5 prescribing physicians, does</p> <p>6 AmerisourceBergen undertake any effort to</p> <p>7 evaluate the nature of the physician in</p> <p>8 comparison with the nature of the</p> <p>9 medicine that's being prescribed?</p> <p>10 MR. NICHOLAS: Object to the</p> <p>11 form.</p> <p>12 THE WITNESS: I don't know</p> <p>13 what medicine -- we get the top</p> <p>14 prescribers for the form, but it</p> <p>15 doesn't indicate what medicines</p> <p>16 they're prescribing.</p> <p>17 BY MR. PIFKO:</p> <p>18 Q. Do you ask, with respect to</p> <p>19 opioids or controlled substances -- let</p> <p>20 me just -- with respect to controlled</p> <p>21 substances, do you ask who the top</p> <p>22 prescribers are of controlled substances?</p> <p>23 MR. NICHOLAS: Objection.</p> <p>24 THE WITNESS: I don't know</p>	<p>1 Go ahead.</p> <p>2 THE WITNESS: I'm not</p> <p>3 understanding your question.</p> <p>4 BY MR. PIFKO:</p> <p>5 Q. I'm trying to assess</p> <p>6 whether, in evaluating activity at a</p> <p>7 pharmacy, AmerisourceBergen considers the</p> <p>8 fact that a large volume of prescriptions</p> <p>9 are being written by an out-of-area</p> <p>10 doctor for that pharmacy?</p> <p>11 MR. NICHOLAS: Objection.</p> <p>12 THE WITNESS: I would need</p> <p>13 to know the totality of the</p> <p>14 information. It goes back to a</p> <p>15 hypothetical of giving me a</p> <p>16 specific, if X then Y. I can't</p> <p>17 give you that. I don't know.</p> <p>18 I don't know if the pharmacy</p> <p>19 is on the border of -- he's in one</p> <p>20 state and the pharmacy is across</p> <p>21 the border. I don't know. I</p> <p>22 don't know.</p> <p>23 BY MR. PIFKO:</p> <p>24 Q. I'm asking a more general</p>
<p>1 exact -- if that's the wording of</p> <p>2 the question. I don't know.</p> <p>3 BY MR. PIFKO:</p> <p>4 Q. So you don't know if the</p> <p>5 question just asks for the top</p> <p>6 prescribing physicians for all things</p> <p>7 that they sell, or if it's just for</p> <p>8 controlled substances?</p> <p>9 A. Correct.</p> <p>10 Q. Based on what you know,</p> <p>11 would it be a red flag if a pharmacy was</p> <p>12 writing -- filling a substantial number</p> <p>13 of prescriptions from an out-of-area</p> <p>14 doctor?</p> <p>15 MR. NICHOLAS: Object to the</p> <p>16 form.</p> <p>17 THE WITNESS: Again, I don't</p> <p>18 know the specific circumstances.</p> <p>19 I don't know.</p> <p>20 BY MR. PIFKO:</p> <p>21 Q. That's not something that</p> <p>22 you're familiar with?</p> <p>23 MR. NICHOLAS: That's not</p> <p>24 what he said. Objection.</p>	<p>1 question.</p> <p>2 Is that -- is that --</p> <p>3 generically, is that information that you</p> <p>4 would seek out, or is that something that</p> <p>5 you're not interested in?</p> <p>6 MR. NICHOLAS: I'll object</p> <p>7 to the form of the question.</p> <p>8 THE WITNESS: I would have</p> <p>9 to defer to the people that are</p> <p>10 doing the checks on the</p> <p>11 prescribers.</p> <p>12 BY MR. PIFKO:</p> <p>13 Q. Let's talk a little bit more</p> <p>14 about this document, Exhibit-12.</p> <p>15 It says, below the migration</p> <p>16 discussion, Identifying a rogue clinic.</p> <p>17 Do you see that?</p> <p>18 A. Yes.</p> <p>19 Q. Cash-only operation.</p> <p>20 Do you see that?</p> <p>21 A. Yes.</p> <p>22 Q. Does AmerisourceBergen</p> <p>23 evaluate the percentage of cash versus</p> <p>24 insurance payments that are made to a</p>
Page 347	Page 349

Page 350	Page 352
<p>1 pharmacy with respect to controlled 2 substances?</p> <p>3 MR. NICHOLAS: Object to the 4 form.</p> <p>5 THE WITNESS: We -- part of 6 the 590 form has that information.</p> <p>7 BY MR. PIFKO:</p> <p>8 Q. Do you do anything to verify 9 that information, like check accounting 10 records from a pharmacy?</p> <p>11 MR. NICHOLAS: Object to the 12 form.</p> <p>13 THE WITNESS: We do not have 14 any way to confirm whether people 15 are paying cash or not.</p> <p>16 BY MR. PIFKO:</p> <p>17 Q. It says down here, Drugs 18 prescribed are cocktail drugs.</p> <p>19 Do you see that?</p> <p>20 Oxy/hydro/Xanax. Do you see 21 that?</p> <p>22 A. Yes.</p> <p>23 Q. Do you know what 24 oxy/hydro/Xanax is referring to?</p>	<p>1 A. We have a presentation that 2 they go through of some of -- long lines, 3 a lot of cash transactions. There's a 4 whole host of things that we ask them to 5 take a look at.</p> <p>6 Q. And then what do you do with 7 that information if they report it back 8 to you?</p> <p>9 A. If they report it back to 10 us, we would investigate.</p> <p>11 Q. What would an investigation 12 entail? Who would take that up?</p> <p>13 MR. NICHOLAS: Let me just 14 interpose an objection to make 15 sure I understand the time frame 16 that we're talking about and 17 whether he's talking about as an 18 individual or in his 30(b)(6) 19 capacity.</p> <p>20 BY MR. PIFKO:</p> <p>21 Q. In his 30(b)(6) capacity is 22 what I'm asking.</p> <p>23 MR. NICHOLAS: 2007 to 2014.</p> <p>24 THE WITNESS: And what was</p>
Page 351	Page 353
<p>1 A. I do not.</p> <p>2 Q. Oxycodone, hydrocodone and 3 Xanax, does that sound right?</p> <p>4 A. I mean, I see those -- that 5 on here. I'm not sure what they're 6 referring to as "cocktail."</p> <p>7 Q. Does AmerisourceBergen 8 evaluate whether a pharmacy is filling 9 multiple prescriptions at one time for 10 certain combinations of controlled 11 substances?</p> <p>12 A. We don't have that 13 information. We don't have patient -- or 14 prescriber dispensing information.</p> <p>15 Q. It talks about site visits 16 in the next line.</p> <p>17 Do you see that?</p> <p>18 A. Yes.</p> <p>19 Q. Do you train your sales 20 associates to observe signs of diversion 21 when they are at a customer site?</p> <p>22 A. Yes.</p> <p>23 Q. What do you train them to 24 look for?</p>	<p>1 your question? I'm sorry.</p> <p>2 BY MR. PIFKO:</p> <p>3 Q. So we talked about efforts 4 that the company may undertake to have 5 its sales associates observe signs of 6 diversion at a pharmacy, okay?</p> <p>7 A. Yes.</p> <p>8 Q. So I asked, if a sales 9 associate reports back to the company, 10 during the time period for which you're a 11 30(b)(6) representative, what does the 12 company do with that information?</p> <p>13 A. We would investigate.</p> <p>14 Q. And is there a specific 15 department who is responsible for 16 investigating it?</p> <p>17 A. It could be the diversion 18 control department. It could be the 19 security group. It could be our 20 consultant that we utilize. It could be 21 any of those areas.</p> <p>22 Q. Is there a set way that you 23 decide who is going to investigate it?</p> <p>24 A. It depends on the</p>

<p style="text-align: right;">Page 354</p> <p>1 circumstances, location, those type of 2 criteria. 3 Q. So you evaluate the 4 circumstances and location of the 5 incident, and that's how you decide who 6 is going to investigate it? 7 MR. NICHOLAS: Object to the 8 form.  15 BY MR. PIFKO: 16 Q. Can you identify any 17 occasions where a sales associate, during 18 the relevant time period for which you 19 are a 30(b)(6), has identified suspicious 20 conduct and the company conducted an 21 investigation? 22 A. I'd have to result back to 23 those records. I don't -- 24 Q. What records would I look at</p>	<p style="text-align: right;">Page 356</p> <p>1 activity? 2 MR. NICHOLAS: Same 3 objection. And objection to form. 4 THE WITNESS: It would -- 5 the time frame you're talking 6 about, it would be in our 7 investigative -- investigation 8 records. 9 BY MR. PIFKO: 10 Q. Is there a specific name? 11 Just investigative records? 12 MR. NICHOLAS: Object to the 13 form. 14 Go ahead. 15 THE WITNESS: It's where we 16 maintain our investigations, yes. 17 BY MR. PIFKO: 18 Q. Have you ever heard the term 19 "due diligence files"? 20 A. Yes. 21 Q. Is that the same thing as 22 your investigation records, or is that 23 something different? 24 A. It could be. There could be</p>
<p style="text-align: right;">Page 355</p> <p>1 to know that information? 2 MR. NICHOLAS: Let me make 3 sure I clarify that you're talking 4 about the Track 1 jurisdictions 5 now, right? 6 MR. PIFKO: Well, I'm 7 talking about their policies and 8 procedures in general. 9 MR. NICHOLAS: But you asked 10 him about identifying particular 11 instances. So I assume that we're 12 talking about Track 1 13 jurisdictions; is that correct? 14 MR. PIFKO: I was talking 15 about any jurisdiction. 16 MR. NICHOLAS: Well, then, I 17 object. It's overbroad and not 18 within the scope of the deposition 19 at all. 20 Go ahead. 21 BY MR. PIFKO: 22 Q. So my question was, what 23 records would I look at to know whether a 24 sales associate had reported suspicious</p>	<p style="text-align: right;">Page 357</p> <p>1 a record of the investigations within the 2 due diligence file. But it also could be 3 in an investigation file, depending upon 4 the type and scope of the investigation. 5 Q. Who is responsible for 6 maintaining investigation files at the 7 company? 8 A. Bruce Gundy. 9 Q. How long has he had that 10 responsibility? 11 A. During the scope of 2007 to 12 2014. 13 Q. Okay. Do you know who has 14 that responsibility currently? 15 A. Bruce Gundy, same person. 16 Q. Does AmerisourceBergen 17 believe it's everybody in the company's 18 responsibility to prevent diversion? 19 MR. NICHOLAS: Object to the 20 form. It's an unfair question. 21 Go ahead. 22 THE WITNESS: We believe 23 that everyone has a responsibility 24 for compliance and need to conduct</p>

Page 358	Page 360
<p>1 themselves such.</p> <p>2 BY MR. PIFKO:</p> <p>3 Q. Do you know if your sales</p> <p>4 associates receive bonuses from hitting</p> <p>5 sales targets?</p> <p>6 A. I don't know --</p> <p>7 MR. NICHOLAS: Hold on.</p> <p>8 This witness is not designated on</p> <p>9 the topic of compensation, as you</p> <p>10 know. So he's not in a position</p> <p>11 to answer that. There are other</p> <p>12 people who can answer that</p> <p>13 question, but not him.</p> <p>14 MR. PIFKO: It's a</p> <p>15 foundational question.</p> <p>16 MR. NICHOLAS: Well, I mean,</p> <p>17 this isn't his topic.</p> <p>18 MR. PIFKO: Okay. But he</p> <p>19 said he doesn't know, so we got</p> <p>20 the answer.</p> <p>21 BY MR. PIFKO:</p> <p>22 Q. Do you think there's a</p> <p>23 potential conflict in having someone who</p> <p>24 is bonus driven be responsible for</p>	<p>1 form.</p> <p>2 THE WITNESS: When the</p> <p>3 premise of your question is if</p> <p>4 they're bonus driven, I don't know</p> <p>5 that. And as you -- and as I</p> <p>6 indicated previously, all of our</p> <p>7 associates have a role in their</p> <p>8 responsibility to make sure that</p> <p>9 we operate in compliance,</p> <p>10 regardless of what their role is;</p> <p>11 whether they're an order filler,</p> <p>12 salesperson, record keeper.</p> <p>13 BY MR. PIFKO:</p> <p>14 Q. Okay. But if someone has a</p> <p>15 compensation structure that's based on</p> <p>16 increasing sales, do you see that as at</p> <p>17 odds with identifying diversion?</p> <p>18 MR. NICHOLAS: Objection.</p> <p>19 Not within the scope of his areas.</p> <p>20 And I object to the form of the</p> <p>21 question. It's a hypothetical</p> <p>22 question as well.</p> <p>23 THE WITNESS: It's a</p> <p>24 hypothetical question.</p>
Page 359	Page 361
<p>1 identifying diversion?</p> <p>2 MR. NICHOLAS: Objection.</p> <p>3 Hold on. This isn't his area.</p> <p>4 It's not his area. You didn't</p> <p>5 designate him for this area. You</p> <p>6 have someone who you're going to</p> <p>7 depose on the issue of</p> <p>8 compensation.</p> <p>9 MR. PIFKO: It has to do</p> <p>10 with suspicious order monitoring</p> <p>11 processes and protocols.</p> <p>12 THE WITNESS: Can you</p> <p>13 restate the --</p> <p>14 MR. PIFKO: Yeah.</p> <p>15 In any event, you can object</p> <p>16 to scope, and we can fight about</p> <p>17 the import of his testimony later.</p> <p>18 BY MR. PIFKO:</p> <p>19 Q. So the question is, do you</p> <p>20 think there is a potential conflict in</p> <p>21 having someone who is bonus driven be</p> <p>22 responsible for identifying diversion?</p> <p>23 MR. NICHOLAS: Same</p> <p>24 objection. Also, object to the</p>	<p>1 It goes back to the --</p> <p>2 you're giving me a set of</p> <p>3 potential facts and asking me to</p> <p>4 arrive at a conclusion. It would</p> <p>5 depend upon the situation.</p> <p>6 I don't think -- what you're</p> <p>7 inferring, I don't think, is</p> <p>8 correct.</p> <p>9 BY MR. PIFKO:</p> <p>10 Q. What am I inferring?</p> <p>11 MR. NICHOLAS: Hold it.</p> <p>12 Hold it. Object to the form of</p> <p>13 the question.</p> <p>14 The question is, what am I</p> <p>15 inferring? I object to the form</p> <p>16 of the question. I suggest we</p> <p>17 move on to some facts and not</p> <p>18 looking for sound bites.</p> <p>19 BY MR. PIFKO:</p> <p>20 Q. I asked you what you thought</p> <p>21 I was inferring.</p> <p>22 MR. NICHOLAS: Same</p> <p>23 objections.</p> <p>24 THE WITNESS: Can you repeat</p>




Page 362	Page 364
<p>1 the question?</p> <p>2 BY MR. PIFKO:</p> <p>3 Q. I asked you, do you think</p> <p>4 there's a potential conflict in having</p> <p>5 someone who is bonus driven be</p> <p>6 responsible for identifying diversion?</p> <p>7 A. My answer is no.</p> <p>8 - - -</p> <p>9 (Whereupon, Amerisource</p> <p>10 Bergen-Zimmerman Exhibit-13,</p> <p>11 ABDCMDL 00278212, was marked for</p> <p>12 identification.)</p> <p>13 - - -</p> <p>14 BY MR. PIFKO:</p> <p>15 Q. I'm handing you what is</p> <p>16 marked as Exhibit-13. For the record,</p> <p>17 it's a single-page document, Bates</p> <p>18 labeled ABDCMDL 00278212. And the</p> <p>19 metadata reflects that it's from your</p> <p>20 files, Mr. Zimmerman.</p> <p>21 Let me know when you're done</p> <p>22 reviewing it.</p> <p>23 A. Okay.</p> <p>24 Q. Do you recall this document?</p>	<p>1 BY MR. PIFKO:</p> <p>2 Q. That's what the document</p> <p>3 says, okay?</p> <p>4 Do you dispute that it came</p> <p>5 from your computer?</p> <p>6 MR. NICHOLAS: Object to the</p> <p>7 form.</p> <p>8 THE WITNESS: I don't know</p> <p>9 if it came -- I mean, you're</p> <p>10 telling me it came from my</p> <p>11 computer. I don't recall ever</p> <p>12 seeing this document.</p> <p>13 BY MR. PIFKO:</p> <p>14 Q. Do you know what this</p> <p>15 document is about?</p> <p>16 A. I've never seen this</p> <p>17 document.</p> <p>18 Q. Your testimony is you've</p> <p>19 never seen this document?</p> <p>20 A. I don't recall ever seeing</p> <p>21 this document.</p> <p>22 Q. Do you recall ever</p> <p>23 discussing this with anyone?</p> <p>24 MR. NICHOLAS: Object to the</p>
<p>1 A. I do not.</p> <p>2 Q. Do you recall writing this</p> <p>3 document?</p> <p>4 A. No.</p> <p>5 Q. Do you have any reason to</p> <p>6 dispute that this is a true and correct</p> <p>7 document that came from your files?</p> <p>8 MR. NICHOLAS: Object to the</p> <p>9 form.</p> <p>10 THE WITNESS: I don't know</p> <p>11 where it came from.</p> <p>12 BY MR. PIFKO:</p> <p>13 Q. Well, you understand that in</p> <p>14 litigation, documents come with</p> <p>15 information that tells you where they</p> <p>16 came from, as far as whose computer, et</p> <p>17 cetera? Do you understand that?</p> <p>18 A. Yes.</p> <p>19 Q. Well, this came from your</p> <p>20 computer.</p> <p>21 MR. NICHOLAS: I think the</p> <p>22 hang up here is you're just</p> <p>23 telling him stuff, and he has,</p> <p>24 really, no way of knowing.</p>	<p>1 form.</p> <p>2 THE WITNESS: This document?</p> <p>3 BY MR. PIFKO:</p> <p>4 Q. The subject matter of this</p> <p>5 document.</p> <p>6 A. As we previously discussed,</p> <p>7 we talked about low-volume accounts, so</p> <p>8 I've had discussions regarding that.</p> <p>9 Q. Do you see here it says --</p> <p>10 it's talking about -- so it's talking</p> <p>11 about those types of customers,</p> <p>12 low-volume, high-controlled substances</p> <p>13 customers.</p> <p>14 It says, I'm rather</p> <p>15 concerned -- I'm in the middle of the</p> <p>16 document.</p> <p>17 I'm rather concerned about</p> <p>18 your pharmacy for a different reason.</p> <p>19 Based on your overall volume with us,</p> <p>20 your percentage of C-II orders is high</p> <p>21 and may be deemed suspicious by either</p> <p>22 our OMP system or regulatory authorities.</p> <p>23 This puts your account with</p> <p>24 AmerisourceBergen at significant risk of</p>

Page 366	Page 368
<p>1 closure or exposure to regulatory and 2 enforcement agencies. 3 Do you see that? 4 A. I do. 5 Q. Do you recall being 6 concerned about certain customers because 7 of their percentage of controlled 8 substances with respect to their overall 9 volume?</p> <p>10 MR. NICHOLAS: Object to the 11 form.</p> <p>12 THE WITNESS: As I 13 indicated, that was one of the 14 areas we were looking at, our 15 low-volume, higher-percentage 16 secondary accounts and whether 17 we -- you know, how we handled 18 those accounts.</p> <p>19 BY MR. PIFKO:</p> <p>20 Q. Did you ever undertake 21 efforts to report accounts for such 22 activity?</p> <p>23 MR. NICHOLAS: Object to the 24 form.</p>	<p>1 A. Yes. 2 Q. -- is, you don't have a 3 position on whether it's appropriate to 4 give guidance to a customer on how to 5 escape your suspicious order monitoring 6 program?</p> <p>7 MR. NICHOLAS: Well, that is 8 not what he said. I object to the 9 characterization of his testimony. 10 I object to the reference to the 11 jury, which is bullying and 12 harassing.</p> <p>13 And why don't you just ask 14 him a factual question?</p> <p>15 Go ahead.</p> <p>16 THE WITNESS: We don't give 17 guidance to our customers on how 18 to circumvent our system.</p> <p>19 BY MR. PIFKO:</p> <p>20 Q. Do you believe that it's 21 inappropriate to do so?</p> <p>22 MR. NICHOLAS: Object to the 23 form.</p> <p>24 THE WITNESS: Again, to do</p>
<p>1 THE WITNESS: Report in what 2 way?</p> <p>3 BY MR. PIFKO:</p> <p>4 Q. As being suspicious.</p> <p>5 A. If they placed an order that 6 met our suspicious order criteria, we 7 would have.</p> <p>8 Q. Do you think it's 9 appropriate to provide guidance to a 10 customer on how to circumvent your 11 suspicious order monitoring program?</p> <p>12 MR. NICHOLAS: Object to the 13 form.</p> <p>14 THE WITNESS: I don't 15 think -- I'm not sure what your 16 question -- again, you're asking 17 me another hypothetical question 18 and asking me to give you a 19 response that -- again, I can't -- 20 I'm not going to answer a 21 hypothetical.</p> <p>22 BY MR. PIFKO:</p> <p>23 Q. So your position, the jury 24 is watching --</p>	<p>1 what?</p> <p>2 BY MR. PIFKO:</p> <p>3 Q. To tell a customer how not 4 to be caught by your system or the DEA's 5 system for engaging in suspicious 6 activity.</p> <p>7 MR. NICHOLAS: Object to the 8 form.</p> <p>9 THE WITNESS: Again --</p> <p>10 MR. NICHOLAS: What DEA 11 system are you talking about?</p> <p>12 THE WITNESS: Again, we have 13 a program that we implement and we 14 have our processes in place. And 15 we don't -- and part of that 16 process is not to tell customers 17 how to get around the system, or 18 however you worded it.</p> <p>19 But that's not how our 20 program works.</p> <p>21 BY MR. PIFKO:</p> <p>22 Q. So here, after saying to 23 this category of customers, based on your 24 overall volume with us, your percentage</p>

Page 370	Page 372
<p>1 of C-II orders is high and may be deemed 2 suspicious by either our OMP system or 3 regulatory authorities, this document 4 then goes on to say, The way I see it is 5 that you have a couple of options. 6 First, you can make ABDC your primary 7 wholesaler and shift all purchases to us. 8 The second option is we arrange a 9 short-term transition process and you 10 stop buying controlled -- Schedule II 11 controlled substances from ABDC and shift 12 them to whomever you're buying other 13 products. The third option would be to 14 do nothing, but this is not a feasible 15 long-term decision.</p> <p>16 Do you see that?</p> <p>17 A. I see that.</p> <p>18 Q. Do you think that's 19 appropriate guidance to give to a 20 customer?</p> <p>21 MR. NICHOLAS: Hold on.</p> <p>22 Objection. You are 23 mischaracterizing the witness's 24 testimony. The witness has said</p>	<p>1 throughout the day.</p> <p>2 MR. NICHOLAS: I'm speaking 3 to you. And I'm speaking for the 4 record.</p> <p>5 THE WITNESS: I don't know 6 who this document was --</p> <p>7 BY MR. PIFKO:</p> <p>8 Q. That's not my question. I 9 didn't ask you who wrote the document, I 10 didn't ask you any of that.</p> <p>11 I asked you if this kind of 12 language is an appropriate communication 13 to a customer?</p> <p>14 MR. NICHOLAS: Objection to 15 the form of the question.</p> <p>16 THE WITNESS: I don't know 17 if -- I don't know if it's a 18 communication to a customer.</p> <p>19 You're asking me a question with a 20 conclusion that this is a 21 communication to a customer. And 22 you want me to answer the 23 question. I don't know it's a 24 communication.</p>
<p>1 he never -- he didn't write the 2 document. He's never seen the 3 document.</p> <p>4 So I object to the line of 5 questions. This is not 30(b)(6) 6 material. I don't know why -- 7 it's not within --</p> <p>8 MR. PIFKO: You're over the 9 top with your objections.</p> <p>10 MR. NICHOLAS: It's not 11 within --</p> <p>12 MR. PIFKO: Okay. Scope.</p> <p>13 MR. NICHOLAS: -- his 14 personal knowledge.</p> <p>15 MR. PIFKO: Scope. Scope, 16 and all the objections you want to 17 make. You need to stop speaking 18 to the witness, okay?</p> <p>19 MR. NICHOLAS: I'm not 20 speaking to the witness. I'm 21 speaking to you.</p> <p>22 MR. PIFKO: You are. He's a 23 smart guy. Obviously, he picks up 24 on this stuff. It has happened</p>	<p>1 BY MR. PIFKO:</p> <p>2 Q. If this is communicated to a 3 customer, is this an appropriate message 4 to be communicated to a customer? It's a 5 simple question.</p> <p>6 MR. NICHOLAS: Object to the 7 form of the question. Whether 8 it's a simple question or not, 9 it's not a fair question.</p> <p>10 BY MR. PIFKO:</p> <p>11 Q. AmerisourceBergen's position 12 is you don't know if this is an 13 appropriate type of conduct; is that what 14 I'm hearing from you?</p> <p>15 MR. NICHOLAS: That's not 16 what he said.</p> <p>17 THE WITNESS: I don't know 18 what -- who wrote it, who the 19 audience is, and what the 20 conversation is. It says, Talking 21 points.</p> <p>22 Is it -- either you bring us 23 your full business or we can't 24 sell you controls, that's the --</p>

Page 374	Page 376
<p>1 that's the option. Is that an 2 appropriate discussion? I think 3 so.</p> <p>4 BY MR. PIFKO:</p> <p>5 Q. How about telling someone 6 that they can stop buying controlled 7 substances from you and shift them to 8 somebody else?</p> <p>9 MR. NICHOLAS: Object to the 10 form of the question. You're just 11 arguing.</p> <p>12 THE WITNESS: I think I 13 answered your question.</p> <p>14 BY MR. PIFKO:</p> <p>15 Q. You talked about the first 16 suggestion. I'm asking about the second 17 one.</p> <p>18 MR. NICHOLAS: Object to the 19 form. Object to the debating.</p> <p>20 THE WITNESS: I answered one 21 and two. One is bring us all your 22 business or, two, stop buying 23 C-IIIs from us.</p> <p>24 BY MR. PIFKO:</p>	<p>1 It's asked and answered.</p> <p>2 THE WITNESS: It's the same 3 answer.</p> <p>4 BY MR. PIFKO:</p> <p>5 Q. I don't believe I've gotten 6 an answer, so I'm going to ask you again.</p> <p>7 A. Is it appropriate to tell a 8 secondary customer that either they bring 9 us their full book of business or we're 10 going to stop selling you controlled 11 substances? Is that your question?</p> <p>12 Q. I'm asking this message in 13 here.</p> <p>14 I'm asking if this message 15 is an appropriate message to communicate 16 to customers?</p> <p>17 MR. NICHOLAS: Object to the 18 form. Because that's how he's 19 reading the message in here. So 20 he's answering --</p> <p>21 MR. PIFKO: Again, you're 22 coaching him.</p> <p>23 MR. NICHOLAS: No, I'm not. 24 You're not listening to his</p>
<p>1 Q. And buy them from someone 2 else? Do you think it's an 3 appropriate --</p> <p>4 A. Buy it from their primary 5 vendor.</p> <p>6 Q. So you think this is an 7 appropriate message to send to people?</p> <p>8 MR. NICHOLAS: Object to the 9 form of the question. It's not 10 his message.</p> <p>11 THE WITNESS: Is your 12 question is it appropriate for 13 customers to buy from a 14 wholesaler?</p> <p>15 BY MR. PIFKO:</p> <p>16 Q. My question is, is this an 17 appropriate message to communicate to 18 customers?</p> <p>19 MR. NICHOLAS: Object to the 20 question. We're obviously 21 disagreeing as to what is the 22 "this." So it's an unfair 23 question.</p> <p>24 But he's answered it anyway.</p>	<p>1 answers.</p> <p>2 MR. PIFKO: You're coaching 3 him. And, honestly, if you keep 4 this up, I'm going to seek to have 5 you removed from defending any 6 depositions in this case, okay?</p> <p>7 MR. NICHOLAS: That's fine.</p> <p>8 MR. PIFKO: It's fine to 9 object vigorously and be 10 passionate about your position. 11 But you're going way above and 12 beyond, and you've been doing it 13 all day long.</p> <p>14 And we are going to read the 15 transcript and it's going to show 16 all the discussion you're having, 17 asking facts, telling me what to 18 ask. That is not okay.</p> <p>19 MR. NICHOLAS: 20 Unfortunately --</p> <p>21 MR. PIFKO: You look like 22 you've been practicing long enough 23 to know that.</p> <p>24 MR. NICHOLAS: If you're</p>
Page 375	Page 377

Page 378	Page 380
<p>1 telling me -- if you're telling 2 me --</p> <p>3 MR. PIFKO: I understand 4 it's a big case and you're 5 stressed out.</p> <p>6 MR. NICHOLAS: If you're 7 telling me I look old, I'm 8 insulted.</p> <p>9 MR. PIFKO: But you have to 10 conduct yourself accordingly.</p> <p>11 MR. NICHOLAS: I think 12 you're making a comment on my 13 personal look. You think I look 14 old?</p> <p>15 MR. PIFKO: I don't think 16 you look old. I think you're an 17 established practitioner and I 18 think you know better and you know 19 that you know better. And you're 20 playing games here, and it needs 21 to stop.</p> <p>22 MR. NICHOLAS: Are you going 23 to let me say something?</p> <p>24 MR. PIFKO: No, I'm not here</p>	<p>1 don't know what their inference 2 was in writing this.</p> <p>3 BY MR. PIFKO:</p> <p>4 Q. So you can't provide an 5 opinion about whether this is an 6 appropriate message to send to somebody?</p> <p>7 MR. NICHOLAS: Object to the 8 form.</p> <p>9 THE WITNESS: And, again, 10 it's a talking point, and it's not 11 being sent to anyone. I don't 12 know -- you're asking me to give 13 you an answer to something I don't 14 know about.</p> <p>15 BY MR. PIFKO:</p> <p>16 Q. All right. That's your 17 position. That's fine.</p> <p>18 - - -</p> <p>19 (Whereupon, Amerisource 20 Bergen-Zimmerman Exhibit-14, 21 ABDCMDL 00000124-147, was marked 22 for identification.)</p> <p>23 - - -</p> <p>24 BY MR. PIFKO:</p>
<p style="text-align: center;">Page 379</p> <p>1 to ask you questions.</p> <p>2 MR. NICHOLAS: Whether you 3 do or not, I'm --</p> <p>4 MR. PIFKO: No, you're not 5 entitled -- you're not the 6 witness. You're not entitled to 7 talk. You're just continuing the 8 problem right now.</p> <p>9 BY MR. PIFKO:</p> <p>10 Q. So I'm asking you, sir, you 11 read this document, you did, do you think 12 this is a message that is appropriate to 13 communicate to consumers -- customers?</p> <p>14 MR. NICHOLAS: Object to the 15 form.</p> <p>16 THE WITNESS: I don't know 17 what the message was. I don't 18 know who wrote the message. I 19 don't know who the audience of the 20 message was. I don't know.</p> <p>21 You're asking me to commit 22 to something -- I don't know who 23 wrote this. I don't know the 24 talking points. I don't know -- I</p>	<p style="text-align: center;">Page 381</p> <p>1 Q. I'm handing you what is 2 marked as Exhibit-14.</p> <p>3 A. Thank you.</p> <p>4 Q. Bates labeled ABDCMDL 5 00000124 through 147.</p> <p>6 According to the metadata on 7 this document, it has a doc date of 8 December 31st, 2007.</p> <p>9 A. Okay.</p> <p>10 Q. Have you seen this document 11 before?</p> <p>12 A. It looks like a 13 presentation.</p> <p>14 Q. Do you know what it's a 15 presentation for?</p> <p>16 A. It says the sales associate 17 role.</p> <p>18 Q. And the sales associate role 19 in what?</p> <p>20 A. In diversion control. I 21 mean, that's the title of the 22 presentation.</p> <p>23 Q. Is this something you 24 reviewed in preparing for your</p>

1 deposition? 2 A. I believe I've seen a copy 3 of this, yes. 4 Q. In your undertaking to 5 familiarize yourself with the company's 6 diversion control practices and policies, 7 did you obtain an understanding of what 8 the purpose of this presentation was for? 9 A. It was for the sales -- I 10 believe it was for the sales group. 11 Q. Do you know when it was 12 given to them? 13 A. I don't. 14 Q. Do you know who would have 15 given this presentation to them? 16 A. I believe it was Ed 17 Hazewski. 18 Q. He was someone who was under 19 your chain of authority? 20 A. Yes. 21 Q. At that time, was he a 22 direct report to you? 23 A. I don't believe so. 24 Q. There was one person in	Page 382	1 A. That's correct. A lot of 2 the information is the same that we've 3 reviewed. 4 Q. Let's look at Page ABDCMDL 5 00000130. 6 Are you there? 7 A. Yes. 	Page 384
	Page 383		Page 385

Page 386

[REDACTED]

Page 388

[REDACTED]

Page 387

[REDACTED]

Page 389


[REDACTED]

Page 390

Page 392


Page 391

Page 393




Page 394

Page 396




Page 395

Page 397




Page 398

Page 400



Page 399

Page 401



[REDACTED]	Page 402 Page 404 8 Q. Let's look at the next one. 9 Have you seen this before? 10 A. I don't recall seeing this one before. 11 Q. Do you understand what it's communicating here? 12 A. It's communicating that -- 13 it's communicating that people are in 14 Florida getting their prescriptions 15 filled. 16 Q. And they're not from 17 Florida, right? 18 MR. NICHOLAS: Object to the 19 form. You're asking him now in his individual capacity, right? 20 Because this is not part of a 21 30(b)(6).
[REDACTED]	Page 403 Page 405 1 MR. PIFKO: It's a training 2 document about the company's 3 diversion policies. 4 MR. NICHOLAS: Object to the 5 scope. Object to the form. 6 Go ahead. 7 THE WITNESS: That's what 8 the comic infers. 9 BY MR. PIFKO: 10 Q. That they're out-of-state 11 people coming to Florida to buy pills, 12 right? 13 A. It doesn't say out of state. 14 Q. It says, tourists. 15 Tourists, thank God. May I suggest 16 restaurants? Hotels? Destinations? 17 And the guy says back, We're 18 just here to buy some pills -- some pain 19 pills. 20 So it's suggesting that 21 they're from out of state. 22 A. Suggesting they're tourists. 23 Q. And they came from out of 24 state to Florida, he has a shirt that

Page 406	Page 408
<p>1 says Florida, to buy pills?</p> <p>2 MR. NICHOLAS: Object to the</p> <p>3 form.</p> <p>4 BY MR. PIFKO:</p> <p>5 Q. Is that what it's saying?</p> <p>6 A. It's not saying they're from</p> <p>7 out of state. But that's what it's</p> <p>8 inferring, that tourists are buying pills</p> <p>9 in Florida.</p> <p>10 Q. That's consistent with the</p> <p>11 issue that we talked about in Exhibit-12,</p> <p>12 do you recall that? The HDMA meeting</p> <p>13 with the DEA, people coming to Florida to</p> <p>14 buy pills and take them to other states.</p> <p>15 Do you recall that?</p> <p>16 A. Yes.</p> <p>17 Q. This is consistent with that</p> <p>18 idea, right?</p> <p>19 MR. NICHOLAS: Object to the</p> <p>20 form.</p> <p>21 THE WITNESS: That's --</p> <p>22 that's what this is inferring,</p> <p>23 yes, this comic strip.</p> <p>24 BY MR. PIFKO:</p>	<p>1 BY MR. PIFKO:</p> <p>2 Q. It's what you said it was.</p> <p>3 A. It's -- yes, a presentation</p> <p>4 to the sales group. Yes.</p> <p>5 Q. So the company is</p> <p>6 acknowledging that there are -- there is</p> <p>7 an issue with people from out of state</p> <p>8 buying pills somewhere, agree?</p> <p>9 MR. NICHOLAS: Object to the</p> <p>10 form.</p> <p>11 THE WITNESS: It indicates</p> <p>12 that that is another flag that</p> <p>13 should be considered, correct.</p> <p>14 BY MR. PIFKO:</p> <p>15 Q. This is a comic.</p> <p>16 Does the company think that</p> <p>17 diversion is a -- is funny?</p> <p>18 MR. NICHOLAS: Object to the</p> <p>19 form. That's a pretty obnoxious</p> <p>20 question.</p> <p>21 THE WITNESS: Absolutely</p> <p>22 not.</p> <p>23 BY MR. PIFKO:</p> <p>24 Q. Does the company take its</p>
<p>1 Q. So as of the date of this</p> <p>2 document, the company knew that that was</p> <p>3 a concern, agree?</p> <p>4 A. It was another -- again, I</p> <p>5 don't know who put this in here and what</p> <p>6 the inference of the comic strip was.</p> <p>7 It's not a picture of the red flags like</p> <p>8 the previous ones are.</p> <p>9 But that's the inference, is</p> <p>10 that people were coming to Florida to get</p> <p>11 their prescriptions filled.</p> <p>12 Q. And then it says, Coming to</p> <p>13 a state near you.</p> <p>14 A. That's the title.</p> <p>15 Q. What does that mean?</p> <p>16 A. I don't know.</p> <p>17 MR. NICHOLAS: Object to the</p> <p>18 form.</p> <p>19 BY MR. PIFKO:</p> <p>20 Q. This is a company training</p> <p>21 document about diversion control</p> <p>22 practices, agree?</p> <p>23 MR. NICHOLAS: Object to the</p> <p>24 form.</p>	<p>1 diversion control practices serious?</p> <p>2 A. Yes.</p> <p>3 Q. Do you know why they would</p> <p>4 use a comic in a document like this to</p> <p>5 communicate this message?</p> <p>6 MR. NICHOLAS: I'll object</p> <p>7 to the form.</p> <p>8 THE WITNESS: It's the slide</p> <p>9 that's -- that's the slide that --</p> <p>10 I mean, I'm not sure what your</p> <p>11 question is.</p> <p>12 Why would they pick this</p> <p>13 slide?</p> <p>14 BY MR. PIFKO:</p> <p>15 Q. And use humor to communicate</p> <p>16 something serious like this.</p> <p>17 MR. NICHOLAS: I'll object</p> <p>18 to the form and to the</p> <p>19 offensiveness of the question.</p> <p>20 Go ahead.</p> <p>21 THE WITNESS: I don't think</p> <p>22 it's depicted in humor. I think</p> <p>23 it's stating another red flag, if</p> <p>24 you see people that are not from</p>
Page 407	Page 409

Page 414

Page 416

Page 415

Page 417



Page 418

Page 420

A grayscale heatmap showing the distribution of a variable across a grid. The x-axis ranges from -10 to 10 and the y-axis from 0 to 10. A vertical dashed line is at x=0. The distribution is highly concentrated around x=0, with a main peak at (0, 5) and smaller peaks at (0, 10) and (0, 0).

A 10x10 grid of black and white squares. The pattern consists of several horizontal bands of alternating black and white squares. The first band is 10 squares wide. Subsequent bands are narrower, starting at 2 squares and increasing by 1 square each time, up to a final band of 5 squares. The vertical position of these bands shifts downwards from left to right across the grid.

Page 419

Page 421

The figure displays a series of horizontal bars arranged vertically. The bars are black on a white background. A vertical dashed line is located on the far left side of the plot area. At the top, there is a solid black bar. Below it, the bars are of varying lengths, creating a stepped or staircase-like pattern. The lengths of the bars decrease as they move downwards.

Category	Value
A	10
B	9
C	8
D	7
E	6
F	5
G	4
H	3
I	2
J	1

Page 422

Page 424

Page 423

Page 425



Page 426

Page 428

Page 427

Page 429



[REDACTED]	Page 430 [REDACTED] Page 432 [REDACTED] 22 MR. PIFKO: I'm going to 23 play a video. 24 (A video was shown.)
[REDACTED]	Page 431 [REDACTED] Page 433 1 MR. NICHOLAS: Before you 2 ask -- 3 BY MR. PIFKO: 4 Q. Did you think -- 5 MR. NICHOLAS: -- a 6 question, I'm going to interpose 7 an objection to the playing of 8 this video in this context in this 9 deposition. 10 I think it's totally 11 inappropriate, and I object to it. 12 BY MR. PIFKO: 13 Q. Did you think that you 14 should be providing protection to anyone 15 else other than AmerisourceBergen when 16 implementing your diversion control 17 practices? 18 MR. NICHOLAS: I object to 19 the form of the question. It's 20 outside the scope. It's an 21 inappropriate question. It 22 doesn't seek any information 23 that's pertinent to any of the 24 topics on your list. I object to

Page 434	Page 436
<p>1 it.</p> <p>2 THE WITNESS: Your question?</p> <p>3 BY MR. PIFKO:</p> <p>4 Q. Having seen the video, do</p> <p>5 you think that you should provide</p> <p>6 protection to anyone else besides</p> <p>7 yourself when you're implementing your</p> <p>8 diversion control practices?</p> <p>9 MR. NICHOLAS: I'll object</p> <p>10 to the form of the question. It</p> <p>11 mischaracterizes prior testimony.</p> <p>12 THE WITNESS: As I</p> <p>13 indicated, that we take our</p> <p>14 responsibility very seriously,</p> <p>15 regardless of the video.</p> <p>16 I understand about the</p> <p>17 opioid crisis, and it doesn't --</p> <p>18 it's impacted my family as well.</p> <p>19 It's impacted a lot of our</p> <p>20 employees as well. We understand</p> <p>21 what the circumstances are.</p> <p>22 And no, we aren't just about</p> <p>23 protecting AmerisourceBergen. We</p> <p>24 have a job to do. We have a job</p>	<p>1 And in order to do so, we</p> <p>2 need to continue to do our</p> <p>3 business diligently and in</p> <p>4 compliance and in a safe -- in a</p> <p>5 safe manner, to ensure that</p> <p>6 product supply to the hospitals</p> <p>7 and pharmacies and doctors is</p> <p>8 available. So it's not just about</p> <p>9 AmerisourceBergen.</p> <p>10 BY MR. PIFKO:</p> <p>11 Q. This is one of the biggest</p> <p>12 public health crises in America. And you</p> <p>13 guys are in the center of it.</p> <p>14 Do you think that you could</p> <p>15 have done more to protect the communities</p> <p>16 around you?</p> <p>17 MR. NICHOLAS: I'll object</p> <p>18 to the form of the question. It's</p> <p>19 argument. It's unfair.</p> <p>20 I'm going to let him answer.</p> <p>21 THE WITNESS: I've</p> <p>22 explained -- I've explained the</p> <p>23 process and the safeguards that we</p> <p>24 have in place and the things that</p>
<p>1 to make sure that the medications</p> <p>2 that we receive are properly</p> <p>3 stored and secure, in order to</p> <p>4 make them available for customers</p> <p>5 and patients that need them.</p> <p>6 These are -- these drugs are</p> <p>7 approved by the FDA. And we sell</p> <p>8 them to licensed pharmacists who</p> <p>9 fill prescriptions written by a</p> <p>10 licensed doctor.</p> <p>11 Again, I'm not -- what we do</p> <p>12 is to ensure that the integrity of</p> <p>13 the product makes it to a licensed</p> <p>14 pharmacy in order for the patient</p> <p>15 to have that product available.</p> <p>16 We implement our policy and</p> <p>17 procedures to ensure that we don't</p> <p>18 have diversion. And that is the</p> <p>19 responsibility we take, not just</p> <p>20 because -- just looking out for</p> <p>21 AmerisourceBergen, we supply 30</p> <p>22 percent of the -- 25 to 30 percent</p> <p>23 of the products within the United</p> <p>24 States.</p>	<p>1 we've done and the training that</p> <p>2 we've done in this area.</p> <p>3 It's a crisis. I don't know</p> <p>4 why, when we had a methamphetamine</p> <p>5 crisis, that there was call to</p> <p>6 action by legislature to include</p> <p>7 additional requirements. I'm not</p> <p>8 sure why they didn't do that in</p> <p>9 1990, '91, '92, all the way to</p> <p>10 today. They issue a guidance --</p> <p>11 they issue -- DEA has issued</p> <p>12 guidance letters.</p> <p>13 And if it's a crisis, I</p> <p>14 would expect them to have a</p> <p>15 call-to-arms and have everybody</p> <p>16 come to Washington, D.C. and --</p> <p>17 like we did with the chemicals,</p> <p>18 and create a solution, or at least</p> <p>19 work on a solution.</p> <p>20 We are -- as a private</p> <p>21 industry, we are trying to do --</p> <p>22 we are not trying to do, we are</p> <p>23 doing what we need to do to</p> <p>24 protect the supply channel with</p>
Page 435	Page 437

Page 438	Page 440
<p>1 the information that we have and 2 that's available to us.</p> <p>3 And we take that very 4 seriously. I take that very 5 seriously. The company takes it 6 very seriously.</p> <p>7 BY MR. PIFKO:</p> <p>8 Q. Do you think that you have 9 any responsibility for the opioid crisis?</p> <p>10 MR. NICHOLAS: Object to the 11 form of the question. It's 12 outside the scope.</p> <p>13 Go ahead.</p> <p>14 THE WITNESS: As I 15 indicated, that our responsibility 16 in the opioid crisis is to ensure 17 that those products that we buy 18 from the manufacturers that have 19 been -- that have been approved by 20 DEA, through quotas to manufacture 21 and distribute, and our job is to 22 make sure when those opioids are 23 within our control, that we 24 maintain adequate security for</p>	<p>1 for identification.) 2 - - - 3 BY MR. PIFKO: 4 Q. I'm handing you what has 5 been marked as Exhibit-15. 6 A. Thank you. 7 Q. For the record, this is a 8 March 2017 code of ethics and business 9 conduct of AmerisourceBergen, which was 10 obtained from the company's website. I 11 just want to ask you a quick couple of 12 questions about this. 13 You're the chief compliance 14 officer, right? 15 A. Correct. 16 Q. You have responsibility -- 17 MR. NICHOLAS: These are in 18 his individual capacity; is that 19 right? 20 MR. PIFKO: Yes. 21 BY MR. PIFKO: 22 Q. You have responsibility for 23 this document? 24 A. Yes.</p>
<p>1 those products, and recordkeeping.</p> <p>2 We also make sure that we 3 vet our customers that we sell to, 4 which are licensed pharmacies by 5 the DEA and the Board of Pharmacy.</p> <p>6 And we distribute those products 7 in a safe and secure manner.</p> <p>8 BY MR. PIFKO:</p> <p>9 Q. Do you think you've done 10 enough?</p> <p>11 A. I think we are doing -- we 12 are always continuing to try to do more.</p> <p>13 We're continually working with our 14 partners. We've been working with 15 legislation to try to create solutions 16 that would impact distribution that may 17 help in this situation. And we continue 18 to do that.</p> <p>19 - - -</p> <p>20 (Whereupon, Amerisource 21 Bergen-Zimmerman Exhibit-15, No 22 Bates, March 2017 23 AmerisourceBergen Code of Ethics 24 and Business Conduct, was marked</p>	<p>1 Page 439</p> <p>1 Q. This document doesn't 2 mention The Controlled Substances Act 3 once. 4 You can look through it, but 5 would you agree with me? 6 A. I don't know. I mean, I can 7 read it. 8 Q. I'll represent to you it 9 doesn't refer to The Controlled 10 Substances Act. You can look at the 11 table of contents here, compliance with 12 laws, Page I here. 13 Is The Controlled Substances 14 Act one of the laws that's mentioned 15 here? 16 MR. NICHOLAS: I'll object 17 to the form of the question. 18 You probably need to read 19 the entire document to really 20 answer a question like this. 21 But go ahead. 22 THE WITNESS: What was your 23 question? I'm sorry. 24 BY MR. PIFKO:</p> <p>Page 441</p>

Page 442	Page 444
<p>1 Q. It's got a discussion of 2 compliance with laws here in the table of 3 contents. 4 A. Okay. 5 Q. You agree that The 6 Controlled Substances Act is not one of 7 those laws that's listed here? 8 MR. NICHOLAS: Object to the 9 form. I'll object to the form. I 10 think the question is misleading. 11 THE WITNESS: In the section 12 that says, Associates must comply 13 with all applicable laws, 14 regulations and rules, including 15 but not limited to those described 16 below.</p> <p>17 BY MR. PIFKO: 18 Q. Does it mention The 19 Controlled Substances Act? 20 MR. NICHOLAS: Object to the 21 form. 22 THE WITNESS: It doesn't 23 state that. 24 - - -</p>	<p>1 remembers or knows. 2 MR. PIFKO: You're coaching 3 him. 4 MR. NICHOLAS: Well, this is 5 just housekeeping. It's silly. 6 It's stupid. 7 THE WITNESS: Your question 8 was? 9 BY MR. PIFKO: 10 Q. Is this a true and correct 11 copy of the document that was -- 12 A. It appears to be. It 13 appears to be. 14 Q. Okay. Is this from your 15 files? 16 MR. NICHOLAS: Objection to 17 the form. 18 THE WITNESS: I don't know 19 where it came from. 20 BY MR. PIFKO: 21 Q. What is this document? Can 22 you tell me what it is? 23 A. It looks like -- it looks 24 like a series of org charts.</p>
<p>1 (Whereupon, Amerisource 2 Bergen-Zimmerman Exhibit-16, No 3 Bates, West Virginia Case 4 Document, Organization Charts, was 5 marked for identification.) 6 - - -</p> <p>7 BY MR. PIFKO: 8 Q. I'm handing you what is 9 marked as Exhibit-16. It's a document 10 that was used in your deposition in the 11 West Virginia litigation. 12 Do you recall this document? 13 A. Yes. I believe from the 14 West Virginia case. 15 Q. Do you agree this is a true 16 and correct copy of the exhibit that 17 was -- 1 was attached to your West 18 Virginia litigation as referenced here on 19 the first page of the document? 20 MR. NICHOLAS: Object to the 21 form -- 22 THE WITNESS: Do I -- 23 MR. NICHOLAS: -- in the 24 sense that I don't know if he</p>	<p>1 Q. Is this an accurate 2 depiction of the -- your department, the 3 CSRA? 4 MR. NICHOLAS: When? 5 THE WITNESS: Yeah, which -- 6 BY MR. PIFKO: 7 Q. Well, it's got various 8 periods on it. The whole document. 9 MR. NICHOLAS: I think you 10 have to focus the question for 11 him. 12 THE WITNESS: Which one? 13 BY MR. PIFKO: 14 Q. Every single page, you're at 15 the top. 16 MR. NICHOLAS: I'll object 17 to the form. I'm not seeing any 18 dates on the document at all. 19 THE WITNESS: I don't see 20 any dates either. 21 BY MR. PIFKO: 22 Q. Your name is at the top of 23 each one of these pages, correct? 24 A. But what year?</p>

Page 446	Page 448
<p>1 Q. You're going to tell me.</p> <p>2 You're the expert here. It's your</p> <p>3 department. This is your document, not</p> <p>4 mine.</p> <p>5 Let's look at the first</p> <p>6 page.</p> <p>7 A. Okay.</p> <p>8 Q. That's your name at the top</p> <p>9 of this, right?</p> <p>10 A. Yes.</p> <p>11 Q. When you look at this and</p> <p>12 see the people here and the positions</p> <p>13 here, can you tell me when this was?</p> <p>14 MR. NICHOLAS: Objection.</p> <p>15 Outside the scope. Object to the</p> <p>16 form.</p> <p>17 THE WITNESS: Possibly 2007.</p> <p>18 I'm not sure exactly.</p> <p>19 BY MR. PIFKO:</p> <p>20 Q. It says, Associates assigned</p> <p>21 to provide resources for the diversion</p> <p>22 control program.</p> <p>23 Do you see that? On the</p> <p>24 left at the top, under the word, Current.</p>	<p>1 form.</p> <p>2 THE WITNESS: In a sense</p> <p>3 they had other duties in addition</p> <p>4 to diversion control. As we</p> <p>5 indicated with investigations,</p> <p>6 they also investigated theft. You</p> <p>7 had -- you have regional directors</p> <p>8 that also ensure compliance with</p> <p>9 other -- not just the controlled</p> <p>10 substance requirements but also</p> <p>11 security and prescription drug</p> <p>12 requirements that always had</p> <p>13 controlled substances and</p> <p>14 diversion as well.</p> <p>15 BY MR. PIFKO:</p> <p>16 Q. Let's look -- can you point</p> <p>17 me to where the investigations department</p> <p>18 is? Who it that -- who is on this first</p> <p>19 page?</p> <p>20 A. Bruce Gundy.</p> <p>21 Q. So there's four</p> <p>22 investigators underneath him?</p> <p>23 A. Correct.</p> <p>24 Q. Does he perform</p>
<p>1 A. Yes.</p> <p>2 Q. And then underneath there,</p> <p>3 it says, Everyone already has a full-time</p> <p>4 job.</p> <p>5 Do you see that?</p> <p>6 A. Yes.</p> <p>7 Q. That's because the people</p> <p>8 responsible to provide resources for the</p> <p>9 diversion control program had other</p> <p>10 responsibilities, right?</p> <p>11 MR. NICHOLAS: Object to the</p> <p>12 form.</p> <p>13 THE WITNESS: We already had</p> <p>14 diversion control. We just --</p> <p>15 this is in 2007. So part of their</p> <p>16 jobs was already in diversion</p> <p>17 control.</p> <p>18 BY MR. PIFKO:</p> <p>19 Q. Part of their job what?</p> <p>20 A. Was part -- was for</p> <p>21 diversion control.</p> <p>22 Q. Right. So all of these</p> <p>23 people had other jobs as well, correct?</p> <p>24 MR. NICHOLAS: Object to the</p>	<p>1 investigations himself?</p> <p>2 A. Yes.</p> <p>3 Q. If we look at the next page,</p> <p>4 there's Bruce Gundy.</p> <p>5 And how many people are</p> <p>6 under him?</p> <p>7 A. Three.</p> <p>8 Q. The next page?</p> <p>9 A. I can't really read it.</p> <p>10 Q. It's next to Mr. Hazewski.</p> <p>11 MR. NICHOLAS: Hazewski.</p> <p>12 MR. PIFKO: Sorry.</p> <p>13 THE WITNESS: Are you</p> <p>14 referring to Bruce or Ed?</p> <p>15 BY MR. PIFKO:</p> <p>16 Q. Bruce.</p> <p>17 You were trying to look for</p> <p>18 his department. How many people were</p> <p>19 in --</p> <p>20 A. Yes.</p> <p>21 Q. -- his department on the</p> <p>22 third page?</p> <p>23 A. He has two.</p> <p>24 Q. Two.</p>

Page 450	Page 452
<p>1 And then let's look at the 2 next page, how many? 3 A. Two. 4 Q. And the last page? 5 A. Two. 6 Q. And all those investigators 7 have duties other than diversion control, 8 correct?</p> <p>9 MR. NICHOLAS: Object to the 10 form.</p> <p>11 THE WITNESS: Yes. But 12 as -- so after the first one, 13 there's a diversion control 14 department, which had 15 investigators contained within 16 there that moved from Bruce to 17 diversion control.</p> <p>18 So now you had diversion 19 control doing investigations, as 20 well as Bruce's people doing 21 investigations.</p> <p>22 The regional directors also 23 performed investigations, and same 24 with the senior directors as well.</p>	<p>1 marked as Exhibit-17. 2 Have you seen this before? 3 It's ABDCMDL 00251392 through 94. I just 4 have some quick questions about this. 5 Are you familiar with this 6 policy and procedure? 7 A. I've seen it, yes. 8 Q. It says that this is retail 9 pharmacy targeted visits. 10 What is that? 11 A. Retail targeted visit; that 12 we've identified a pharmacy that they 13 want to do additional investigation -- 14 Q. Okay. 15 A. -- which consisted of a 16 targeted visit. 17 Q. I want to direct your 18 attention to the bottom where it says, 2, 19 pre-visit preparation. 20 Are you there? 21 A. Yes, I am. 22 Q. It says, The CSRA 23 representative conducting the visit will 24 request, in writing, that the account</p>
<p>1 And then you had a 2 compliance staff at each of the 3 distribution centers. We have 26 4 distribution centers, all with a 5 compliance staff of either two to 6 six individuals. So -- also with 7 a role within -- looking into 8 these issues.</p> <p>9 BY MR. PIFKO:</p> <p>10 Q. Let's look at the last page 11 for completeness here.</p> <p>12 Four people as investigators 13 there?</p> <p>14 A. Yes. Four investigators 15 under Bruce. And then you see 16 investigators under diversion control.</p> <p>17 - - -</p> <p>18 (Whereupon, Amerisource 19 Bergen-Zimmerman Exhibit-17, 20 ABDCMDL 00251392-94, was marked 21 for identification.)</p> <p>22 - - -</p> <p>23 BY MR. PIFKO:</p> <p>24 Q. I'm handing you what is</p>	<p>1 manager contact the owner/pharmacist in 2 charge, inform him/her of the visit and 3 ensure that the owner, person in charge, 4 or their designee, will be present on the 5 arranged date in order to give their 6 undivided attention to the CSRA 7 representative for a minimum of one hour. 8 The account manager is responsible for 9 coordinating the visit date and time with 10 the owner and/or person in charge or 11 their designee.</p> <p>12 Do you see that?</p> <p>13 A. Yes.</p> <p>14 Q. So I just want to confirm, 15 under AmerisourceBergen's policy for 16 investigating and visiting pharmacies, 17 the owner or person in charge or designee 18 is provided advanced notice of those 19 visits, correct?</p> <p>20 A. Yes. We need them there in 21 order to conduct our site visit.</p> <p>22 - - -</p> <p style="text-align: right;">[REDACTED]</p>

Page 454

Page 456

Page 455

Page 457








Page 458

Page 460

Page 459

Page 461



<p>Page 462</p> 	<p>Page 464</p> 
<p>Page 463</p> 	<p>Page 465</p> 

Page 466

Page 468

Page 467

Page 469




Page 470

Page 472


Page 471

Page 473




Page 474

Page 476



Page 475

Page 477



Page 478

8 MR. PIFKO: We're going to
9 take a break.

10 VIDEO TECHNICIAN: Going off
11 the record. 6:02 p.m.
12 - - -

13 (Whereupon, a brief recess
14 was taken.)
15 - - -

16 VIDEO TECHNICIAN: Back on
17 the record at 6:11 p.m.

18 BY MR. PIFKO:

19 Q. If I wanted to ask you about
20 the company's records regarding specific
21 sales of controlled substances products
22 in the Track 1 jurisdictions -- are you
23 familiar with what the Track 1
24 jurisdictions are? If I use that term,

Page 479

1 does that mean anything to you?

2 A. Not exactly. I've seen it,
3 but I don't --

4 Q. Sorry. Let me ask it a
5 different way.

6 If I wanted to talk to
7 someone who was familiar with the
8 company's records of which products they
9 shipped to specific customers and amounts
10 and when, who would that be?

11 MR. NICHOLAS: I'll object
12 to the form.

13 THE WITNESS: I believe if
14 you're just looking for data, it
15 would be somebody in our IT
16 department.

17 BY MR. PIFKO:

18 Q. But to understand how the
19 system works?

20 MR. NICHOLAS: Object to the
21 form.

22 THE WITNESS: The system --
23 the suspicious order monitoring
24 system or our operating system?

Page 480

[REDACTED]

Page 481

7 Q. Is there someone, though,
8 from the CSRA who would be familiar about
9 how the system works and what the data in
10 the different databases reflects?

11 MR. NICHOLAS: Object to the
12 form.

13 THE WITNESS: I am not sure
14 who that would be. It would be
15 somebody, I would think, in our IT
16 group.

17 BY MR. PIFKO:

18 Q. Is there a specific type of
19 title that that person would have?

20 MR. NICHOLAS: Object to the
21 form.

22 THE WITNESS: I don't know
23 who would -- I don't know that
24 person.

Page 482	Page 484
<p>1 BY MR. PIFKO:</p> <p>2 Q. What about for your</p> <p>3 investigations and due diligence files,</p> <p>4 who would be familiar with those?</p> <p>5 A. That would be, if they are</p> <p>6 CSRA files, that would be my department,</p> <p>7 or our department.</p> <p>8 Q. Who within your department</p> <p>9 would have the most expertise about that?</p> <p>10 MR. NICHOLAS: Object to the</p> <p>11 form.</p> <p>12 THE WITNESS: What time</p> <p>13 frame?</p> <p>14 BY MR. PIFKO:</p> <p>15 Q. Well, let's -- any time</p> <p>16 frame. Tell me.</p> <p>17 A. We've changed systems</p> <p>18 through the course. In addition to the</p> <p>19 SAP, we have also changed internal</p> <p>20 systems within CSRA.</p> <p>21 Q. Okay. How about for the --</p> <p>22 2007 to 2012?</p> <p>23 A. The investigation,</p> <p>24 investigations would probably be, you</p>	<p>1 deposition, did you understand yourself</p> <p>2 to be designated to testify about topics</p> <p>3 concerning the company's involvement with</p> <p>4 the had?</p> <p>5 A. Yes.</p> <p>6 Q. What steps did you take to</p> <p>7 become familiar with the company's</p> <p>8 involvement with the had?</p> <p>9 A. I had my personal</p> <p>10 involvement with the -- we talked about</p> <p>11 the committees I participated on. I</p> <p>12 reviewed the had document, I can't</p> <p>13 remember the title of it, the guidelines.</p> <p>14 And that's pretty much it.</p> <p>15 Q. Did you talk to anyone</p> <p>16 besides reviewing your own documents?</p> <p>17 A. Outside -- no. Outside of</p> <p>18 counsel, no.</p> <p>19 Q. Did you review any documents</p> <p>20 that weren't your own documents?</p> <p>21 A. I indicated the document of</p> <p>22 the had guidelines. That's not my</p> <p>23 document, but I reviewed that document.</p> <p>24 Q. There's many people at the</p>
<p>1 want a name?</p> <p>2 It would probably be Bruce</p> <p>3 Gundy. And Steve Mays, who you've</p> <p>4 mentioned. He has some system</p> <p>5 responsibilities -- not responsibilities,</p> <p>6 but knowledge within CSRA as well.</p> <p>7 Q. And then how about for the</p> <p>8 more recent period, 2012 to present, do</p> <p>9 you know?</p> <p>10 MR. NICHOLAS: Object to the</p> <p>11 form and to the scope, to some</p> <p>12 extent.</p> <p>13 THE WITNESS: If your</p> <p>14 question is who in CSRA would have</p> <p>15 that information up to the</p> <p>16 present, I assume, would be --</p> <p>17 David May would have information</p> <p>18 regarding that process.</p> <p>19 And then Bruce Gundy is also</p> <p>20 still in investigations. He would</p> <p>21 be that person for investigations.</p> <p>22 BY MR. PIFKO:</p> <p>23 Q. Okay. Thanks.</p> <p>24 In preparing for this</p>	<p>1 company who have participated with the</p> <p>2 had, correct?</p> <p>3 A. Yes.</p> <p>4 Q. Who all, to your knowledge,</p> <p>5 has participated in the had?</p> <p>6 A. It's a lot.</p> <p>7 Q. Okay.</p> <p>8 A. It could be 50. Because</p> <p>9 they have different segments, whether</p> <p>10 it's tax, whether it's procurement,</p> <p>11 whether it's government affairs.</p> <p>12 Q. How about with respect to</p> <p>13 diversion issues?</p> <p>14 A. It would be Steve Mays,</p> <p>15 David May.</p> <p>16 Q. Steve Mays, has he been</p> <p>17 involved in the had? What is the time</p> <p>18 period?</p> <p>19 A. He's been involved with the</p> <p>20 regulatory affairs committee for years</p> <p>21 prior to 2007.</p> <p>22 Q. Prior to 2007?</p> <p>23 A. Yes. I believe so.</p> <p>24 Q. Does he still have</p>

Page 486	Page 488
<p>1 involvement with the had?</p> <p>2 A. Yes.</p> <p>3 Q. I understand that there's a</p> <p>4 gap in your document production from</p> <p>5 August 24th, 2007 to July 15th, 2010.</p> <p>6 Do you have any reason to</p> <p>7 believe that there would be documents not</p> <p>8 in your system from then from you?</p> <p>9 A. No.</p> <p>10 Q. Were you still working for</p> <p>11 the company during that time period?</p> <p>12 A. Yes.</p> <p>13 Q. Did you have a computer and</p> <p>14 e-mail during that time period?</p> <p>15 A. I did.</p> <p>16 Q. Are you aware of any system</p> <p>17 crashes during that time period?</p> <p>18 MR. NICHOLAS: Let me</p> <p>19 interpose an objection to the</p> <p>20 extent that I personally don't</p> <p>21 know if the representation you're</p> <p>22 making is right about the</p> <p>23 documents.</p> <p>24 But go ahead and ask your</p>	<p>1 like, ten seconds to decide</p> <p>2 whether to ask him any questions.</p> <p>3 MR. PIFKO: Sure.</p> <p>4 VIDEO TECHNICIAN: Going off</p> <p>5 the record. 6:19 p.m.</p> <p>6 - - -</p> <p>7 (Whereupon, a brief recess</p> <p>8 was taken.)</p> <p>9 - - -</p> <p>10 VIDEO TECHNICIAN: Back on</p> <p>11 record at 6:22 p.m.</p> <p>12 MR. NICHOLAS: I have no</p> <p>13 questions for the witness. So,</p> <p>14 Mr. Zimmerman, thank you very much</p> <p>15 and you're excused. Although you</p> <p>16 can sit here to listen to us argue</p> <p>17 about one last thing.</p> <p>18 Just you said -- you said,</p> <p>19 you know, five minutes ago that</p> <p>20 there was a gap in the documents.</p> <p>21 It's the first I've heard of that.</p> <p>22 You haven't raised that with us up</p> <p>23 until now.</p> <p>24 I suspect there's not a gap</p>
<p>1 questions.</p> <p>2 THE WITNESS: What was the</p> <p>3 last question? Sorry.</p> <p>4 BY MR. PIFKO:</p> <p>5 Q. I was just asking if you</p> <p>6 were aware of any system failures or</p> <p>7 crashes of servers during that time</p> <p>8 period at the company?</p> <p>9 A. Not that I know of.</p> <p>10 MR. PIFKO: Okay. Well,</p> <p>11 it's my understanding that there's</p> <p>12 that gap in those documents and</p> <p>13 there may be other documents that</p> <p>14 might come into the production.</p> <p>15 So subject to additional</p> <p>16 documents that might be produced,</p> <p>17 we will reserve our right to</p> <p>18 recall. And I'm sure we can meet</p> <p>19 and confer about it if we have a</p> <p>20 dispute.</p> <p>21 And other than that, I don't</p> <p>22 have any questions for you at the</p> <p>23 moment.</p> <p>24 MR. NICHOLAS: Give me,</p>	<p>1 in the documents. But in any</p> <p>2 event, this is all my way of</p> <p>3 saying we don't necessarily agree</p> <p>4 that you're going to be able to</p> <p>5 come back, you know, for another</p> <p>6 deposition. That's something</p> <p>7 we'll have to fight about.</p> <p>8 MR. PIFKO: I agree. That</p> <p>9 was my statement, that we can meet</p> <p>10 and confer about it.</p> <p>11 So we can dispute about</p> <p>12 whether that happens or not.</p> <p>13 MR. NICHOLAS: Okay. I've</p> <p>14 got nothing else.</p> <p>15 VIDEO TECHNICIAN: This ends</p> <p>16 today's deposition. We're going</p> <p>17 off the record at 6:23 p.m.</p> <p>18 - - -</p> <p>19 (Whereupon, the deposition</p> <p>20 was concluded at 6:23 p.m.)</p> <p>21 - - -</p> <p>22</p> <p>23</p> <p>24</p>
	Page 489

Page 490	Page 492
1 CERTIFICATE	1 - - - - - 2 E R R A T A 3
4 I HEREBY CERTIFY that the 5 witness was duly sworn by me and that the 6 deposition is a true record of the 7 testimony given by the witness. 8 9	4 PAGE LINE CHANGE 5 6 REASON: _____ 7 8 REASON: _____ 9 10 REASON: _____ 11 12 REASON: _____ 13 14 REASON: _____ 15 16 REASON: _____ 17 18 REASON: _____ 19 20 REASON: _____ 21 22 REASON: _____ 23 24 REASON: _____
10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Page 491	Page 493
1 INSTRUCTIONS TO WITNESS 2 3 Please read your deposition 4 over carefully and make any necessary 5 corrections. You should state the reason 6 in the appropriate space on the errata 7 sheet for any corrections that are made. 8 After doing so, please sign 9 the errata sheet and date it. 10 You are signing same subject 11 to the changes you have noted on the 12 errata sheet, which will be attached to 13 your deposition. 14 It is imperative that you 15 return the original errata sheet to the 16 deposing attorney within thirty (30) days 17 of receipt of the deposition transcript 18 by you. If you fail to do so, the 19 deposition transcript may be deemed to be 20 accurate and may be used in court. 21 22 23 24	1 ACKNOWLEDGMENT OF DEPONENT 2 3 I, _____, do 4 hereby certify that I have read the 5 foregoing pages, 1 - 489, and that the 6 same is a correct transcription of the 7 answers given by me to the questions 8 therein propounded, except for the 9 corrections or changes in form or 10 substance, if any, noted in the attached 11 Errata Sheet. 12 13 CHRISTOPHER ZIMMERMAN DATE 14 Subscribed and sworn 15 to before me this 16 day of _____, 20 _____. 17 My commission expires: _____ 18 19 Notary Public 20 21 22 23 24

Page 494	
1 LAWYER'S NOTES	
2 PAGE LINE	
3	_____
4	_____
5	_____
6	_____
7	_____
8	_____
9	_____
10	_____
11	_____
12	_____
13	_____
14	_____
15	_____
16	_____
17	_____
18	_____
19	_____
20	_____
21	_____
22	_____
23	_____
24	_____